[{"id": 245001, "ingredient1": "Gabapentin", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with gabapentinoids (e.g., gabapentin, pregabalin) may increase the risk of opioid overdose and serious adverse effects such as profound sedation, respiratory depression, syncope, and death due to potentially additive depressant effects on the central nervous system.", "source": "DDInter", "management_text": "Caution is advised when opioids and gabapentinoids are coadministered, particularly in patients with additional risk factors for respiratory depression such as advanced age, renal insufficiency, or chronic lung disease.  The dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Use of additional central nervous system depressants should be avoided if possible.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  For patients who have been receiving extended therapy with both an opioid and a gabapentinoid (either for analgesia or seizure control) and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms and increased seizure risk.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids and gabapentinoids are coadministered, particularly in patients with additional risk factors for respiratory depression such as advanced age, renal insufficiency, or chronic lung disease.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288858/", "reference_text": "[1] \"Product Information. Neurontin (gabapentin).\" Parke-Davis  (2001):[2] \"Product Information. Lyrica (pregabalin).\" Pfizer U.S. Pharmaceuticals Group  (2005):[3] US Food and Drug Administration \"FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) When used with CNS depressants or in patients with lung problems.  https://www.fda.gov/media/1336\"   (2020):[4] Government of Canada \"Summary Safety Review - Gabapentin - Assessing the Potential Risk of Serious Breathing Problems.  https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-gabapentin-assessing-potential-ri\"   (2020):[5] Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G \"Gabapentin enhances the analgesic effect of morphine in healthy volunteers.\" Anesth Analg 91 (2000):  185-91[6] Eipe N, Penning J \"Postoperative respiratory depression associated with pregabalin: a case series and a preoperative decision algorithm.\" Pain Res Manag 16 (2011):  353-6[7] Smith RV, Havens JR, Walsh SL \"Gabapentin misuse, abuse and diversion: a systematic review.\" Addiction 111 (2016):  1160-74[8] Peckham AM, Evoy KE, Covvey JR, Ochs L, Fairman KA, Sclar DA \"Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured U.S. population.\" Pharmacotherapy 38 (2018):  436-43", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245002, "ingredient1": "Ginkgo biloba", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures.  There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation.  Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288860/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001):  344[3] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001):  280-1[4] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002):  325-7[5] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005):  755-8[6] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006):  323-9[7] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001):  523-5[8] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001):  524-32", "alternatives_a": "Rivastigmine, Galantamine, Donepezil, Tacrine, Memantine, Aducanumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245003, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288861/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245004, "ingredient1": "Glycopyrronium", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288862/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Budesonide, Aclidinium, Mometasone, Fluticasone, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245005, "ingredient1": "Golimumab", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288863/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245006, "ingredient1": "Granisetron", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288864/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rolapitant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245007, "ingredient1": "Griseofulvin", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288865/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Econazole, Flucytosine, Tioconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245008, "ingredient1": "Guanabenz", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288866/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245009, "ingredient1": "Guanadrel", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288867/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245010, "ingredient1": "Guanethidine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288868/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245011, "ingredient1": "Guanfacine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288869/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245012, "ingredient1": "Guselkumab", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288870/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245013, "ingredient1": "Halazepam", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288871/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245014, "ingredient1": "Haloperidol", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288872/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245015, "ingredient1": "Halothane", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Opioids may decrease the minimum alveolar concentration required for inhalation anesthetics.  When these agents are used concomitantly, less inhalation anesthetic may be required.  In addition, inhalation anesthetics may cause respiratory depression which may be increased by opioid premedication or other agents causing respiratory depression.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.  Patients should be monitored closely for respiratory depression.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288873/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical  (2001):[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997):  100-5", "alternatives_a": "Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245016, "ingredient1": "Diamorphine", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288874/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245017, "ingredient1": "Hydralazine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288875/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245018, "ingredient1": "Hydrochlorothiazide", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288876/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245019, "ingredient1": "Hydrocodone", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288877/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Benzonatate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245020, "ingredient1": "Hydroflumethiazide", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288878/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245021, "ingredient1": "Hydromorphone", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288879/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245022, "ingredient1": "Hydroxyzine", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288880/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245023, "ingredient1": "Hyoscyamine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288881/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245024, "ingredient1": "Idelalisib", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288882/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245025, "ingredient1": "Ifosfamide", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide.", "source": "DDInter", "management_text": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.  Patients should be advised to avoid driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how the medications affect them.  If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued.  Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.", "mechanism_text": "Synergism", "recommendation": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288883/", "reference_text": "[1] Simonian NA, Gilliam FG, Chiappa KH \"Ifosfamide causes a diazepam-sensitive encephalopathy.\" Neurology 43 (1993):  2700-2[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245026, "ingredient1": "Iloperidone", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288884/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245027, "ingredient1": "Imatinib", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288885/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245028, "ingredient1": "Imipramine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288886/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245029, "ingredient1": "Indapamide", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288887/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245030, "ingredient1": "Indinavir", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288888/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245031, "ingredient1": "Infliximab", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288890/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245032, "ingredient1": "Iohexol", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures.  Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline).  These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.  Otherwise, close monitoring is advised during and after contrast administration.  The manufacturers typically recommend avoiding concomitant administration of phenothiazines (including those used for their antihistamine properties), monoamine oxidase inhibitors, tricyclic antidepressants, central nervous system stimulants, and psychoactive drugs.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288891/", "reference_text": "[1] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975):  129-35[2] \"Product Information. Amipaque (metrizamide).\" Nycomed Inc  (2001):[3] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc  (2001):[4] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health  (2007):[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc  (2007):", "alternatives_a": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245033, "ingredient1": "Iopamidol", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures.  Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline).  These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.  Otherwise, close monitoring is advised during and after contrast administration.  The manufacturers typically recommend avoiding concomitant administration of phenothiazines (including those used for their antihistamine properties), monoamine oxidase inhibitors, tricyclic antidepressants, central nervous system stimulants, and psychoactive drugs.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288893/", "reference_text": "[1] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975):  129-35[2] \"Product Information. Amipaque (metrizamide).\" Nycomed Inc  (2001):[3] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc  (2001):[4] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health  (2007):[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc  (2007):", "alternatives_a": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245034, "ingredient1": "Irbesartan", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288894/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245035, "ingredient1": "Isavuconazonium", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288895/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245036, "ingredient1": "Isocarboxazid", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288896/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987):  251-2[7] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993):  1270-1[8] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[9] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[10] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[11] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[12] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[13] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[14] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[15] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[16] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245037, "ingredient1": "Isoflurane", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Opioids may decrease the minimum alveolar concentration required for inhalation anesthetics.  When these agents are used concomitantly, less inhalation anesthetic may be required.  In addition, inhalation anesthetics may cause respiratory depression which may be increased by opioid premedication or other agents causing respiratory depression.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.  Patients should be monitored closely for respiratory depression.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288897/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical  (2001):[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997):  100-5", "alternatives_a": "Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245038, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288898/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245039, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288899/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Nesiritide, Vericiguat", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245040, "ingredient1": "Isradipine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288900/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245041, "ingredient1": "Itraconazole", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288901/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245042, "ingredient1": "Benzhydrocodone", "ingredient2": "Ivosidenib", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288902/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245043, "ingredient1": "Benzhydrocodone", "ingredient2": "Ixekizumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288903/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245044, "ingredient1": "Benzhydrocodone", "ingredient2": "Kaolin", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288904/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pectin, Activated charcoal", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245045, "ingredient1": "Benzhydrocodone", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288905/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245046, "ingredient1": "Benzhydrocodone", "ingredient2": "Ketamine", "severity": "Major", "effect": "Coadministration of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.  Concomitant use of ketamine with other CNS depressants can potentiate CNS depression and/or increase the risk of developing respiratory depression.  In addition, opioid analgesics, barbiturates, and benzodiazepines may prolong the time to complete recovery from anesthesia.", "source": "DDInter", "management_text": "During concomitant use of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, close monitoring of neurologic status and respiratory parameters, including respiratory rate and pulse oximetry, is recommended.  Dosage adjustments should be considered according to the patient's clinical situation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, close monitoring of neurologic status and respiratory parameters, including respiratory rate and pulse oximetry, is recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288906/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245047, "ingredient1": "Benzhydrocodone", "ingredient2": "Ketoconazole", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288907/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245048, "ingredient1": "Benzhydrocodone", "ingredient2": "Labetalol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288908/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245049, "ingredient1": "Benzhydrocodone", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288909/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245050, "ingredient1": "Benzhydrocodone", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever larotrectinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  Some authorities recommend avoiding concomitant use of larotrectinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.  These drugs include, but are not limited to:  alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288910/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc  (2018):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245051, "ingredient1": "Benzhydrocodone", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with alcohol or other central nervous system (CNS) depressants may enhance the sedative effects of lasmiditan and increase the likelihood and/or severity of cognitive and/or neuropsychiatric adverse reactions.", "source": "DDInter", "management_text": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.  Patients should be advised against driving and other activities that require complete mental alertness for at least 8 hours after lasmiditan is administered.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288911/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company  (2019):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245052, "ingredient1": "Benzhydrocodone", "ingredient2": "Lemborexant", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288912/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245053, "ingredient1": "Benzhydrocodone", "ingredient2": "Lesinurad", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288915/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Pegloticase, Febuxostat, Colchicine, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245054, "ingredient1": "Benzhydrocodone", "ingredient2": "Letermovir", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288916/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245055, "ingredient1": "Benzhydrocodone", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288917/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245056, "ingredient1": "Benzhydrocodone", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288918/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245057, "ingredient1": "Benzhydrocodone", "ingredient2": "Levocetirizine", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288919/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc  (2007):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245058, "ingredient1": "Benzhydrocodone", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288920/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245059, "ingredient1": "Benzhydrocodone", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288922/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245060, "ingredient1": "Benzhydrocodone", "ingredient2": "Levomilnacipran", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288923/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245061, "ingredient1": "Benzhydrocodone", "ingredient2": "Levorphanol", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288924/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245062, "ingredient1": "Benzhydrocodone", "ingredient2": "Lindane", "severity": "Moderate", "effect": "Lindane penetrates human skin and has the potential to cause central nervous system toxicity.  Seizures have been reported after excessive use or oral ingestion of lindane.  There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).  These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections).  Lindane should be used according to recommended dosage and directions for application.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288925/", "reference_text": "[1] Telch J, Jarvis DA \"Acute intoxication with lindane (gamma benzene hexachloride).\" Can Med Assoc J 126 (1982):  662-3[2] Munk ZM, Nantel A \"Acute lindane poisoning with development of muscle necrosis.\" Can Med Assoc J 117 (1977):  1050-4[3] Tenenbein M \"Seizures after lindane therapy.\" J Am Geriatr Soc 39 (1991):  394-5[4] Pramanik AK, Hansen RC \"Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children.\" Arch Dermatol 115 (1979):  1224-5[5] Matsuoka LY \"Convulsions following application of gamma benzene hexachloride.\" J Am Acad Dermatol 5 (1981):  98-9[6] Solomon BA, Haut SR, Carr EM, Shalita AR \"Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem.\" J Fam Pract 40 (1995):  291-6[7] \"Product Information. Kwell (lindane).\" Reed and Carnrick, Jersey City, NJ.[8] Ramchander V, Cameron ES, Reid HF \"Lindane toxicity in an infant.\" West Indian Med J 40 (1991):  41-3[9] Cox R, Krupnick J, Bush N, Houpt A \"Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder.\" J Miss State Med Assoc 41 (2000):  690-2", "alternatives_a": "Disulfiram", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245063, "ingredient1": "Benzhydrocodone", "ingredient2": "Linezolid", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288926/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987):  251-2[7] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993):  1270-1[8] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[9] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[10] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[11] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[12] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[13] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[14] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[15] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[16] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):", "alternatives_a": "Tinidazole, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245064, "ingredient1": "Benzhydrocodone", "ingredient2": "Lisinopril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288927/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245065, "ingredient1": "Benzhydrocodone", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288928/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245066, "ingredient1": "Benzhydrocodone", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288929/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245067, "ingredient1": "Benzhydrocodone", "ingredient2": "Lonafarnib", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288930/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245068, "ingredient1": "Benzhydrocodone", "ingredient2": "Loperamide", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288932/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Diphenoxylate, Difenoxin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245069, "ingredient1": "Benzhydrocodone", "ingredient2": "Lorazepam", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288933/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245070, "ingredient1": "Benzhydrocodone", "ingredient2": "Lorlatinib", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288934/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245071, "ingredient1": "Benzhydrocodone", "ingredient2": "Losartan", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288935/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245072, "ingredient1": "Benzhydrocodone", "ingredient2": "Loxapine", "severity": "Major", "effect": "Concomitant use of opioids with central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, antipsychotics).", "source": "DDInter", "management_text": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.  Delayed diagnosis and treatment of constipation may increase the risk of severe complications, which can result in hospitalization, surgery, and death.  Patients should be advised to maintain adequate hydration, physical activity and fiber intake, and to report any changes in the frequency or character of bowel movements as well as signs and symptoms of potential complications of ileus such as nausea, vomiting, abdominal distension, and abdominal pain.  If constipation or gastrointestinal hypomotility is identified, monitor closely and treat promptly with appropriate laxatives to prevent severe complications.  Consider prophylactic laxatives in high risk patients, such as those with a history of constipation, colonic disease, or lower abdominal surgery.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288936/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[3] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. FazaClo (clozapine).\" Jazz Pharmaceuticals  (2015):[7] \"Product Information. Versacloz (clozapine).\" Jazz Pharmaceuticals  (2015):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245073, "ingredient1": "Benzhydrocodone", "ingredient2": "Lumateperone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288937/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245074, "ingredient1": "Benzhydrocodone", "ingredient2": "Lurasidone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288938/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245075, "ingredient1": "Benzhydrocodone", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288939/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245076, "ingredient1": "Benzhydrocodone", "ingredient2": "Mebrofenin", "severity": "Moderate", "effect": "Prior administration of opioids may delay transit of Technetium Tc 99m mebrofenin due to opioid-induced contraction of the distal common bile duct, which may result in nonvisualization.", "source": "DDInter", "management_text": "Nonvisualization may occur in patients who have been receiving opioids prior to cholescintigraphy.", "mechanism_text": "Others", "recommendation": "Nonvisualization may occur in patients who have been receiving opioids prior to cholescintigraphy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288941/", "reference_text": "[1] Flancbaum L, Choban PS, Sinha R, Jonasson O \"Morphine cholescintigraphy in the evaluation of hospitalized patients with suspected acute cholecystitis.\" Ann Surg 220 (1994): 25-31[2] \"Product Information. Choletec (mebrofenin).\" Bracco Diagnostics Inc, Princeton, NJ.[3] Chen CC, Holder LE, Maunoury C, Drachenberg CI \"Morphine augmentation increases galllbladder visualization in patients pretreated with cholecystokinin.\" J Nucl Med 38 (1997): 644-7[4] Kim EE, Pjura G, Lowry P, Nguyen M, Pollack M \"Morphine-augmented cholescintigraphy in the diagnosis of acute cholecystitis.\" AJR Am J Roentgenol 147 (1986): 1177-9[5] Oates E, Selland DL, Chin CT, Achong DM \"Gallbladder nonvisualization with pericholecystic rim sign: morphine-augmentation optimizes diagnosis of acute cholecystitis.\" J Nucl Med 37 (1996): 267-9[6] Fink-Bennett D, Balon H, Robbins T, Tsai D \"Morphine-augmented cholescintigraphy: its efficacy in detecting acute cholecystitis.\" J Nucl Med 32 (1991): 1231-3[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245077, "ingredient1": "Benzhydrocodone", "ingredient2": "Meclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288942/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245078, "ingredient1": "Benzhydrocodone", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288943/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245079, "ingredient1": "Benzhydrocodone", "ingredient2": "Mepenzolate", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288944/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245080, "ingredient1": "Benzhydrocodone", "ingredient2": "Meperidine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288945/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245081, "ingredient1": "Benzhydrocodone", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288946/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245082, "ingredient1": "Benzhydrocodone", "ingredient2": "Methylphenobarbital", "severity": "Major", "effect": "Barbiturates may potentiate the central nervous system (CNS) depressant effects of opioids.  Concomitant use may result in profound sedation, respiratory depression, coma, and death.  On the other hand, some barbiturates can also induce the hepatic metabolism of opioids that are metabolized by CYP450 3A4 such as butorphanol, fentanyl, hydrocodone, methadone and oxycodone, resulting in enhanced clearance.  Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on their opioid regimen following the addition of a barbiturate.  Conversely, discontinuation of the barbiturate may increase plasma concentrations of the opioid and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Particular caution is advisable when a barbiturate is added to or withdrawn from therapy in patients receiving opioids that are CYP450 3A4 substrates, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the barbiturate and overdose following discontinuation.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Metabolism, Synergism", "recommendation": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288947/", "reference_text": "[1] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[2] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[9] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):[10] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Lacosamide, Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245083, "ingredient1": "Benzhydrocodone", "ingredient2": "Meprobamate", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288948/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245084, "ingredient1": "Benzhydrocodone", "ingredient2": "Mesoridazine", "severity": "Major", "effect": "Concomitant use of opioids with central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, antipsychotics).", "source": "DDInter", "management_text": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.  Delayed diagnosis and treatment of constipation may increase the risk of severe complications, which can result in hospitalization, surgery, and death.  Patients should be advised to maintain adequate hydration, physical activity and fiber intake, and to report any changes in the frequency or character of bowel movements as well as signs and symptoms of potential complications of ileus such as nausea, vomiting, abdominal distension, and abdominal pain.  If constipation or gastrointestinal hypomotility is identified, monitor closely and treat promptly with appropriate laxatives to prevent severe complications.  Consider prophylactic laxatives in high risk patients, such as those with a history of constipation, colonic disease, or lower abdominal surgery.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288949/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[3] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. FazaClo (clozapine).\" Jazz Pharmaceuticals  (2015):[7] \"Product Information. Versacloz (clozapine).\" Jazz Pharmaceuticals  (2015):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245085, "ingredient1": "Benzhydrocodone", "ingredient2": "Metaxalone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288950/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245086, "ingredient1": "Benzhydrocodone", "ingredient2": "Methadone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288951/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245087, "ingredient1": "Benzhydrocodone", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288952/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245088, "ingredient1": "Benzhydrocodone", "ingredient2": "Methocarbamol", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288953/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245089, "ingredient1": "Benzhydrocodone", "ingredient2": "Methohexital", "severity": "Moderate", "effect": "Narcotic analgesics may reduce the dosage of barbiturate anesthetics needed to induce anesthesia by as much as 40%.", "source": "DDInter", "management_text": "Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.", "mechanism_text": "Synergism", "recommendation": "Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288954/", "reference_text": "[1] DeLapa RJ \"Influence of alphaprodine hydrochloride on intravenous barbiturate induction dosage.\" J Oral Surg 18 (1960):  163-8[2] Dundee JW, Halliday NJ, McMurray TJ, Harper KW \"Pretreatment with opioids: the effect on thiopentone induction requirements and on the onset of action of midazolam.\" Anaesthesia 41 (1986):  159-61[3] Stambaugh JE, Hemphill DM, Wainer IW, Schwartz I \"A potentially toxic drug interaction between pethidine (meperidine) and phenobarbitone.\" Lancet 1 (1977):  398-9[4] Stambaugh JE, Wainer IW, Schwartz I \"The effect of phenobarbital on the metabolism of meperidine in normal volunteers.\" J Clin Pharmacol 18 (1978):  482-90", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone, Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245090, "ingredient1": "Benzhydrocodone", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288955/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245091, "ingredient1": "Benzhydrocodone", "ingredient2": "Methoxyflurane", "severity": "Moderate", "effect": "Opioids may decrease the minimum alveolar concentration required for inhalation anesthetics.  When these agents are used concomitantly, less inhalation anesthetic may be required.  In addition, inhalation anesthetics may cause respiratory depression which may be increased by opioid premedication or other agents causing respiratory depression.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.  Patients should be monitored closely for respiratory depression.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288956/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical  (2001):[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997):  100-5", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Salsalate, Acetylsalicylic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245092, "ingredient1": "Benzhydrocodone", "ingredient2": "Methscopolamine", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288957/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Ketorolac, Homatropine, Ephedrine, Tropicamide, Phenylephrine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245093, "ingredient1": "Benzhydrocodone", "ingredient2": "Methsuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288958/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245094, "ingredient1": "Benzhydrocodone", "ingredient2": "Methyldopa", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288960/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245095, "ingredient1": "Benzhydrocodone", "ingredient2": "Methylene blue", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288961/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987):  251-2[7] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993):  1270-1[8] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[9] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[10] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[11] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[12] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[13] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[14] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[15] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[16] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245096, "ingredient1": "Benzhydrocodone", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288962/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cisapride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245097, "ingredient1": "Benzhydrocodone", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288963/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245098, "ingredient1": "Benzhydrocodone", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288964/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245099, "ingredient1": "Benzhydrocodone", "ingredient2": "Metreleptin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288965/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245100, "ingredient1": "Benzhydrocodone", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288967/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245101, "ingredient1": "Benzhydrocodone", "ingredient2": "Miconazole", "severity": "Moderate", "effect": "Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme.  No formal drug interaction studies have been conducted with miconazole buccal tablets.  Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.", "source": "DDInter", "management_text": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288969/", "reference_text": "[1] \"Product Information. ORAVIG (miconazole).\" Strativa  Pharmaceuticals, a Division of Par Pharmaceuticals, Inc.  (2010):", "alternatives_a": "Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, Neomycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245102, "ingredient1": "Benzhydrocodone", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288970/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245103, "ingredient1": "Benzhydrocodone", "ingredient2": "Mifepristone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288971/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245104, "ingredient1": "Benzhydrocodone", "ingredient2": "Milnacipran", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288972/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245105, "ingredient1": "Benzhydrocodone", "ingredient2": "Minoxidil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288973/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tacrolimus, Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245106, "ingredient1": "Benzhydrocodone", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288974/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245107, "ingredient1": "Benzhydrocodone", "ingredient2": "Mitotane", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288975/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245108, "ingredient1": "Benzhydrocodone", "ingredient2": "Modafinil", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288976/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245109, "ingredient1": "Benzhydrocodone", "ingredient2": "Moexipril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288977/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245110, "ingredient1": "Benzhydrocodone", "ingredient2": "Molindone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288978/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245111, "ingredient1": "Benzhydrocodone", "ingredient2": "Morphine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288979/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Diphenoxylate, Difenoxin, Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245112, "ingredient1": "Benzhydrocodone", "ingredient2": "Nabilone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288981/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Rolapitant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245113, "ingredient1": "Benzhydrocodone", "ingredient2": "Nadolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288982/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245114, "ingredient1": "Benzhydrocodone", "ingredient2": "Nafcillin", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288983/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245115, "ingredient1": "Benzhydrocodone", "ingredient2": "Nalbuphine", "severity": "Major", "effect": "Concomitant use of opioids with other central nervous system (CNS) depressants including mixed agonist-antagonist or partial agonist opioids may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased.  On the other hand, mixed agonist-antagonist or partial agonist opioids can reduce the pharmacologic effects of other opioid agonists.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary (e.g., when initiating a switch from one opioid to the other), the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Additional caution is advisable when a mixed agonist-antagonist or partial agonist opioid is added to an existing opioid regimen, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the mixed agonist-antagonist or partial agonist opioid.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Others", "recommendation": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288984/", "reference_text": "[1] Moldenhauer CC, Roach GW, Finlayson DC, et al. \"Nalbuphine antagonism of ventilatory depression following high-dose fentanyl anesthesia.\" Anesthesiology 62 (1985):  647-50[2] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[3] Strain EC, Preston KL, Liebson IA, Bigelow GE \"Precipitated withdrawal by pentazocine in methadone-maintained volunteers.\" J Pharmacol Exp Ther 267 (1993):  624-34[4] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[5] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[6] \"Product Information. Talwin NX (pentazocine).\" Sanofi Winthrop Pharmaceuticals  (2001):[7] \"Product Information. Stadol (butorphanol).\" Allscrips Pharmaceutical Company  (2001):[8] \"Product Information. Dalgan (dezocine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Suboxone (buprenorphine-naloxone).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[10] \"Product Information. Subutex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[11] \"Product Information. Butrans (buprenorphine).\" Purdue Pharma LP  (2010):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245116, "ingredient1": "Benzhydrocodone", "ingredient2": "Naloxone", "severity": "Moderate", "effect": "This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines.  Naloxone injection is an antagonist that will reverse the actions of opiates.  This reversal can occur when the opiate drug is being used clinically and when it is being abused.  Physically dependent patients may experience withdrawal symptoms.  Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.", "source": "DDInter", "management_text": "Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288985/", "reference_text": "[1] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[2] \"Product Information. Narcan (naloxone).\" DuPont Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245117, "ingredient1": "Benzhydrocodone", "ingredient2": "Naltrexone", "severity": "Major", "effect": "Naltrexone can antagonize the effects of opioids via competitive inhibition of opioid receptors.  Patients receiving naltrexone may not benefit from opioid-containing medications such as cough and cold products, antidiarrheal preparations, and narcotic analgesics.", "source": "DDInter", "management_text": "The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine).  Naltrexone should also not be given to patients in acute opioid withdrawal.  In an urgent situation when analgesia may be required in a patient who has received full blocking doses of naltrexone, consideration should be given to regional analgesia, conscious sedation with a benzodiazepine, use of non-opioid analgesics, or general anesthesia.  If opioid analgesia is required, the amount of opioid needed may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.  A rapidly-acting opioid analgesic that minimizes the duration of respiratory depression is preferred.  Clinicians should be aware that reversal of full naltrexone blockade by administration of large doses of opiates can cause histamine release.  Therefore, patients may experience non-opioid receptor-mediated effects such as facial swelling, itching, generalized erythema, and bronchoconstriction.  Irrespective of the drug chosen to reverse naltrexone blockade, the patient should be monitored closely by appropriately trained personnel in a setting equipped and staffed for cardiopulmonary resuscitation.", "mechanism_text": "Antagonism", "recommendation": "The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288986/", "reference_text": "[1] \"Product Information. ReVia (naltrexone).\" DuPont Pharmaceuticals  (2001):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen, Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine, Ephedrine, Phentermine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245118, "ingredient1": "Benzhydrocodone", "ingredient2": "Naratriptan", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288987/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245119, "ingredient1": "Benzhydrocodone", "ingredient2": "Nebivolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288988/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245120, "ingredient1": "Benzhydrocodone", "ingredient2": "Nefazodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288989/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245121, "ingredient1": "Benzhydrocodone", "ingredient2": "Nelfinavir", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288990/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245122, "ingredient1": "Benzhydrocodone", "ingredient2": "Nevirapine", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288991/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245123, "ingredient1": "Benzhydrocodone", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288992/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245124, "ingredient1": "Benzhydrocodone", "ingredient2": "Nifedipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288993/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245125, "ingredient1": "Benzhydrocodone", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288994/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245126, "ingredient1": "Benzhydrocodone", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288995/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245127, "ingredient1": "Benzhydrocodone", "ingredient2": "Nitroglycerin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288996/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245128, "ingredient1": "Benzhydrocodone", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288997/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245129, "ingredient1": "Benzhydrocodone", "ingredient2": "Nitrous oxide", "severity": "Moderate", "effect": "Opioids may decrease the minimum alveolar concentration required for inhalation anesthetics.  When these agents are used concomitantly, less inhalation anesthetic may be required.  In addition, inhalation anesthetics may cause respiratory depression which may be increased by opioid premedication or other agents causing respiratory depression.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.  Patients should be monitored closely for respiratory depression.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288998/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical  (2001):[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997):  100-5", "alternatives_a": "Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245130, "ingredient1": "Benzhydrocodone", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/288999/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245131, "ingredient1": "Benzhydrocodone", "ingredient2": "Olanzapine", "severity": "Major", "effect": "Concomitant use of opioids with central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, antipsychotics).", "source": "DDInter", "management_text": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.  Delayed diagnosis and treatment of constipation may increase the risk of severe complications, which can result in hospitalization, surgery, and death.  Patients should be advised to maintain adequate hydration, physical activity and fiber intake, and to report any changes in the frequency or character of bowel movements as well as signs and symptoms of potential complications of ileus such as nausea, vomiting, abdominal distension, and abdominal pain.  If constipation or gastrointestinal hypomotility is identified, monitor closely and treat promptly with appropriate laxatives to prevent severe complications.  Consider prophylactic laxatives in high risk patients, such as those with a history of constipation, colonic disease, or lower abdominal surgery.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289000/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[3] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. FazaClo (clozapine).\" Jazz Pharmaceuticals  (2015):[7] \"Product Information. Versacloz (clozapine).\" Jazz Pharmaceuticals  (2015):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245132, "ingredient1": "Benzhydrocodone", "ingredient2": "Oliceridine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289001/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245133, "ingredient1": "Benzhydrocodone", "ingredient2": "Olmesartan", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289002/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245134, "ingredient1": "Benzhydrocodone", "ingredient2": "Olopatadine (nasal)", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289003/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc  (2008):[2] \"Product Information. Ryaltris (mometasone-olopatadine nasal).\" Hikma Americas, Inc  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245135, "ingredient1": "Benzhydrocodone", "ingredient2": "Ondansetron", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289006/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rolapitant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245136, "ingredient1": "Benzhydrocodone", "ingredient2": "Opicapone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289007/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245137, "ingredient1": "Benzhydrocodone", "ingredient2": "Opium", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289008/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Diphenoxylate, Difenoxin, Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245138, "ingredient1": "Benzhydrocodone", "ingredient2": "Oritavancin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289009/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Tinidazole, Bacitracin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245139, "ingredient1": "Benzhydrocodone", "ingredient2": "Orphenadrine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289010/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245140, "ingredient1": "Benzhydrocodone", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289011/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245141, "ingredient1": "Benzhydrocodone", "ingredient2": "Oxazepam", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289012/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245142, "ingredient1": "Benzhydrocodone", "ingredient2": "Oxcarbazepine", "severity": "Major", "effect": "Coadministration with enzyme-inducing anticonvulsants may decrease the plasma concentrations of opioids that are primarily metabolized by CYP450 3A4 such as butorphanol, fentanyl, hydrocodone, and oxycodone.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever an enzyme-inducing anticonvulsant is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.  Due to the potential for additive central nervous system depressant effects, ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever an enzyme-inducing anticonvulsant is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289013/", "reference_text": "[1] Tempelhoff R, Modica PA, Spitznagel Jr EL \"Anticonvulsant therapy increases fentanyl requirements during anaesthesthia for craniotomy.\" Can J Anaesth 37 (1990):  327-32[2] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[4] \"Product Information. Actiq (fentanyl).\" Abbott Pharmaceutical  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[9] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245143, "ingredient1": "Benzhydrocodone", "ingredient2": "Oxybutynin", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289014/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, Phenyl salicylate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245144, "ingredient1": "Benzhydrocodone", "ingredient2": "Oxycodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289015/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245145, "ingredient1": "Benzhydrocodone", "ingredient2": "Oxymorphone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289016/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245146, "ingredient1": "Benzhydrocodone", "ingredient2": "Ozanimod", "severity": "Moderate", "effect": "Coadministration of opioid analgesics with drugs that possess monoamine oxidase inhibition (MAOI) activity, including selective MAO-B inhibitors, has been associated with rare reports of severe and sometimes fatal adverse reactions.  Because an active metabolite of ozanimod inhibits MAO-B in vitro, the interaction may theoretically occur with ozanimod.  There appear to be two types of interaction, an excitatory and a depressive one.  Symptoms of the excitatory reaction may include agitation, headache, diaphoresis, hyperpyrexia, flushing, shivering, myoclonus, rigidity, tremor, diarrhea, hypertension, tachycardia, seizures, and coma.  Death has occurred in some cases.  In contrast, symptoms of the depressive reaction probably stem from potentiation of CNS effects by MAOIs and include respiratory depression, cyanosis, hypotension, and coma.  There have also been reports of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors, with symptoms similar to the excitatory reaction described above.  Some opioids such as fentanyl, meperidine, methadone, tapentadol, and tramadol can inhibit serotonin reuptake and are more likely to cause serotonin syndrome.  However, serotonin syndrome has also occurred with other opioids.", "source": "DDInter", "management_text": "Until more information is available, concomitant use of ozanimod with opioid analgesics should be avoided when possible.  Blood pressure and other vitals should be monitored if coadministration is required.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, concomitant use of ozanimod with opioid analgesics should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289017/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[4] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[6] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[7] Vigran IM \"Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride.\" JAMA 187 (1964):  953-4[8] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[9] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[10] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[11] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[12] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[13] Starr C \"Interaction between pethidine and selegiline.\" Lancet 337 (1991):  554[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[15] Youssef MS, Wilkinson PA \"Epidural fentanyl and monoamine oxidase inhibitors.\" Anaesthesia 43 (1988):  210-2[16] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[17] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987):  251-2[20] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993):  1270-1[21] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[22] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[23] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[24] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[26] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[28] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[29] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[30] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[31] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989):  577-8[32] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation  (2001):[35] \"Product Information. Actiq (fentanyl).\" Abbott Pharmaceutical  (2001):[36] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[37] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[38] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[39] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[40] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[41] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[42] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[43] Upton R, Graff A, Williamson E, et al. \"American Herbal Pharmacopoeia and Therapeutic Compendium. Monograph printed in Herbalgram.\" Herbalgram 40 (1997):  1-38(monograph)[44] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[45] \"Product Information. Meperidine Hydrochloride (meperidine).\" Astra-Zeneca Pharmaceuticals  (2022):[46] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[47] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[48] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[49] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[50] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995):  219-23[51] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):[52] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA  (2006):[53] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[54] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[55] Cerner Multum, Inc. \"Australian Product Information.\" O 0[56] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[57] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc  (2012):[58] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation  (2020):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245147, "ingredient1": "Benzhydrocodone", "ingredient2": "Paliperidone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289018/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245148, "ingredient1": "Benzhydrocodone", "ingredient2": "Palonosetron", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289019/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rolapitant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245149, "ingredient1": "Benzhydrocodone", "ingredient2": "Paraldehyde", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289020/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245150, "ingredient1": "Benzhydrocodone", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289021/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245151, "ingredient1": "Benzhydrocodone", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289022/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245152, "ingredient1": "Benzhydrocodone", "ingredient2": "Pazopanib", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289023/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245153, "ingredient1": "Benzhydrocodone", "ingredient2": "Pegvisomant", "severity": "Moderate", "effect": "In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.  The mechanism of interaction is unknown.", "source": "DDInter", "management_text": "Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289024/", "reference_text": "[1] \"Product Information. Somavert (pegvisomant).\" Pharmacia and Upjohn  (2003):", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245154, "ingredient1": "Benzhydrocodone", "ingredient2": "Penbutolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289025/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245155, "ingredient1": "Benzhydrocodone", "ingredient2": "Pentazocine", "severity": "Major", "effect": "Concomitant use of opioids with other central nervous system (CNS) depressants including mixed agonist-antagonist or partial agonist opioids may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased.  On the other hand, mixed agonist-antagonist or partial agonist opioids can reduce the pharmacologic effects of other opioid agonists.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary (e.g., when initiating a switch from one opioid to the other), the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Additional caution is advisable when a mixed agonist-antagonist or partial agonist opioid is added to an existing opioid regimen, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the mixed agonist-antagonist or partial agonist opioid.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Others", "recommendation": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289026/", "reference_text": "[1] Moldenhauer CC, Roach GW, Finlayson DC, et al. \"Nalbuphine antagonism of ventilatory depression following high-dose fentanyl anesthesia.\" Anesthesiology 62 (1985):  647-50[2] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[3] Strain EC, Preston KL, Liebson IA, Bigelow GE \"Precipitated withdrawal by pentazocine in methadone-maintained volunteers.\" J Pharmacol Exp Ther 267 (1993):  624-34[4] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[5] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[6] \"Product Information. Talwin NX (pentazocine).\" Sanofi Winthrop Pharmaceuticals  (2001):[7] \"Product Information. Stadol (butorphanol).\" Allscrips Pharmaceutical Company  (2001):[8] \"Product Information. Dalgan (dezocine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Suboxone (buprenorphine-naloxone).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[10] \"Product Information. Subutex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[11] \"Product Information. Butrans (buprenorphine).\" Purdue Pharma LP  (2010):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245156, "ingredient1": "Benzhydrocodone", "ingredient2": "Pentobarbital", "severity": "Major", "effect": "Barbiturates may potentiate the central nervous system (CNS) depressant effects of opioids.  Concomitant use may result in profound sedation, respiratory depression, coma, and death.  On the other hand, some barbiturates can also induce the hepatic metabolism of opioids that are metabolized by CYP450 3A4 such as butorphanol, fentanyl, hydrocodone, methadone and oxycodone, resulting in enhanced clearance.  Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on their opioid regimen following the addition of a barbiturate.  Conversely, discontinuation of the barbiturate may increase plasma concentrations of the opioid and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Particular caution is advisable when a barbiturate is added to or withdrawn from therapy in patients receiving opioids that are CYP450 3A4 substrates, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the barbiturate and overdose following discontinuation.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Metabolism, Synergism", "recommendation": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289027/", "reference_text": "[1] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[2] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[9] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):[10] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245157, "ingredient1": "Benzhydrocodone", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289028/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245158, "ingredient1": "Benzhydrocodone", "ingredient2": "Pergolide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289029/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245159, "ingredient1": "Benzhydrocodone", "ingredient2": "Perindopril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289030/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245160, "ingredient1": "Benzhydrocodone", "ingredient2": "Perphenazine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289031/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245161, "ingredient1": "Benzhydrocodone", "ingredient2": "Pexidartinib", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289032/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245162, "ingredient1": "Benzhydrocodone", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289033/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245163, "ingredient1": "Benzhydrocodone", "ingredient2": "Phenelzine", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.  Concomitant use of pentazocine with MAOIs may also cause CNS excitation and hypertension through their respective effects on catecholamines.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.  However, morphine has been safely used in MAOI-treated patients who previously had an adverse reaction with meperidine and is generally suggested as an alternative to meperidine in anesthesia.  A sensitivity test should be performed in which repeated, small, incremental doses of morphine are administered over the course of several hours while overall clinical status and vital signs are carefully monitored.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289034/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[7] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[8] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[9] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[10] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[14] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] Cerner Multum, Inc. \"Australian Product Information.\" O 0[17] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245164, "ingredient1": "Benzhydrocodone", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289035/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245165, "ingredient1": "Benzhydrocodone", "ingredient2": "Phenobarbital", "severity": "Major", "effect": "Barbiturates may potentiate the central nervous system (CNS) depressant effects of opioids.  Concomitant use may result in profound sedation, respiratory depression, coma, and death.  On the other hand, some barbiturates can also induce the hepatic metabolism of opioids that are metabolized by CYP450 3A4 such as butorphanol, fentanyl, hydrocodone, methadone and oxycodone, resulting in enhanced clearance.  Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on their opioid regimen following the addition of a barbiturate.  Conversely, discontinuation of the barbiturate may increase plasma concentrations of the opioid and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Particular caution is advisable when a barbiturate is added to or withdrawn from therapy in patients receiving opioids that are CYP450 3A4 substrates, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the barbiturate and overdose following discontinuation.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Metabolism, Synergism", "recommendation": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289036/", "reference_text": "[1] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[2] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[9] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):[10] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245166, "ingredient1": "Benzhydrocodone", "ingredient2": "Phenoxybenzamine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289037/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Cyclandelate, Tolazoline, Isoxsuprine, Pentoxifylline, Niacin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245167, "ingredient1": "Benzhydrocodone", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289038/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245168, "ingredient1": "Benzhydrocodone", "ingredient2": "Phentolamine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289039/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245169, "ingredient1": "Benzhydrocodone", "ingredient2": "Phenylbutazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289040/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Acetylsalicylic acid, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, Etodolac, Ketorolac, Misoprostol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245170, "ingredient1": "Benzhydrocodone", "ingredient2": "Phenytoin", "severity": "Major", "effect": "Coadministration with enzyme-inducing anticonvulsants may decrease the plasma concentrations of opioids that are primarily metabolized by CYP450 3A4 such as butorphanol, fentanyl, hydrocodone, and oxycodone.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever an enzyme-inducing anticonvulsant is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.  Due to the potential for additive central nervous system depressant effects, ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever an enzyme-inducing anticonvulsant is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289041/", "reference_text": "[1] Tempelhoff R, Modica PA, Spitznagel Jr EL \"Anticonvulsant therapy increases fentanyl requirements during anaesthesthia for craniotomy.\" Can J Anaesth 37 (1990):  327-32[2] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[3] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[4] \"Product Information. Actiq (fentanyl).\" Abbott Pharmaceutical  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[9] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245171, "ingredient1": "Benzhydrocodone", "ingredient2": "Pimavanserin", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289042/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245172, "ingredient1": "Benzhydrocodone", "ingredient2": "Pimozide", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289043/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245173, "ingredient1": "Benzhydrocodone", "ingredient2": "Pindolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289044/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245174, "ingredient1": "Benzhydrocodone", "ingredient2": "Pitolisant", "severity": "Moderate", "effect": "Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.  Pitolisant is a borderline/weak inducer of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.  Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary.  It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289045/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Wakix (pitolisant).\" Harmony Biosciences, LLC  (2019):", "alternatives_a": "Dalfampridine, Inotersen, Riluzole, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245175, "ingredient1": "Benzhydrocodone", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289048/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245176, "ingredient1": "Benzhydrocodone", "ingredient2": "Polythiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289049/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245177, "ingredient1": "Benzhydrocodone", "ingredient2": "Posaconazole", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289050/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245178, "ingredient1": "Benzhydrocodone", "ingredient2": "Pramipexole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289051/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245179, "ingredient1": "Benzhydrocodone", "ingredient2": "Prasugrel", "severity": "Moderate", "effect": "Coadministration with opioid agonists may delay and reduce the absorption of orally administered P2Y12 inhibitors (e.g., clopidogrel, prasugrel, ticagrelor).  The proposed mechanism may involve opioid-mediated slowed gastric emptying.", "source": "DDInter", "management_text": "Although data are limited, caution is recommended when orally administered P2Y12 inhibitors are given concomitantly with opioid agonists.  In acute coronary syndrome patients who require an opioid agonist, the use of a parenteral antiplatelet agent, such as cangrelor, should be considered.", "mechanism_text": "Absorption", "recommendation": "Although data are limited, caution is recommended when orally administered P2Y12 inhibitors are given concomitantly with opioid agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289052/", "reference_text": "[1] \"Product Information. Plavix (clopidogrel).\" Bristol-Myers Squibb  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[5] \"Product Information. Effient (prasugrel).\" Lilly, Eli and Company  (2009):[6] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals  (2011):[7] Hobl EL, Stimpfl T, Ebner J, et al. \"Morphine Decreases Clopidogrel Concentrations and Effects: A Randomized, Double Blind, Placebo-Controlled Trial.\" J Am Coll Cardiol  (2013):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] Hobl EL, Reiter B, Schoergenhofer C, et al. \"Morphine Decreases Ticagrelor Concentrations but not its Antiplatelet Effects: A  Randomized Trial in Healthy Volunteers.\" Eur J Clin Invest 46 (2015):  7-14[10] Hobl EL, Reiter B, Schoergenhofer C, et al. \"Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy  volunteers.\" Clin Res Cardiol 105 (2015):  349-55[11] Kubica J, Adamski P, Ostrowska M, et al. \"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.\" Eur Heart J  (2015):[12] Kubica J, Kubica A, Jilma B, et al. \"Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors.\" Int J Cardiol 215 (2016):  201-208", "alternatives_a": "Betrixaban, Apixaban, Cilostazol, Iloprost, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245180, "ingredient1": "Benzhydrocodone", "ingredient2": "Prazosin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289053/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245181, "ingredient1": "Benzhydrocodone", "ingredient2": "Pregabalin", "severity": "Major", "effect": "Concomitant use of opioids with gabapentinoids (e.g., gabapentin, pregabalin) may increase the risk of opioid overdose and serious adverse effects such as profound sedation, respiratory depression, syncope, and death due to potentially additive depressant effects on the central nervous system.", "source": "DDInter", "management_text": "Caution is advised when opioids and gabapentinoids are coadministered, particularly in patients with additional risk factors for respiratory depression such as advanced age, renal insufficiency, or chronic lung disease.  The dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Use of additional central nervous system depressants should be avoided if possible.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  For patients who have been receiving extended therapy with both an opioid and a gabapentinoid (either for analgesia or seizure control) and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms and increased seizure risk.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids and gabapentinoids are coadministered, particularly in patients with additional risk factors for respiratory depression such as advanced age, renal insufficiency, or chronic lung disease.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289054/", "reference_text": "[1] \"Product Information. Neurontin (gabapentin).\" Parke-Davis  (2001):[2] \"Product Information. Lyrica (pregabalin).\" Pfizer U.S. Pharmaceuticals Group  (2005):[3] US Food and Drug Administration \"FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) When used with CNS depressants or in patients with lung problems.  https://www.fda.gov/media/1336\"   (2020):[4] Government of Canada \"Summary Safety Review - Gabapentin - Assessing the Potential Risk of Serious Breathing Problems.  https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-gabapentin-assessing-potential-ri\"   (2020):[5] Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G \"Gabapentin enhances the analgesic effect of morphine in healthy volunteers.\" Anesth Analg 91 (2000):  185-91[6] Eipe N, Penning J \"Postoperative respiratory depression associated with pregabalin: a case series and a preoperative decision algorithm.\" Pain Res Manag 16 (2011):  353-6[7] Smith RV, Havens JR, Walsh SL \"Gabapentin misuse, abuse and diversion: a systematic review.\" Addiction 111 (2016):  1160-74[8] Peckham AM, Evoy KE, Covvey JR, Ochs L, Fairman KA, Sclar DA \"Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured U.S. population.\" Pharmacotherapy 38 (2018):  436-43", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245182, "ingredient1": "Benzhydrocodone", "ingredient2": "Primidone", "severity": "Major", "effect": "Barbiturates may potentiate the central nervous system (CNS) depressant effects of opioids.  Concomitant use may result in profound sedation, respiratory depression, coma, and death.  On the other hand, some barbiturates can also induce the hepatic metabolism of opioids that are metabolized by CYP450 3A4 such as butorphanol, fentanyl, hydrocodone, methadone and oxycodone, resulting in enhanced clearance.  Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on their opioid regimen following the addition of a barbiturate.  Conversely, discontinuation of the barbiturate may increase plasma concentrations of the opioid and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Particular caution is advisable when a barbiturate is added to or withdrawn from therapy in patients receiving opioids that are CYP450 3A4 substrates, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the barbiturate and overdose following discontinuation.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Metabolism, Synergism", "recommendation": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289055/", "reference_text": "[1] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[2] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[9] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):[10] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone, Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245183, "ingredient1": "Benzhydrocodone", "ingredient2": "Procarbazine", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289056/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987):  251-2[7] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993):  1270-1[8] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[9] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[10] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[11] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[12] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[13] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[14] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[15] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[16] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245184, "ingredient1": "Benzhydrocodone", "ingredient2": "Prochlorperazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289057/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245185, "ingredient1": "Benzhydrocodone", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Central anticholinergic agents may have additive central nervous system (CNS) effects with cannabinoids, barbiturates, opiates, and alcohol.", "source": "DDInter", "management_text": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.  Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289058/", "reference_text": "[1] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245186, "ingredient1": "Benzhydrocodone", "ingredient2": "Promazine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289059/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245187, "ingredient1": "Benzhydrocodone", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289060/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine, Lidocaine, Tetracaine, Pheniramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245188, "ingredient1": "Benzhydrocodone", "ingredient2": "Propantheline", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289061/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245189, "ingredient1": "Benzhydrocodone", "ingredient2": "Propiomazine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289062/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245190, "ingredient1": "Benzhydrocodone", "ingredient2": "Propofol", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289063/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245191, "ingredient1": "Dextropropoxyphene", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene.", "source": "DDInter", "management_text": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.  Dosage reductions may be appropriate.  Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects.  Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289064/", "reference_text": "[1] Abernethy DR, Greenblatt DJ, Morse DS, Shader RI \"Interaction of propoxyphene with diazepam, alprazolam and lorazepam.\" Br J Clin Pharmacol 19 (1985):  51-7[2] Hansen BS, Dam M, Brandt J, et al. \"Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man.\" Acta Neurol Scand 61 (1980):  357-67[3] Abernethy DR, Greenblatt DJ, Steel K, Shader RI \"Impairment of hepatic drug oxidation by propoxyphene.\" Ann Intern Med 97 (1982):  223-4[4] Peterson GR, Covault HP, Hostetler RM \"Acute inhibition of microsomal drug metabolism by propoxphene in narcotic tolerant/dependent mice.\" Life Sci 22 (1978):  2087-96[5] Shorr RI, Griffin MR, Daugherty JR, Ray WA \"Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene.\" J Gerontol 47 (1992):  m111-5[6] Puckett WH Jr, Visconti JA \"Orphenadrine and propoxyphene.\" N Engl J Med 283 (1970):  544[7] Pearson RE, Salter FJ \"Drug interaction? Orphenadrine with propoxyphene.\" N Engl J Med 282 (1970):  1215[8] \"Product Information. Darvon (propoxyphene).\" Lilly, Eli and Company  (2001):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245192, "ingredient1": "Benzhydrocodone", "ingredient2": "Propranolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289065/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245193, "ingredient1": "Benzhydrocodone", "ingredient2": "Protriptyline", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289066/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245194, "ingredient1": "Benzhydrocodone", "ingredient2": "Mepyramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289067/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245195, "ingredient1": "Benzhydrocodone", "ingredient2": "Quazepam", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289068/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245196, "ingredient1": "Benzhydrocodone", "ingredient2": "Quetiapine", "severity": "Major", "effect": "Concomitant use of opioids with central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, antipsychotics).", "source": "DDInter", "management_text": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.  Delayed diagnosis and treatment of constipation may increase the risk of severe complications, which can result in hospitalization, surgery, and death.  Patients should be advised to maintain adequate hydration, physical activity and fiber intake, and to report any changes in the frequency or character of bowel movements as well as signs and symptoms of potential complications of ileus such as nausea, vomiting, abdominal distension, and abdominal pain.  If constipation or gastrointestinal hypomotility is identified, monitor closely and treat promptly with appropriate laxatives to prevent severe complications.  Consider prophylactic laxatives in high risk patients, such as those with a history of constipation, colonic disease, or lower abdominal surgery.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289069/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[3] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. FazaClo (clozapine).\" Jazz Pharmaceuticals  (2015):[7] \"Product Information. Versacloz (clozapine).\" Jazz Pharmaceuticals  (2015):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245197, "ingredient1": "Benzhydrocodone", "ingredient2": "Quinapril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289070/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245198, "ingredient1": "Benzhydrocodone", "ingredient2": "Ramelteon", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289071/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245199, "ingredient1": "Benzhydrocodone", "ingredient2": "Ramipril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289072/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245200, "ingredient1": "Benzhydrocodone", "ingredient2": "Ranolazine", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289073/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Ivabradine, Adenosine, Regadenoson", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245201, "ingredient1": "Benzhydrocodone", "ingredient2": "Rasagiline", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289074/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245202, "ingredient1": "Benzhydrocodone", "ingredient2": "Remimazolam", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289077/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245203, "ingredient1": "Benzhydrocodone", "ingredient2": "Reserpine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289078/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245204, "ingredient1": "Benzhydrocodone", "ingredient2": "Ribociclib", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289079/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245205, "ingredient1": "Benzhydrocodone", "ingredient2": "Rifabutin", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289080/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245206, "ingredient1": "Benzhydrocodone", "ingredient2": "Rifampicin", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289081/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245207, "ingredient1": "Benzhydrocodone", "ingredient2": "Rifapentine", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289082/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245208, "ingredient1": "Benzhydrocodone", "ingredient2": "Rilonacept", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289083/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245209, "ingredient1": "Benzhydrocodone", "ingredient2": "Risperidone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289084/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245210, "ingredient1": "Benzhydrocodone", "ingredient2": "Ritonavir", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289085/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245211, "ingredient1": "Benzhydrocodone", "ingredient2": "Rizatriptan", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289086/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245212, "ingredient1": "Benzhydrocodone", "ingredient2": "Ropinirole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289088/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245213, "ingredient1": "Benzhydrocodone", "ingredient2": "Rotigotine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289089/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245214, "ingredient1": "Benzhydrocodone", "ingredient2": "Rufinamide", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289090/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245215, "ingredient1": "Benzhydrocodone", "ingredient2": "Safinamide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289091/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245216, "ingredient1": "Benzhydrocodone", "ingredient2": "Saquinavir", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289092/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245217, "ingredient1": "Benzhydrocodone", "ingredient2": "Sarilumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289093/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245218, "ingredient1": "Benzhydrocodone", "ingredient2": "Satralizumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289094/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245219, "ingredient1": "Benzhydrocodone", "ingredient2": "Scopolamine", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289095/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone, Ketorolac, Homatropine, Ephedrine, Tropicamide, Phenylephrine, Rolapitant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245220, "ingredient1": "Benzhydrocodone", "ingredient2": "Secobarbital", "severity": "Major", "effect": "Barbiturates may potentiate the central nervous system (CNS) depressant effects of opioids.  Concomitant use may result in profound sedation, respiratory depression, coma, and death.  On the other hand, some barbiturates can also induce the hepatic metabolism of opioids that are metabolized by CYP450 3A4 such as butorphanol, fentanyl, hydrocodone, methadone and oxycodone, resulting in enhanced clearance.  Reduced analgesic efficacy or withdrawal symptoms may occur in patients maintained on their opioid regimen following the addition of a barbiturate.  Conversely, discontinuation of the barbiturate may increase plasma concentrations of the opioid and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Particular caution is advisable when a barbiturate is added to or withdrawn from therapy in patients receiving opioids that are CYP450 3A4 substrates, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the barbiturate and overdose following discontinuation.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Metabolism, Synergism", "recommendation": "The use of opioids in conjunction with other CNS depressants such as barbiturates should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289096/", "reference_text": "[1] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[2] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Cerner Multum, Inc. \"Australian Product Information.\" O 0[8] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[9] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):[10] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245221, "ingredient1": "Benzhydrocodone", "ingredient2": "Secukinumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289097/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245222, "ingredient1": "Benzhydrocodone", "ingredient2": "Selegiline", "severity": "Major", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs), such as selegiline (an MAO-B inhibitor), with opioid analgesics may result in serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5HT1A receptors.", "source": "DDInter", "management_text": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with an opioid analgesic.  If coadministration is unavoidable, patients should be monitored for signs and symptoms of serotonin syndrome which may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea.  Some authorities consider the use of selegiline with opioid analgesics to be contraindicated (UK).", "mechanism_text": "Synergism", "recommendation": "Concomitant use of MAOIs, such as selegiline, with opioid analgesics should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289098/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zelapar (selegiline).\" Valeant Pharmaceuticals  (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245223, "ingredient1": "Benzhydrocodone", "ingredient2": "Selpercatinib", "severity": "Moderate", "effect": "Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  The mechanism is reduced clearance due to inhibition of CYP450 3A4 by selpercatinib.  The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index.", "source": "DDInter", "management_text": "Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever selpercatinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289099/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Retevmo (selpercatinib).\" Lilly, Eli and Company  (2020):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245224, "ingredient1": "Benzhydrocodone", "ingredient2": "Sertraline", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289100/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245225, "ingredient1": "Benzhydrocodone", "ingredient2": "Sevoflurane", "severity": "Moderate", "effect": "Opioids may decrease the minimum alveolar concentration required for inhalation anesthetics.  When these agents are used concomitantly, less inhalation anesthetic may be required.  In addition, inhalation anesthetics may cause respiratory depression which may be increased by opioid premedication or other agents causing respiratory depression.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.  Patients should be monitored closely for respiratory depression.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289101/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical  (2001):[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997):  100-5", "alternatives_a": "Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245226, "ingredient1": "Benzhydrocodone", "ingredient2": "Sibutramine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289102/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245227, "ingredient1": "Benzhydrocodone", "ingredient2": "Sildenafil", "severity": "Moderate", "effect": "Acute intake of opiates during sildenafil use may result in prolonged erections.  The proposed mechanism is an opiate-induced acute increase in cyclic guanosine monophosphate concentrations in peripheral nerve endings, which can be additive with that produced by sildenafil.  The interaction has been reported specifically with dihydrocodeine but could conceivably occur with other opiates.", "source": "DDInter", "management_text": "Patients using sildenafil should be advised of the potential for prolonged erections during acute intake of opiates, and to contact their physician if problems occur.  The interaction may not occur during chronic use of opiates.", "mechanism_text": "Synergism", "recommendation": "Patients using sildenafil should be advised of the potential for prolonged erections during acute intake of opiates, and to contact their physician if problems occur.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289103/", "reference_text": "[1] Goldmeier D, Lamba H \"Prolonged erections produced by dihydrocodeine and sildenafil.\" BMJ 324 (2002):  1555", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245228, "ingredient1": "Benzhydrocodone", "ingredient2": "Silodosin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289104/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Finasteride, Dutasteride, Tadalafil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245229, "ingredient1": "Benzhydrocodone", "ingredient2": "Siltuximab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289105/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245230, "ingredient1": "Benzhydrocodone", "ingredient2": "Sodium oxybate", "severity": "Major", "effect": "The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects.", "source": "DDInter", "management_text": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.  Otherwise, close monitoring and/or dosage reductions should be considered.  If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.  All patients treated with sodium oxybate should be advised not to drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking the second nightly dose of sodium oxybate and until they know how the medication affects them.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289106/", "reference_text": "[1] \"Product Information. Xyrem (sodium oxybate).\" Orphan Medical  (2002):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Xywav (calcium/magnesium/potass/sodium oxybates).\" Jazz Pharmaceuticals  (2020):", "alternatives_a": "Etomidate, Dalfampridine, Inotersen, Riluzole, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245231, "ingredient1": "Tolevamer", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Coadministration with medications that can cause constipation such as opioids may increase the risk of intestinal injuries associated with the use of sodium polystyrene sulfonate.", "source": "DDInter", "management_text": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.  The prescribing information recommends avoiding the use of sodium polystyrene sulfonate in patients who are at risk for developing constipation or impaction, including those with a history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction, as well as those who have not had a bowel movement post-surgery.  If clinically significant constipation develops, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed.  Concomitant administration of sorbitol is not recommended.", "mechanism_text": "Synergism", "recommendation": "Because opioids commonly cause constipation, caution is advised when used during treatment with sodium polystyrene sulfonate.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289107/", "reference_text": "[1] Foresti V \"Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate.\" Clin Nephrol 41 (1994):  252[2] \"Product Information. Kayexalate (sodium polystyrene sulfonate).\" Sanofi Winthrop Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Deferoxamine, Levoleucovorin, Arginine, Methionine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245232, "ingredient1": "Benzhydrocodone", "ingredient2": "Solifenacin", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289108/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, Phenyl salicylate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245233, "ingredient1": "Benzhydrocodone", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289109/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245234, "ingredient1": "Benzhydrocodone", "ingredient2": "Somatrem", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289110/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245235, "ingredient1": "Benzhydrocodone", "ingredient2": "Somatotropin", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289111/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245236, "ingredient1": "Benzhydrocodone", "ingredient2": "Sotalol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289112/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245237, "ingredient1": "Benzhydrocodone", "ingredient2": "Spironolactone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289115/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Finerenone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245238, "ingredient1": "Benzhydrocodone", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289116/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245239, "ingredient1": "Benzhydrocodone", "ingredient2": "Stiripentol", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289117/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245240, "ingredient1": "Benzhydrocodone", "ingredient2": "Sulfinpyrazone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289119/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Pegloticase, Febuxostat, Colchicine, Rasburicase, Probenecid, Allopurinol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245241, "ingredient1": "Benzhydrocodone", "ingredient2": "Sumatriptan", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289120/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab, Tinidazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245242, "ingredient1": "Benzhydrocodone", "ingredient2": "Suvorexant", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289121/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245243, "ingredient1": "Benzhydrocodone", "ingredient2": "Tamsulosin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289122/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Finasteride, Dutasteride, Tadalafil, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245244, "ingredient1": "Benzhydrocodone", "ingredient2": "Tapentadol", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289123/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245245, "ingredient1": "Benzhydrocodone", "ingredient2": "Tasimelteon", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289124/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245246, "ingredient1": "Benzhydrocodone", "ingredient2": "Tazemetostat", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289125/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245247, "ingredient1": "Benzhydrocodone", "ingredient2": "Telaprevir", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289129/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Simeprevir, Cabotegravir, Valaciclovir, Zanamivir, Velpatasvir, Rilpivirine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245248, "ingredient1": "Benzhydrocodone", "ingredient2": "Telithromycin", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289130/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245249, "ingredient1": "Benzhydrocodone", "ingredient2": "Telmisartan", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289131/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245250, "ingredient1": "Benzhydrocodone", "ingredient2": "Telotristat ethyl", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289132/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245251, "ingredient1": "Benzhydrocodone", "ingredient2": "Temazepam", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289133/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245252, "ingredient1": "Benzhydrocodone", "ingredient2": "Terazosin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289134/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Finasteride, Dutasteride, Tadalafil", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245253, "ingredient1": "Benzhydrocodone", "ingredient2": "Terbinafine", "severity": "Moderate", "effect": "Coadministration with terbinafine may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by terbinafine, which is expected to occur in patients who are CYP450 2D6 extensive metabolizers (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent).", "source": "DDInter", "management_text": "Caution is advised if terbinafine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever terbinafine is added to or withdrawn from therapy.  Due to the long elimination half-life of terbinafine, especially following prolonged use, such interactions may be observed for several months after discontinuation of terbinafine therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if terbinafine must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289135/", "reference_text": "[1] \"Product Information. Lamisil (terbinafine).\" Sandoz Pharmaceuticals Corporation  (2001):[2] Van der Kuy PH, Hooymans PM, Verkaaik AJ \"Nortriptyline intoxication induced by terbinafine.\" BMJ 316 (1998):  441[3] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL \"Investigation of terbinafine as a CYP2D6 inhibitor in vivo.\" Clin Pharmacol Ther 65 (1999):  465-72[4] Gupta AK, Katz HI, Shear NH \"Terbinafine and potential drug interactions - Reply.\" J Am Acad Dermatol 43 (2000):  883-4", "alternatives_a": "Salicylic acid, Selenium Sulfide, Thiabendazole, Nystatin, Ciclopirox, Econazole, Flucytosine, Tioconazole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245254, "ingredient1": "Benzhydrocodone", "ingredient2": "Tetrabenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289136/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dalfampridine, Inotersen, Riluzole, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245255, "ingredient1": "Benzhydrocodone", "ingredient2": "Thalidomide", "severity": "Moderate", "effect": "Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.  Patients should be advised to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  Dosage reductions may be necessary.  Thalidomide should preferably be administered at bedtime to reduce the impact of somnolence.  Alcohol use is not recommended.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289137/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation  (2001):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245256, "ingredient1": "Benzhydrocodone", "ingredient2": "Thiethylperazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289138/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245257, "ingredient1": "Benzhydrocodone", "ingredient2": "Thiopental", "severity": "Moderate", "effect": "Narcotic analgesics may reduce the dosage of barbiturate anesthetics needed to induce anesthesia by as much as 40%.", "source": "DDInter", "management_text": "Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.", "mechanism_text": "Synergism", "recommendation": "Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289139/", "reference_text": "[1] DeLapa RJ \"Influence of alphaprodine hydrochloride on intravenous barbiturate induction dosage.\" J Oral Surg 18 (1960):  163-8[2] Dundee JW, Halliday NJ, McMurray TJ, Harper KW \"Pretreatment with opioids: the effect on thiopentone induction requirements and on the onset of action of midazolam.\" Anaesthesia 41 (1986):  159-61[3] Stambaugh JE, Hemphill DM, Wainer IW, Schwartz I \"A potentially toxic drug interaction between pethidine (meperidine) and phenobarbitone.\" Lancet 1 (1977):  398-9[4] Stambaugh JE, Wainer IW, Schwartz I \"The effect of phenobarbital on the metabolism of meperidine in normal volunteers.\" J Clin Pharmacol 18 (1978):  482-90", "alternatives_a": "Etomidate, Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245258, "ingredient1": "Benzhydrocodone", "ingredient2": "Thioridazine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289140/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245259, "ingredient1": "Benzhydrocodone", "ingredient2": "Thiothixene", "severity": "Major", "effect": "Concomitant use of opioids with central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, antipsychotics).", "source": "DDInter", "management_text": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.  Delayed diagnosis and treatment of constipation may increase the risk of severe complications, which can result in hospitalization, surgery, and death.  Patients should be advised to maintain adequate hydration, physical activity and fiber intake, and to report any changes in the frequency or character of bowel movements as well as signs and symptoms of potential complications of ileus such as nausea, vomiting, abdominal distension, and abdominal pain.  If constipation or gastrointestinal hypomotility is identified, monitor closely and treat promptly with appropriate laxatives to prevent severe complications.  Consider prophylactic laxatives in high risk patients, such as those with a history of constipation, colonic disease, or lower abdominal surgery.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289141/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[3] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. FazaClo (clozapine).\" Jazz Pharmaceuticals  (2015):[7] \"Product Information. Versacloz (clozapine).\" Jazz Pharmaceuticals  (2015):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245260, "ingredient1": "Benzhydrocodone", "ingredient2": "Tiagabine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289142/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245261, "ingredient1": "Benzhydrocodone", "ingredient2": "Ticagrelor", "severity": "Moderate", "effect": "Coadministration with opioid agonists may delay and reduce the absorption of orally administered P2Y12 inhibitors (e.g., clopidogrel, prasugrel, ticagrelor).  The proposed mechanism may involve opioid-mediated slowed gastric emptying.", "source": "DDInter", "management_text": "Although data are limited, caution is recommended when orally administered P2Y12 inhibitors are given concomitantly with opioid agonists.  In acute coronary syndrome patients who require an opioid agonist, the use of a parenteral antiplatelet agent, such as cangrelor, should be considered.", "mechanism_text": "Absorption", "recommendation": "Although data are limited, caution is recommended when orally administered P2Y12 inhibitors are given concomitantly with opioid agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289143/", "reference_text": "[1] \"Product Information. Plavix (clopidogrel).\" Bristol-Myers Squibb  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[5] \"Product Information. Effient (prasugrel).\" Lilly, Eli and Company  (2009):[6] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals  (2011):[7] Hobl EL, Stimpfl T, Ebner J, et al. \"Morphine Decreases Clopidogrel Concentrations and Effects: A Randomized, Double Blind, Placebo-Controlled Trial.\" J Am Coll Cardiol  (2013):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] Hobl EL, Reiter B, Schoergenhofer C, et al. \"Morphine Decreases Ticagrelor Concentrations but not its Antiplatelet Effects: A  Randomized Trial in Healthy Volunteers.\" Eur J Clin Invest 46 (2015):  7-14[10] Hobl EL, Reiter B, Schoergenhofer C, et al. \"Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy  volunteers.\" Clin Res Cardiol 105 (2015):  349-55[11] Kubica J, Adamski P, Ostrowska M, et al. \"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.\" Eur Heart J  (2015):[12] Kubica J, Kubica A, Jilma B, et al. \"Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors.\" Int J Cardiol 215 (2016):  201-208", "alternatives_a": "Betrixaban, Apixaban, Cilostazol, Iloprost, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245262, "ingredient1": "Benzhydrocodone", "ingredient2": "Timolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289144/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, Brinzolamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245263, "ingredient1": "Benzhydrocodone", "ingredient2": "Tizanidine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289145/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245264, "ingredient1": "Benzhydrocodone", "ingredient2": "Tocilizumab", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289146/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245265, "ingredient1": "Benzhydrocodone", "ingredient2": "Tofacitinib", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289147/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245266, "ingredient1": "Tolcapone", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289148/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245267, "ingredient1": "Tolterodine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289149/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, Phenyl salicylate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245268, "ingredient1": "Topiramate", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289150/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245269, "ingredient1": "Torasemide", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289151/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245270, "ingredient1": "Tramadol", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of tramadol with other central nervous system (CNS) depressants including other opioids may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension and seizures may also be increased.", "source": "DDInter", "management_text": "Concomitant use of tramadol with other opioids should generally be avoided.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect.  Patients should be monitored closely for development of seizures, respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients on tramadol.  In addition, tramadol should not be used in opioid-dependent patients, and use in patients who are chronically on opioids is also not recommended.  Tramadol is contraindicated in patients with acute opioid intoxication.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of tramadol with other opioids should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289152/", "reference_text": "[1] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245271, "ingredient1": "Trandolapril", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289153/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245272, "ingredient1": "Tranylcypromine", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.  Concomitant use of pentazocine with MAOIs may also cause CNS excitation and hypertension through their respective effects on catecholamines.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.  However, morphine has been safely used in MAOI-treated patients who previously had an adverse reaction with meperidine and is generally suggested as an alternative to meperidine in anesthesia.  A sensitivity test should be performed in which repeated, small, incremental doses of morphine are administered over the course of several hours while overall clinical status and vital signs are carefully monitored.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289154/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[7] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[8] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[9] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[10] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[14] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] Cerner Multum, Inc. \"Australian Product Information.\" O 0[17] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245273, "ingredient1": "Trazodone", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289155/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245274, "ingredient1": "Triamterene", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289156/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Finerenone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245275, "ingredient1": "Triazolam", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289157/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245276, "ingredient1": "Trichlormethiazide", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289158/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245277, "ingredient1": "Trifluoperazine", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289159/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245278, "ingredient1": "Triflupromazine", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289160/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245279, "ingredient1": "Trihexyphenidyl", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central anticholinergic agents may have additive central nervous system (CNS) effects with cannabinoids, barbiturates, opiates, and alcohol.", "source": "DDInter", "management_text": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.  Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289161/", "reference_text": "[1] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245280, "ingredient1": "Alimemazine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289162/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245281, "ingredient1": "Trimethadione", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289163/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245282, "ingredient1": "Trimethaphan", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289164/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Mecamylamine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245283, "ingredient1": "Trimethobenzamide", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289165/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245284, "ingredient1": "Trimipramine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289166/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245285, "ingredient1": "Tripelennamine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289167/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine, Lidocaine, Tetracaine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245286, "ingredient1": "Triprolidine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289168/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245287, "ingredient1": "Troglitazone", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289169/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Empagliflozin, Dulaglutide, Exenatide, Tolbutamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245288, "ingredient1": "Troleandomycin", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289170/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Dirithromycin, Lincomycin, Azithromycin, Clindamycin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245289, "ingredient1": "Trospium", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289171/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, Phenyl salicylate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245290, "ingredient1": "Tryptophan", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289172/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245291, "ingredient1": "Tucatinib", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289173/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Pralsetinib, Asciminib, Acalabrutinib, Dacomitinib, Pacritinib, Tepotinib, Avapritinib, Bosutinib, Lapatinib, Selumetinib, Vandetanib, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245292, "ingredient1": "Upadacitinib", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289174/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245293, "ingredient1": "Ustekinumab", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin (IL) inhibitors, tumor necrosis factor (TNF) blockers, or interferon (IFN) inhibitors in patients with chronic inflammatory diseases.  Because the formation of hepatic CYP450 enzymes is down-regulated during infection and chronic inflammation by increased levels of certain cytokines (e.g., interleukins-1, -6, and -10; tumor necrosis factor alpha; interferons), treatment targeting these cytokines may restore or normalize CYP450 enzyme levels resulting in increased metabolism of these drugs.", "source": "DDInter", "management_text": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.g., antiarrhythmics, anticonvulsants, immunosuppressants, theophylline) or sensitive substrates where decreases in plasma levels may be significant or undesirable (e.g., oral contraceptives, statins, benzodiazepines, opioids).  Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of such treatments, and the dosage(s) of the CYP450 substrate(s) adjusted accordingly.  Clinicians should note that the effects of IL inhibitors, TNF blockers, and IFN inhibitors on CYP450 activities may persist for several weeks after stopping therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when treatments targeting cytokines such as interleukins, tumor necrosis factors, or interferons are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289175/", "reference_text": "[1] \"Product Information. Remicade (infliximab).\" Centocor Inc  (2001):[2] \"Product Information. Amevive (alefacept).\" Biogen  (2003):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Arcalyst (rilonacept).\" Regeneron Pharmaceuticals Inc  (2008):[5] \"Product Information. Stelara (ustekinumab).\" Centocor Inc  (2009):[6] \"Product Information. Simponi (golimumab).\" Centocor Inc  (2009):[7] \"Product Information. Ilaris (canakinumab).\" Novartis Pharmaceuticals  (2009):[8] \"Product Information. Actemra (tocilizumab).\" Genentech  (2010):[9] \"Product Information. Sylvant (siltuximab).\" Janssen Biotech, Inc.  (2014):[10] \"Product Information. Cosentyx (secukinumab).\" Novartis Pharmaceuticals  (2015):[11] \"Product Information. Taltz Autoinjector (ixekizumab).\" Eli Lilly and Company  (2016):[12] \"Product Information. Kevzara (sarilumab).\" sanofi-aventis  (2017):[13] \"Product Information. Ilumya (tildrakizumab).\" Merck & Co., Inc  (2018):[14] \"Product Information. Gamifant (emapalumab).\" Sobi Inc  (2018):[15] \"Product Information. Skyrizi (risankizumab).\" AbbVie US LLC  (2019):", "alternatives_a": "Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Siponimod, Apremilast, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245294, "ingredient1": "Valbenazine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289176/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dalfampridine, Inotersen, Riluzole, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245295, "ingredient1": "Valerian", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289177/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245296, "ingredient1": "Valsartan", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289178/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245297, "ingredient1": "Vemurafenib", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289179/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245298, "ingredient1": "Venlafaxine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289180/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245299, "ingredient1": "Verapamil", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289181/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245300, "ingredient1": "Vigabatrin", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289182/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245301, "ingredient1": "Vilazodone", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289183/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245302, "ingredient1": "Voriconazole", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289184/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245303, "ingredient1": "Vortioxetine", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289185/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Viloxazine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245304, "ingredient1": "Voxelotor", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of hydrocodone, which is substantially metabolized by the isoenzyme.  Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.  Because hydrocodone is also partially metabolized by CYP450 2D6, the magnitude of interaction may be even greater with concomitant use of a CYP450 3A4 and a CYP450 2D6 inhibitor, or concomitant use of a drug that is a dual inhibitor of both isoenzymes.", "source": "DDInter", "management_text": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.g., azole antifungal agents, protease inhibitors, aprepitant, ceritinib, ciprofloxacin, chloramphenicol, clarithromycin, cobicistat, conivaptan, crizotinib, delavirdine, diltiazem, dronedarone, erythromycin, fusidic acid, idelalisib, imatinib, letermovir, mibefradil, mifepristone, nefazodone, netupitant, quinupristin-dalfopristin, telithromycin, verapamil) or weak inhibitors that also inhibit CYP450 2D6 (e.g., abiraterone, amiodarone, cimetidine, pazopanib, ranolazine).  A fatal overdose may occur following the initiation of a CYP450 3A4 inhibitor in patients already receiving hydrocodone.  Patients should be closely monitored for signs and symptoms of sedation, respiratory depression, and hypotension.  Following discontinuation of the CYP450 3A4 inhibitor, patients should be monitored for reduced efficacy of hydrocodone or development of withdrawal symptoms due to reduced plasma hydrocodone levels.", "mechanism_text": "Metabolism", "recommendation": "Extreme caution is advised if hydrocodone is prescribed with CYP450 3A4 inhibitors, particularly potent and moderate inhibitors (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289186/", "reference_text": "[1] Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA \"CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.\" Br J Clin Pharmacol 57 (2004):  287-97[2] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):", "alternatives_a": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245305, "ingredient1": "Zaleplon", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289187/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245306, "ingredient1": "Ziconotide", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289188/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Salsalate, Acetylsalicylic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245307, "ingredient1": "Ziprasidone", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289189/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245308, "ingredient1": "Zolmitriptan", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289190/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245309, "ingredient1": "Zolpidem", "ingredient2": "Benzhydrocodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289191/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245310, "ingredient1": "Zonisamide", "ingredient2": "Benzhydrocodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289192/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245311, "ingredient1": "Butalbital", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289194/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Chlorcyclizine, Azelastine, Fexofenadine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, Meclizine, Cyclizine, More", "alternatives_b": "Nitrazepam, Zopiclone", "updated_at": 1767369485}, {"id": 245312, "ingredient1": "Butalbital", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289195/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Suvorexant, Nitrazepam, Thiopental, Eszopiclone, Ramelteon, Scopolamine, Lemborexant, Methohexital, Estazolam, Zopiclone, Tasimelteon, More", "alternatives_b": "Irbesartan, Candesartan, Eprosartan, Olmesartan, Irbesartan, Hydrochlorothiazide, Olmesartan, Candesartan, Eprosartan, Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 245313, "ingredient1": "Diamorphine", "ingredient2": "Butalbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289198/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Zopiclone", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 245314, "ingredient1": "Butalbital", "ingredient2": "Levobupivacaine", "severity": "Minor", "effect": "Coadministration with inducers of CYP450 1A2 and/or 3A4 may decrease the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.", "source": "DDInter", "management_text": "However, the clinical significance is unknown, as the interaction has not been studied nor reported in the medical literature.", "mechanism_text": "Metabolism", "recommendation": "However, the clinical significance is unknown, as the interaction has not been studied nor reported in the medical literature.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289200/", "reference_text": "[1] \"Product Information. Chirocaine (levobupivacaine).\" Organon  (2001):", "alternatives_a": "Suvorexant, Methohexital, Zolpidem, Zaleplon, Dichloralphenazone, Valerian, Chloral hydrate, Paraldehyde, Ramelteon, Lemborexant, Ethchlorvynol, More", "alternatives_b": "Ropivacaine, Chloroprocaine, Bupivacaine, Tetracaine, Mepivacaine, Meloxicam, Procaine, Prilocaine, Articaine, Etidocaine", "updated_at": 1767369485}, {"id": 245315, "ingredient1": "Butalbital", "ingredient2": "Phenacemide", "severity": "Minor", "effect": "A study with ethylphenacemide has suggested that phenacemide may increase serum levels of barbiturates.  The mechanism is unknown.", "source": "DDInter", "management_text": "The combination of ethylphenacemide and barbiturates is not clinically frequent and their concomitant use is generally not recommended.", "mechanism_text": "Others", "recommendation": "The combination of ethylphenacemide and barbiturates is not clinically frequent and their concomitant use is generally not recommended.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289203/", "reference_text": "[1] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):", "alternatives_a": "Nitrazepam, Chloral hydrate, Paraldehyde, Propiomazine, Ethchlorvynol, Zopiclone", "alternatives_b": "Lacosamide, Methylphenobarbital", "updated_at": 1767369485}, {"id": 245316, "ingredient1": "Butalbital", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289204/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Ethchlorvynol, Zopiclone, Amobarbital, Dichloralphenazone", "alternatives_b": "Levomilnacipran, Oxitriptan, Viloxazine, Milnacipran, Tryptophan", "updated_at": 1767369485}, {"id": 245317, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Chlorpheniramine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289206/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245318, "ingredient1": "Diamorphine", "ingredient2": "Chlorpheniramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289207/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, Tripelennamine, Azelastine, Cyclizine, More", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 245319, "ingredient1": "Chlorpheniramine", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289208/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Methdilazine, Azatadine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, Astemizole, Desloratadine, More", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 245320, "ingredient1": "Codeine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289209/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone, Benzonatate, Clofedanol, Dextromethorphan, Pentoxyverine", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 245321, "ingredient1": "Codeine", "ingredient2": "Benazepril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289210/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tapentadol, Naloxone, Dezocine, Oxymorphone, Benzonatate, Clofedanol, Dextromethorphan, Pentoxyverine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245322, "ingredient1": "Eplerenone", "ingredient2": "Codeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289211/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Dezocine, Tramadol, Methadone, Naloxone, Nalbuphine, Benzonatate, Clofedanol, More", "alternatives_b": "Finerenone", "updated_at": 1767369485}, {"id": 245323, "ingredient1": "Guanfacine", "ingredient2": "Codeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289212/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Acetaminophen, Dezocine, Tramadol, Methadone, Ibuprofen, Celecoxib, Acetylsalicylic acid, More", "alternatives_b": "Rauwolfia serpentina root, Deserpidine", "updated_at": 1767369485}, {"id": 245324, "ingredient1": "Diamorphine", "ingredient2": "Codeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289213/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Benzonatate", "alternatives_b": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 245325, "ingredient1": "Codeine", "ingredient2": "Methyldopa", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289214/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tapentadol, Oxymorphone, Butorphanol, Dezocine, Naloxone, Benzonatate, Pentoxyverine", "alternatives_b": "Rauwolfia serpentina root, Deserpidine", "updated_at": 1767369485}, {"id": 245326, "ingredient1": "Codeine", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289215/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone, Benzonatate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245327, "ingredient1": "Codeine", "ingredient2": "Reserpine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289217/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Acetaminophen, Dezocine, Tramadol, Opium, Dextropropoxyphene, Ibuprofen, Celecoxib, More", "alternatives_b": "Rauwolfia serpentina root, Deserpidine, Rauwolfia serpentina root, Deserpidine", "updated_at": 1767369485}, {"id": 245328, "ingredient1": "Codeine", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Coadministration of codeine or dihydrocodeine with CYP450 3A4 inducers such as St. John's Wort may result in lower codeine or dihydrocodeine plasma concentrations, higher levels of the inactive metabolite norcodeine or dihydronorcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine or dihydromorphine levels, respectively.", "source": "DDInter", "management_text": "Caution and clinical monitoring are advised if codeine or dihydrocodeine are to be used in combination with St. John's Wort, particularly when it is added to or withdrawn from therapy.  Dosage adjustments may be required.  Some manufacturers of products containing codeine recommend against using codeine concomitantly with CYP450 3A4 inducers.  Patients should be advised to monitor for symptoms of serotonin excess or serotonin syndrome.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately, and supportive care rendered as necessary.  Patients should also be advised to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these medications affect them.", "mechanism_text": "Metabolism", "recommendation": "Caution and clinical monitoring are advised if codeine or dihydrocodeine are to be used in combination with St.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289218/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Trezix (acetaminophen/caffeine/dihydrocodeine).\" WraSer Pharmaceuticals  (2016):[7] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[8] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6[9] \"Product Information. Dvorah (acetaminophen/caffeine/dihydrocodeine).\" Skylar Laboratories  (2020):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone, Benzonatate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245329, "ingredient1": "Codeine", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289219/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245330, "ingredient1": "Codeine", "ingredient2": "Upadacitinib", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289221/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, Methadone, Naloxone, More", "alternatives_b": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "updated_at": 1767369485}, {"id": 245331, "ingredient1": "Codeine", "ingredient2": "Verapamil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289222/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone, Benzonatate, Clofedanol, Pentoxyverine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245332, "ingredient1": "Amlodipine", "ingredient2": "Diphenhydramine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289223/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Aliskiren, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate, More", "alternatives_b": "Tripelennamine, Clemastine, Tetracaine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, More", "updated_at": 1767369485}, {"id": 245333, "ingredient1": "Diphenhydramine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289224/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Lidocaine, Clemastine, Tetracaine, Tripelennamine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, More", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 245334, "ingredient1": "Diphenhydramine", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289225/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Lidocaine, Clemastine, Tetracaine, Tripelennamine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, More", "updated_at": 1767369485}, {"id": 245335, "ingredient1": "Diphenhydramine", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289226/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Lidocaine, Clemastine, Tetracaine, Tripelennamine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, More", "updated_at": 1767369485}, {"id": 245336, "ingredient1": "Diphenhydramine", "ingredient2": "Chlorothiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289227/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Lidocaine, Clemastine, Tetracaine, Tripelennamine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, More", "updated_at": 1767369485}, {"id": 245337, "ingredient1": "Diphenhydramine", "ingredient2": "Chlorthalidone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289228/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Tripelennamine, Clemastine, Tetracaine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, More", "updated_at": 1767369485}, {"id": 245338, "ingredient1": "Felodipine", "ingredient2": "Diphenhydramine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289229/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tripelennamine, Clemastine, Tetracaine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, More", "alternatives_b": "Acetylsalicylic acid, Ivabradine, Celecoxib", "updated_at": 1767369485}, {"id": 245339, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Diphenhydramine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289230/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "Lidocaine, Tetracaine, Ketotifen, Levocetirizine, Cetirizine, Fexofenadine, Loratadine, Trimethobenzamide, Desloratadine, Azelastine, Terfenadine, Astemizole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245340, "ingredient1": "Diphenhydramine", "ingredient2": "Diamorphine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289231/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tripelennamine, Lidocaine, Tetracaine, Methdilazine, Azatadine, Ketotifen, Alimemazine, Fexofenadine, Loratadine, Phenindamine, Desloratadine, More", "alternatives_b": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 245341, "ingredient1": "Hydroflumethiazide", "ingredient2": "Diphenhydramine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289232/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Lidocaine, Clemastine, Tetracaine, Tripelennamine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, More", "alternatives_b": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 245342, "ingredient1": "Indapamide", "ingredient2": "Diphenhydramine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289233/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tripelennamine, Clemastine, Tetracaine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, More", "alternatives_b": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "updated_at": 1767369485}, {"id": 245343, "ingredient1": "Isradipine", "ingredient2": "Diphenhydramine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289234/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Lidocaine, Clemastine, Tetracaine, Tripelennamine, Doxepin, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, More", "alternatives_b": "Celecoxib", "updated_at": 1767369485}, {"id": 245344, "ingredient1": "Diphenhydramine", "ingredient2": "Methyldopa", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289235/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Lidocaine, Clemastine, Tetracaine, Tripelennamine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Triprolidine, Tripelennamine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245345, "ingredient1": "Diphenhydramine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289236/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tripelennamine, Clemastine, Tetracaine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, More", "alternatives_b": "Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "updated_at": 1767369485}, {"id": 245346, "ingredient1": "Diphenhydramine", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289237/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Clemastine, Tetracaine, Pheniramine, Tripelennamine, Doxepin, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, More", "alternatives_b": "Celecoxib", "updated_at": 1767369485}, {"id": 245347, "ingredient1": "Diphenhydramine", "ingredient2": "Nifedipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289238/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tripelennamine, Clemastine, Tetracaine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, More", "alternatives_b": "Celecoxib, Acetylsalicylic acid, Ivabradine", "updated_at": 1767369485}, {"id": 245348, "ingredient1": "Diphenhydramine", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289239/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Lidocaine, Clemastine, Tetracaine, Tripelennamine, Doxepin, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, More", "alternatives_b": "Celecoxib", "updated_at": 1767369485}, {"id": 245349, "ingredient1": "Diphenhydramine", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289240/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tripelennamine, Clemastine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245350, "ingredient1": "Diphenhydramine", "ingredient2": "Polythiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289241/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Lidocaine, Clemastine, Tetracaine, Tripelennamine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, More", "alternatives_b": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "updated_at": 1767369485}, {"id": 245351, "ingredient1": "Diphenhydramine", "ingredient2": "St. John's Wort", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289242/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tetracaine, Pheniramine, Methdilazine, Azatadine, Ketotifen, Meclizine, Chlorcyclizine, Thiethylperazine, Dexchlorpheniramine, Loratadine, Phenindamine, More", "alternatives_b": "Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone", "updated_at": 1767369485}, {"id": 245352, "ingredient1": "Diphenhydramine", "ingredient2": "Valsartan", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289243/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tripelennamine, Clemastine, Tetracaine, Pheniramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, More", "alternatives_b": "Sacubitril, Aliskiren, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "updated_at": 1767369485}, {"id": 245353, "ingredient1": "Diphenhydramine", "ingredient2": "Verapamil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289244/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tripelennamine, Clemastine, Tetracaine, Pheniramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245354, "ingredient1": "Ibuprofen", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289245/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Black cohosh, Bromocriptine, Alprostadil, Ranolazine, Ubidecarenone, Ivabradine, Adenosine, Regadenoson, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 245355, "ingredient1": "Ibuprofen", "ingredient2": "Brentuximab vedotin", "severity": "Moderate", "effect": "Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity may potentiate the risk of liver injury.", "source": "DDInter", "management_text": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; HIV reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice).  Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.  Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations.  Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.", "mechanism_text": "Synergism", "recommendation": "The risk of hepatic injury should be considered when brentuximab vedotin is used with other agents that are potentially hepatotoxic (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289246/", "reference_text": "[1] \"Product Information. Adcetris (brentuximab vedotin).\" Seattle Genetics Inc  (2011):", "alternatives_a": "Ritodrine, Bremelanotide, Bromocriptine, Cabergoline, Alprostadil, Ubidecarenone, Ivabradine, Adenosine, Regadenoson, Rabeprazole, Misoprostol, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 245356, "ingredient1": "Ibuprofen", "ingredient2": "Diroximel fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289247/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Siponimod, More", "alternatives_b": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Bromocriptine, Alprostadil, Indomethacin, Ranolazine, Ivabradine, Ubidecarenone, Adenosine, More", "updated_at": 1767369485}, {"id": 245357, "ingredient1": "Ibuprofen", "ingredient2": "Ibritumomab tiuxetan", "severity": "Major", "effect": "Coadministration of radiolabeled ibritumomab tiuxetan and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Caution is advised if radiolabeled ibritumomab tiuxetan is used in combination with drugs that interfere with platelet function or coagulation.  Close clinical and laboratory observation for bleeding complications is recommended during and after treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if radiolabeled ibritumomab tiuxetan is used in combination with drugs that interfere with platelet function or coagulation.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289248/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab tiuxetan).\" IDEC Pharmaceuticals Corporation", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Alprostadil, Ranolazine, Ubidecarenone, Ivabradine, Adenosine, More", "alternatives_b": "Iodide I-131", "updated_at": 1767369485}, {"id": 245358, "ingredient1": "Ibuprofen", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity (e.g., aminoglycosides, diuretics, nonsteroidal anti-inflammatory drugs, cyclosporine, lithium, methotrexate) may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "The use of fumaric acid esters in patients who receive concomitant treatment with potentially nephrotoxic agents, particularly for longer durations, has not been evaluated and should be approached with caution.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289249/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Bromocriptine, Alprostadil, Indomethacin, Ranolazine, Ivabradine, Ubidecarenone, Adenosine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245359, "ingredient1": "Ibuprofen", "ingredient2": "Tafasitamab", "severity": "Moderate", "effect": "Coadministration of tafasitamab with drugs that can affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextrans, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of bleeding.", "source": "DDInter", "management_text": "When possible, consideration should be given to withholding concomitant medications that may increase bleeding risk in patients treated with tafasitamab.  Close clinical and laboratory monitoring for bleeding complications is recommended if concomitant use is unavoidable.  Refer to the product labeling for guidance on frequency of laboratory monitoring and dose modifications or withholding recommendations for platelet counts below 50,000/mcL.  Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "When possible, consideration should be given to withholding concomitant medications that may increase bleeding risk in patients treated with tafasitamab.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289251/", "reference_text": "[1] \"Product Information. Monjuvi (tafasitamab).\" Morphosys US  (2020):[2] \"Product Information. Minjuvi (tafasitamab).\" Incyte Biosciences UK Ltd  (2022):[3] \"Product Information. Minjuvi (tafasitamab).\" Incyte Corporation  (2021):", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Alprostadil, Indomethacin, Ranolazine, Ivabradine, Ubidecarenone, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 245360, "ingredient1": "Ibuprofen", "ingredient2": "Upadacitinib", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289252/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Ritodrine, Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Alprostadil, Indomethacin, Ranolazine, Ivabradine, Ubidecarenone, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Siponimod, More", "updated_at": 1767369485}, {"id": 245361, "ingredient1": "Azilsartan medoxomil", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289253/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "alternatives_b": "Sacubitril, Aliskiren", "updated_at": 1767369485}, {"id": 245362, "ingredient1": "Chlorothiazide", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289255/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Methazolamide, Trichlormethiazide, Tioconazole, Brinzolamide, Diiodohydroxyquinoline, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245363, "ingredient1": "Eplerenone", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289256/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Finerenone", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Dezocine, Tramadol, Methadone, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245364, "ingredient1": "Guanfacine", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289257/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Rauwolfia serpentina root, Deserpidine", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Acetaminophen, Dezocine, Tramadol, Methadone, Ibuprofen, Celecoxib, Acetylsalicylic acid, More", "updated_at": 1767369485}, {"id": 245365, "ingredient1": "Diamorphine", "ingredient2": "Oxycodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289258/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid", "alternatives_b": "Nalmefene, Disulfiram", "updated_at": 1767369485}, {"id": 245366, "ingredient1": "Oxycodone", "ingredient2": "Methyldopa", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289259/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Rauwolfia serpentina root, Deserpidine", "alternatives_b": "Tapentadol, Oxymorphone, Butorphanol, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245367, "ingredient1": "Oxycodone", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289260/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245368, "ingredient1": "Reserpine", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289262/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Acetaminophen, Dezocine, Tramadol, Opium, Dextropropoxyphene, Ibuprofen, Celecoxib, More", "alternatives_b": "Rauwolfia serpentina root, Deserpidine, Rauwolfia serpentina root, Deserpidine", "updated_at": 1767369485}, {"id": 245369, "ingredient1": "Somapacitan", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, methadone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289263/", "reference_text": "[1] Holmes VF \"Rifampin-induced methadone withdrawal in AIDS.\" J Clin Psychopharmacol 10 (1991):  443-4[2] Liu S-J, Wang RI \"Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome.\" Am J Psychiatry 141 (1984):  1287-8[3] Bell J, Seres V, Bowron P, Lewis J, Batey R \"The use of serum methadone levels in patients receiving methadone maintenance.\" Clin Pharmacol Ther 43 (1988):  623-9[4] Finelli PF \"Phenytoin and methadone tolerance.\" N Engl J Med 294 (1976):  227[5] Tong TG, Pond SM, Kreek MJ, et al. \"Phenytoin-induced methadone withdrawal.\" Ann Intern Med 94 (1981):  349-51[6] Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM \"Rifampin-induced methadone withdrawal.\" N Engl J Med 294 (1976):  1104-6[7] Bending MR, Skacel PO \"Rifampicin and methadone withdrawal.\" Lancet 1 (1977):  1211[8] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[9] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[10] Raistrick D, Hay A, Wolff K \"Methadone maintenance and tuberculosis treatment.\" BMJ 313 (1996):  925-6[11] Altice FL, Friedland GH, Cooney EL \"Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.\" AIDS 13 (1999):  957-62[12] Otero MJ, Fuertes A, Sanchez R, Luna G \"Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.\" AIDS 13 (1999):  1004-5[13] Pinzani V, Faucherre V, Peyriere H, Blayac JP \"Methadone withdrawal symptoms with nevirapine and efavirenz.\" Ann Pharmacother 34 (2000):  405-7[14] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[15] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[16] \"Product Information. Diskets (methadone).\" Cebert Pharmaceuticals Inc  (2007):[17] Cerner Multum, Inc. \"Australian Product Information.\" O 0[18] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[19] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate", "updated_at": 1767369485}, {"id": 245370, "ingredient1": "St. John's Wort", "ingredient2": "Oxycodone", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289264/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245371, "ingredient1": "Telotristat ethyl", "ingredient2": "Oxycodone", "severity": "Major", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of opioids that are primarily metabolized by the isoenzyme such as butorphanol, fentanyl, hydrocodone, and oxycodone.  Reduced efficacy or withdrawal symptoms may occur in patients maintained on their narcotic pain regimen following the addition of a CYP450 3A4 inducer.  Conversely, discontinuation of the inducer may increase opioid plasma concentrations and potentiate the risk of overdose and fatal respiratory depression.", "source": "DDInter", "management_text": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "Pharmacologic response to the opioid should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the opioid dosage adjusted as necessary.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289265/", "reference_text": "[1] \"Product Information. Mycobutin (rifabutin).\" Pharmacia and Upjohn  (2001):[2] \"Product Information. Rifadin (rifampin).\" Hoechst Marion Roussel  (2001):[3] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[4] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[5] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[6] \"Product Information. Ionsys (fentanyl).\" Ortho McNeil Pharmaceutical  (2006):[7] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[8] Cerner Multum, Inc. \"Australian Product Information.\" O 0[9] \"Product Information. Zohydro ER (hydrocodone).\" Zogenix, Inc  (2013):[10] \"Product Information. Butorphanol Tartrate (butorphanol).\" Apotex Corporation  (2017):", "alternatives_a": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245372, "ingredient1": "Upadacitinib", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289267/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, Methadone, Naloxone, Nalbuphine", "alternatives_b": "Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Siponimod, Apremilast, Inebilizumab, Cladribine, Belumosudil, Belimumab, More", "updated_at": 1767369485}, {"id": 245373, "ingredient1": "Botulinum toxin type A", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289268/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "Atracurium, Doxacurium, Succinylcholine, Rocuronium, Vecuronium, Tubocurarine, Mivacurium, Pancuronium, Pipecuronium, Cisatracurium", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245374, "ingredient1": "Aclidinium", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289271/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, Cromoglicic acid, Betamethasone, Nedocromil, Triamcinolone, Beclomethasone dipropionate, Mometasone furoate, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245375, "ingredient1": "Acrivastine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289272/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245376, "ingredient1": "Alfentanil", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289273/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245377, "ingredient1": "Alprazolam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289274/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245378, "ingredient1": "Amantadine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "The anticholinergic-like adverse effects of amantadine may be potentiated by agents with anticholinergic properties such as antihistamines, antispasmodics, class IA antiarrhythmics, neuroleptics, phenothiazines, skeletal muscle relaxants, and tricyclic antidepressants.", "source": "DDInter", "management_text": "Caution is advised when amantadine is used in combination with anticholinergic agents, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic and/or amantadine dosage may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when amantadine is used in combination with anticholinergic agents, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289275/", "reference_text": "[1] Postma JU, van Tilburg W \"Visual hallucinations and delirium during treatment with amantadine (Symmetrel).\" J Am Geriatr Soc 23 (1975):  212-5[2] \"Product Information. Symmetrel (amantadine).\" DuPont Pharmaceuticals  (2002):", "alternatives_a": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245379, "ingredient1": "Amitriptyline", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289276/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245380, "ingredient1": "Amobarbital", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289277/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245381, "ingredient1": "Amoxapine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289278/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245382, "ingredient1": "Phenyltoloxamine", "ingredient2": "Apomorphine", "severity": "Moderate", "effect": "Central nervous system (CNS) depressant effects may be additively or synergistically increased in patients using apomorphine in combination with other drugs that can also cause these effects.", "source": "DDInter", "management_text": "The use of other sedating drugs should generally be avoided during apomorphine treatment.  Patients prescribed these agents concurrently should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.  Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  If patients experience increased episodes of falling asleep during normal daily activities, they should avoid driving and other potentially hazardous activities until they have contacted their physician.", "mechanism_text": "Synergism", "recommendation": "The use of other sedating drugs should generally be avoided during apomorphine treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289279/", "reference_text": "[1] \"Product Information. Apokyn (apomorphine).\" Mylan Pharmaceuticals Inc  (2004):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245383, "ingredient1": "Phenyltoloxamine", "ingredient2": "Aripiprazole", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289281/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245384, "ingredient1": "Phenyltoloxamine", "ingredient2": "Asenapine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289282/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245385, "ingredient1": "Phenyltoloxamine", "ingredient2": "Atropine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289283/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketorolac, Homatropine, Ephedrine, Tropicamide, Phenylephrine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245386, "ingredient1": "Azatadine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289284/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245387, "ingredient1": "Baclofen", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289285/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245388, "ingredient1": "Belladonna", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289286/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245389, "ingredient1": "Benzatropine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289287/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245390, "ingredient1": "Biperiden", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289288/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245391, "ingredient1": "Brexanolone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.  Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring.  During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation.  After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate.  If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia.  Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.  Patients must be accompanied during interactions with their child(ren) while receiving brexanolone because of the potential for excessive sedation and sudden loss of consciousness.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289289/", "reference_text": "[1] \"Product Information. Zulresso (brexanolone).\" Sage Therapeutics, Inc.  (2019):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245392, "ingredient1": "Brexpiprazole", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289290/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245393, "ingredient1": "Brimonidine (ophthalmic)", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.  Additive hypotensive effects and orthostasis may also occur with some CNS depressants and other agents that have these effects, particularly during initial dosing and/or parenteral administration.", "source": "DDInter", "management_text": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289291/", "reference_text": "[1] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[2] \"Product Information. Alphagan (brimonidine ophthalmic).\" Allergan Inc  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Pekdemir M, Yanturali S, Karakus G \"More than just an ocular solution.\" Emerg Med J 22 (2005):  753-4[5] \"Product Information. Mirvaso (brimonidine topical).\" Galderma Laboratories Inc  (2013):", "alternatives_a": "Tacrolimus, Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245394, "ingredient1": "Brimonidine (topical)", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.  Additive hypotensive effects and orthostasis may also occur with some CNS depressants and other agents that have these effects, particularly during initial dosing and/or parenteral administration.", "source": "DDInter", "management_text": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289292/", "reference_text": "[1] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[2] \"Product Information. Alphagan (brimonidine ophthalmic).\" Allergan Inc  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Pekdemir M, Yanturali S, Karakus G \"More than just an ocular solution.\" Emerg Med J 22 (2005):  753-4[5] \"Product Information. Mirvaso (brimonidine topical).\" Galderma Laboratories Inc  (2013):", "alternatives_a": "Tacrolimus, Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245395, "ingredient1": "Brivaracetam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289293/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245396, "ingredient1": "Bromocriptine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289294/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole, Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245397, "ingredient1": "Brompheniramine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289295/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245398, "ingredient1": "Buprenorphine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289296/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245399, "ingredient1": "Buspirone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289297/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245400, "ingredient1": "Butabarbital", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289298/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245401, "ingredient1": "Butalbital", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289299/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245402, "ingredient1": "Butorphanol", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289300/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245403, "ingredient1": "Candida albicans", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Antihistamines may diminish the response to diagnostic skin test antigens.", "source": "DDInter", "management_text": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "mechanism_text": "Antagonism", "recommendation": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289301/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] NLM. National Library of Medicine. NIH. National Institutes of Health \"Trichophyton for intradermal skin testing (trichophyton mentagrophytes and trichophyton rubrum) injection [Allermed Laboratories, Inc.]  http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaeffe62-b538-43ca-a3b9-47e28b765d89\"   (2014):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245404, "ingredient1": "Cannabidiol", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289302/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245405, "ingredient1": "Carbamazepine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289305/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245406, "ingredient1": "Phenyltoloxamine", "ingredient2": "Pentoxyverine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289306/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245407, "ingredient1": "Carbinoxamine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289307/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245408, "ingredient1": "Cariprazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289308/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245409, "ingredient1": "Carisoprodol", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289309/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245410, "ingredient1": "Cenobamate", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289310/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245411, "ingredient1": "Cetirizine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289311/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc  (2007):", "alternatives_a": "Ketotifen, Olopatadine, Cromoglicic acid, Nedocromil, Phenylephrine, Azelastine, Brimonidine, Ketotifen, Fexofenadine, Loratadine, Astemizole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245412, "ingredient1": "Clofedanol", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289312/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245413, "ingredient1": "Chloral hydrate", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289313/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245414, "ingredient1": "Chlorcyclizine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289314/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245415, "ingredient1": "Chlordiazepoxide", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289315/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245416, "ingredient1": "Chlormezanone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289316/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245417, "ingredient1": "Chlorphenesin", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289317/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Terbinafine, Econazole, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245418, "ingredient1": "Chlorpheniramine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289318/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245419, "ingredient1": "Chlorpromazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289319/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245420, "ingredient1": "Chlorzoxazone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289320/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245421, "ingredient1": "Citalopram", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289321/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245422, "ingredient1": "Clemastine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289322/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245423, "ingredient1": "Clidinium", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289323/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245424, "ingredient1": "Clobazam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289324/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245425, "ingredient1": "Clomipramine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289325/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245426, "ingredient1": "Clonazepam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289326/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245427, "ingredient1": "Clonidine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289327/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245428, "ingredient1": "Clorazepic acid", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289328/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245429, "ingredient1": "Clozapine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289329/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245430, "ingredient1": "Coccidioides immitis spherule", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Antihistamines may diminish the response to diagnostic skin test antigens.", "source": "DDInter", "management_text": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "mechanism_text": "Antagonism", "recommendation": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289330/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] NLM. National Library of Medicine. NIH. National Institutes of Health \"Trichophyton for intradermal skin testing (trichophyton mentagrophytes and trichophyton rubrum) injection [Allermed Laboratories, Inc.]  http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaeffe62-b538-43ca-a3b9-47e28b765d89\"   (2014):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245431, "ingredient1": "Codeine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289331/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone, Benzonatate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245432, "ingredient1": "Cyclizine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289332/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245433, "ingredient1": "Cyclobenzaprine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289333/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245434, "ingredient1": "Cyproheptadine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289334/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245435, "ingredient1": "Dantrolene", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289335/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245436, "ingredient1": "Darifenacin", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289337/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245437, "ingredient1": "Demecarium (ophthalmic)", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289339/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245438, "ingredient1": "Desipramine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289340/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245439, "ingredient1": "Desvenlafaxine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289341/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245440, "ingredient1": "Deutetrabenazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289342/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245441, "ingredient1": "Dexbrompheniramine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289343/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245442, "ingredient1": "Dextromethorphan", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289345/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate, Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245443, "ingredient1": "Dezocine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289346/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245444, "ingredient1": "Diazepam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289347/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245445, "ingredient1": "Dicyclomine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289348/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245446, "ingredient1": "Dimenhydrinate", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289350/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245447, "ingredient1": "Diphenhydramine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289351/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245448, "ingredient1": "Disopyramide", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289352/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Quinidine, Amiodarone, Dronedarone, Lidocaine, Propafenone, Procainamide, Tocainide, Flecainide, Mexiletine, Dofetilide, Bretylium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245449, "ingredient1": "Valproic acid", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289353/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245450, "ingredient1": "Donepezil", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.  For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible.  Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered.  For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.  Caution is required, however, since anticholinergic withdrawal may occur.  Seizures have been reported following abrupt discontinuation of anticholinergics during acetylcholinesterase inhibitor therapy.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289354/", "reference_text": "[1] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991):  1825-32[2] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998):  8-13[3] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002):  836-42[4] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002):  1165-6[5] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003):  2716-2724[6] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004):  2082-7", "alternatives_a": "Ginkgo biloba, Aducanumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245451, "ingredient1": "Doxepin", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289355/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245452, "ingredient1": "Doxepin (topical)", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289356/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245453, "ingredient1": "Doxylamine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289357/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245454, "ingredient1": "Dronabinol", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289358/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245455, "ingredient1": "Droperidol", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289359/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245456, "ingredient1": "Duloxetine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289360/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245457, "ingredient1": "Echothiophate (ophthalmic)", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289361/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245458, "ingredient1": "Eluxadoline", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.  Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs.  Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289362/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc.  (2015):", "alternatives_a": "Diphenoxylate, Difenoxin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245459, "ingredient1": "Escitalopram", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289363/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245460, "ingredient1": "Esketamine", "ingredient2": "Phenyltoloxamine", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289364/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245461, "ingredient1": "Eslicarbazepine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289365/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245462, "ingredient1": "Estazolam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289366/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245463, "ingredient1": "Eszopiclone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289367/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245464, "ingredient1": "Ethanol", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.  Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.", "source": "DDInter", "management_text": "Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.  Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289368/", "reference_text": "[1] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986):  31-7[2] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[5] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245465, "ingredient1": "Ethosuximide", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289369/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245466, "ingredient1": "Ethotoin", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289370/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245467, "ingredient1": "Ezogabine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289371/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245468, "ingredient1": "Fenfluramine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289372/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dexfenfluramine, Naltrexone, Ephedrine, Bupropion, Phentermine, Orlistat, Lorcaserin, Sibutramine, Diethylpropion, Mazindol, Tiagabine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245469, "ingredient1": "Fentanyl", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289373/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Naltrexone, Acetaminophen, Ibuprofen, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245470, "ingredient1": "Fesoterodine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289374/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245471, "ingredient1": "Flavoxate", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289375/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245472, "ingredient1": "Flibanserin", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "The central nervous system (CNS) effects of flibanserin such as somnolence and fatigue may be potentiated by concomitant use of other agents with CNS depressant effects.", "source": "DDInter", "management_text": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue.  Patients should not drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking flibanserin and until they know how the medication affects them.", "mechanism_text": "Synergism", "recommendation": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289376/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals  (2015):", "alternatives_a": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245473, "ingredient1": "Fluoxetine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289377/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245474, "ingredient1": "Fluphenazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289378/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245475, "ingredient1": "Flurazepam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289379/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245476, "ingredient1": "Gabapentin", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289381/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245477, "ingredient1": "Galantamine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.  For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible.  Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered.  For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.  Caution is required, however, since anticholinergic withdrawal may occur.  Seizures have been reported following abrupt discontinuation of anticholinergics during acetylcholinesterase inhibitor therapy.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289382/", "reference_text": "[1] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991):  1825-32[2] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998):  8-13[3] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002):  836-42[4] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002):  1165-6[5] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003):  2716-2724[6] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004):  2082-7", "alternatives_a": "Ginkgo biloba, Aducanumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245478, "ingredient1": "Glycopyrronium", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289384/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245479, "ingredient1": "Glycopyrronium (topical)", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289385/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245480, "ingredient1": "Halazepam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289386/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245481, "ingredient1": "Haloperidol", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289387/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245482, "ingredient1": "Diamorphine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289388/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245483, "ingredient1": "Histamine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Antihistamines may suppress the patient's response to histamine phosphate.", "source": "DDInter", "management_text": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering histamine phosphate to patients treated with antihistamines.", "mechanism_text": "Antagonism", "recommendation": "Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering histamine phosphate to patients treated with antihistamines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289389/", "reference_text": "[1] \"Product Information. Histatrol (histamine phosphate).\" Center Laboratories  (2002):", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Peginterferon beta-1a, Interferon beta-1a, Aldesleukin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245484, "ingredient1": "Hyaluronidase", "ingredient2": "Phenyltoloxamine", "severity": "Minor", "effect": "Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.  These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.", "source": "DDInter", "management_text": "Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.  These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.", "mechanism_text": "Antagonism", "recommendation": "Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289391/", "reference_text": "[1] \"Product Information. Vitrase (hyaluronidase).\" Bausch and Lomb Americas, Inc.  (2004):", "alternatives_a": "Hemin, Voxelotor, Conestat alfa, Betibeglogene autotemcel, Streptokinase, Human C1-esterase inhibitor, Berotralstat, Lanadelumab, Icatibant, Crizanlizumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245485, "ingredient1": "Hydrocodone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289392/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245486, "ingredient1": "Hydromorphone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289393/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245487, "ingredient1": "Hydroxyzine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289394/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245488, "ingredient1": "Hyoscyamine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289395/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245489, "ingredient1": "Ifosfamide", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide.", "source": "DDInter", "management_text": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.  Patients should be advised to avoid driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how the medications affect them.  If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued.  Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.", "mechanism_text": "Synergism", "recommendation": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289396/", "reference_text": "[1] Simonian NA, Gilliam FG, Chiappa KH \"Ifosfamide causes a diazepam-sensitive encephalopathy.\" Neurology 43 (1993):  2700-2[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245490, "ingredient1": "Iloperidone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289397/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245491, "ingredient1": "Imipramine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289398/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245492, "ingredient1": "Ipratropium", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289399/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, Cromoglicic acid, Betamethasone, Nedocromil, Triamcinolone, Beclomethasone dipropionate, Flunisolide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245493, "ingredient1": "Ipratropium (nasal)", "ingredient2": "Phenyltoloxamine", "severity": "Minor", "effect": "Theoretically, the potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (new onset or exacerbation) when ipratropium nasal spray is used with other agents that possess anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide).", "source": "DDInter", "management_text": "Theoretically, the potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (new onset or exacerbation) when ipratropium nasal spray is used with other agents that possess anticholinergic properties (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide).  However, due to the poor systemic absorption of ipratropium when administered nasally, the interaction would be unlikely at regularly recommended dosages.", "mechanism_text": "Synergism", "recommendation": "Theoretically, the potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (new onset or exacerbation) when ipratropium nasal spray is used with other agents that possess anticholinergic properties (e.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289400/", "reference_text": "[1] \"Product Information. Atrovent Nasal (ipratropium nasal).\" Boehringer-Ingelheim", "alternatives_a": "Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, Cromoglicic acid, Betamethasone, Nedocromil, Triamcinolone, Beclomethasone dipropionate, Flunisolide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245494, "ingredient1": "Isocarboxazid", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided.  If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  It may be appropriate to monitor some patients for increased anticholinergic effects (e.g., constipation, urinary retention, fever, heat intolerance, blurred vision, confusion, hallucinations, dizziness, palpitations, arrhythmias, syncope), since certain populations such as the elderly and those with underlying organic brain disease tend to be more sensitive to these effects and may be susceptible to anticholinergic intoxication.  It should be noted that the manufacturers of many of the sedating antihistamines (e.g., chlorpheniramine, dexchlorpheniramine, diphenhydramine, pheniramine, promethazine) consider their use within 14 days of MAOIs to be contraindicated.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289401/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987):  1242-3[2] \"Product Information. Periactin (cyproheptadine).\" Merck & Co., Inc  (2002):[3] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis  (2002):[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[5] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004):  62-5[6] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005):  151-4[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245495, "ingredient1": "Isoflurophate (ophthalmic)", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289402/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245496, "ingredient1": "Phenyltoloxamine", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289403/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245497, "ingredient1": "Phenyltoloxamine", "ingredient2": "Ketamine", "severity": "Major", "effect": "Coadministration of ketamine with other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.", "source": "DDInter", "management_text": "During concomitant use of ketamine with other CNS depressants, including alcohol, close monitoring of neurologic status and respiratory parameters, including respiratory rate and pulse oximetry, is recommended.  Dosage adjustments should be considered according to the patient's clinical situation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of ketamine with other CNS depressants, including alcohol, close monitoring of neurologic status and respiratory parameters, including respiratory rate and pulse oximetry, is recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289404/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245498, "ingredient1": "Phenyltoloxamine", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with alcohol or other central nervous system (CNS) depressants may enhance the sedative effects of lasmiditan and increase the likelihood and/or severity of cognitive and/or neuropsychiatric adverse reactions.", "source": "DDInter", "management_text": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.  Patients should be advised against driving and other activities that require complete mental alertness for at least 8 hours after lasmiditan is administered.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289405/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company  (2019):", "alternatives_a": "Frovatriptan, Dihydroergotamine, Rimegepant, Eptinezumab, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Naratriptan, Galcanezumab, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245499, "ingredient1": "Phenyltoloxamine", "ingredient2": "Lemborexant", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289406/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245500, "ingredient1": "Phenyltoloxamine", "ingredient2": "Levocetirizine", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289407/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc  (2007):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245501, "ingredient1": "Phenyltoloxamine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289408/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245502, "ingredient1": "Phenyltoloxamine", "ingredient2": "Levacetylmethadol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289409/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245503, "ingredient1": "Phenyltoloxamine", "ingredient2": "Levorphanol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289410/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245504, "ingredient1": "Phenyltoloxamine", "ingredient2": "Linezolid", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided.  If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  It may be appropriate to monitor some patients for increased anticholinergic effects (e.g., constipation, urinary retention, fever, heat intolerance, blurred vision, confusion, hallucinations, dizziness, palpitations, arrhythmias, syncope), since certain populations such as the elderly and those with underlying organic brain disease tend to be more sensitive to these effects and may be susceptible to anticholinergic intoxication.  It should be noted that the manufacturers of many of the sedating antihistamines (e.g., chlorpheniramine, dexchlorpheniramine, diphenhydramine, pheniramine, promethazine) consider their use within 14 days of MAOIs to be contraindicated.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289411/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987):  1242-3[2] \"Product Information. Periactin (cyproheptadine).\" Merck & Co., Inc  (2002):[3] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis  (2002):[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[5] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004):  62-5[6] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005):  151-4[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Lefamulin, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245505, "ingredient1": "Phenyltoloxamine", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289412/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245506, "ingredient1": "Phenyltoloxamine", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289413/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245507, "ingredient1": "Phenyltoloxamine", "ingredient2": "Loperamide", "severity": "Moderate", "effect": "Coadministration with drugs that possess significant anticholinergic activity may potentiate the antimotility effect of loperamide.", "source": "DDInter", "management_text": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.g., antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide).  Ambulatory patients should also be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Until further information is available, loperamide should be used with caution in combination with drugs that possess significant anticholinergic activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289414/", "reference_text": "[1] Eronen M, Putkonen H, Hallikainen T, Vartiainen H \"Lethal gastroenteritis associated with clozapine and loperamide.\" Am J Psychiatry 160 (2003):  2242-2243", "alternatives_a": "Diphenoxylate, Difenoxin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245508, "ingredient1": "Phenyltoloxamine", "ingredient2": "Lorazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289415/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245509, "ingredient1": "Phenyltoloxamine", "ingredient2": "Loxapine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289416/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245510, "ingredient1": "Phenyltoloxamine", "ingredient2": "Lumateperone", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289417/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245511, "ingredient1": "Phenyltoloxamine", "ingredient2": "Lurasidone", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289418/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245512, "ingredient1": "Phenyltoloxamine", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289419/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245513, "ingredient1": "Phenyltoloxamine", "ingredient2": "Meclizine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289420/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245514, "ingredient1": "Phenyltoloxamine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289421/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245515, "ingredient1": "Phenyltoloxamine", "ingredient2": "Mepenzolate", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289422/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245516, "ingredient1": "Phenyltoloxamine", "ingredient2": "Meperidine", "severity": "Moderate", "effect": "The central nervous system and respiratory depressant effects of meperidine may be potentiated by concomitant use of other agents with CNS depressant effects.", "source": "DDInter", "management_text": "Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol.  A lower dosage of meperidine should be considered initially, then titrated carefully according to pain level and clinical response.  Meperidine dosage reductions of 25% to 50% have been recommended for patients receiving phenothiazines and other tranquilizers.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position, and to notify their physician if they experience dizziness, lightheadedness, orthostasis, syncope, tachycardia, or excessive CNS effects that interfere with their normal activities.  Patients should also avoid driving or operating hazardous machinery until they know how these medications affect them.", "mechanism_text": "Synergism", "recommendation": "Caution and dosage adjustments are advisable when meperidine is used in combination with other narcotic analgesics, general anesthetics, phenothiazines, sedative-hypnotics, tranquilizers, tricyclic antidepressants, or other CNS depressants such as alcohol.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289423/", "reference_text": "[1] Lambertsen CJ, Wendel H, Longenhagen JB \"The separate and combined respiratory effects of chlorpromazine and meperidine in normal men controlled at 46 mm Hg alveolar pCO2.\" J Pharmacol Exp Ther 131 (1961):  381-93[2] Hoffman JC, Smith TC \"The respiratory effects of meperidine and propiomazine in man.\" Anesthesiology 32 (1970):  325-31[3] Stambaugh JE, Wainer IW \"Drug interaction: meperidine and chlorpromazine, a toxic combination.\" J Clin Pharmacol 21 (1981):  140-6[4] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[5] \"Product Information. Meperidine Hydrochloride (meperidine).\" Astra-Zeneca Pharmaceuticals  (2022):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245517, "ingredient1": "Phenyltoloxamine", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289424/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245518, "ingredient1": "Phenyltoloxamine", "ingredient2": "Methylphenobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289425/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam, Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245519, "ingredient1": "Phenyltoloxamine", "ingredient2": "Meprobamate", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289426/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245520, "ingredient1": "Phenyltoloxamine", "ingredient2": "Mesoridazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289427/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245521, "ingredient1": "Phenyltoloxamine", "ingredient2": "Metaxalone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289428/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245522, "ingredient1": "Phenyltoloxamine", "ingredient2": "Methadone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289429/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245523, "ingredient1": "Phenyltoloxamine", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289430/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245524, "ingredient1": "Phenyltoloxamine", "ingredient2": "Methocarbamol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289431/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245525, "ingredient1": "Phenyltoloxamine", "ingredient2": "Methohexital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289432/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone, Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245526, "ingredient1": "Phenyltoloxamine", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289433/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245527, "ingredient1": "Phenyltoloxamine", "ingredient2": "Methscopolamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289434/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketorolac, Homatropine, Ephedrine, Tropicamide, Phenylephrine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245528, "ingredient1": "Phenyltoloxamine", "ingredient2": "Methsuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289435/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245529, "ingredient1": "Phenyltoloxamine", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289436/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Cisapride", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245530, "ingredient1": "Phenyltoloxamine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289437/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Macitentan, Riociguat, Tadalafil, Bosentan, Ambrisentan", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245531, "ingredient1": "Phenyltoloxamine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289438/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245532, "ingredient1": "Phenyltoloxamine", "ingredient2": "Molindone", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289439/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245533, "ingredient1": "Phenyltoloxamine", "ingredient2": "Morphine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289440/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Diphenoxylate, Difenoxin, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245534, "ingredient1": "Phenyltoloxamine", "ingredient2": "Nabilone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289441/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Granisetron, Rolapitant, Aprepitant, Dolasetron, Ondansetron, Palonosetron", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245535, "ingredient1": "Phenyltoloxamine", "ingredient2": "Nalbuphine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289442/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245536, "ingredient1": "Phenyltoloxamine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289443/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245537, "ingredient1": "Phenyltoloxamine", "ingredient2": "Olanzapine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289444/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245538, "ingredient1": "Phenyltoloxamine", "ingredient2": "Oliceridine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289445/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245539, "ingredient1": "Phenyltoloxamine", "ingredient2": "Olopatadine (nasal)", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289446/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc  (2008):[2] \"Product Information. Ryaltris (mometasone-olopatadine nasal).\" Hikma Americas, Inc  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245540, "ingredient1": "Phenyltoloxamine", "ingredient2": "Opicapone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289447/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245541, "ingredient1": "Phenyltoloxamine", "ingredient2": "Opium", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289448/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Diphenoxylate, Difenoxin, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245542, "ingredient1": "Phenyltoloxamine", "ingredient2": "Orphenadrine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289449/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245543, "ingredient1": "Phenyltoloxamine", "ingredient2": "Oxazepam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289450/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245544, "ingredient1": "Phenyltoloxamine", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289451/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245545, "ingredient1": "Phenyltoloxamine", "ingredient2": "Oxybutynin", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289452/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245546, "ingredient1": "Phenyltoloxamine", "ingredient2": "Oxycodone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289453/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245547, "ingredient1": "Phenyltoloxamine", "ingredient2": "Oxymorphone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289454/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245548, "ingredient1": "Phenyltoloxamine", "ingredient2": "Paliperidone", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289455/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245549, "ingredient1": "Phenyltoloxamine", "ingredient2": "Paraldehyde", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289456/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245550, "ingredient1": "Phenyltoloxamine", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289457/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245551, "ingredient1": "Phenyltoloxamine", "ingredient2": "Pentazocine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289458/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245552, "ingredient1": "Phenyltoloxamine", "ingredient2": "Pentobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289459/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245553, "ingredient1": "Phenyltoloxamine", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289460/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245554, "ingredient1": "Phenyltoloxamine", "ingredient2": "Pergolide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289461/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245555, "ingredient1": "Phenyltoloxamine", "ingredient2": "Perphenazine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289462/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245556, "ingredient1": "Phenyltoloxamine", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289463/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245557, "ingredient1": "Phenyltoloxamine", "ingredient2": "Phenelzine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided.  If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  It may be appropriate to monitor some patients for increased anticholinergic effects (e.g., constipation, urinary retention, fever, heat intolerance, blurred vision, confusion, hallucinations, dizziness, palpitations, arrhythmias, syncope), since certain populations such as the elderly and those with underlying organic brain disease tend to be more sensitive to these effects and may be susceptible to anticholinergic intoxication.  It should be noted that the manufacturers of many of the sedating antihistamines (e.g., chlorpheniramine, dexchlorpheniramine, diphenhydramine, pheniramine, promethazine) consider their use within 14 days of MAOIs to be contraindicated.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289464/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987):  1242-3[2] \"Product Information. Periactin (cyproheptadine).\" Merck & Co., Inc  (2002):[3] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis  (2002):[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[5] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004):  62-5[6] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005):  151-4[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245558, "ingredient1": "Phenyltoloxamine", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289465/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245559, "ingredient1": "Phenyltoloxamine", "ingredient2": "Phenobarbital", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289466/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone, Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245560, "ingredient1": "Phenyltoloxamine", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289467/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245561, "ingredient1": "Phenytoin", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289468/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245562, "ingredient1": "Physostigmine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.  For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible.  Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered.  For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.  Caution is required, however, since anticholinergic withdrawal may occur.  Seizures have been reported following abrupt discontinuation of anticholinergics during acetylcholinesterase inhibitor therapy.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289469/", "reference_text": "[1] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991):  1825-32[2] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998):  8-13[3] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002):  836-42[4] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002):  1165-6[5] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003):  2716-2724[6] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004):  2082-7", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Betaxolol, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, Acetazolamide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245563, "ingredient1": "Physostigmine (ophthalmic)", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289470/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245564, "ingredient1": "Pilocarpine (ophthalmic)", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Theoretically, anticholinergic agents and other agents with significant anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, class IA antiarrhythmics especially disopyramide) may antagonize the effects of topically administered cholinergic agents such as acetylcholine, carbachol, demecarium, echothiophate, isoflurophate, physostigmine, and pilocarpine.", "source": "DDInter", "management_text": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving long-term therapy with anticholinergic agents should be monitored for potentially diminished therapeutic (miotic) response to ophthalmic cholinergic therapy, and dosages adjusted as necessary.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289471/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] \"Product Information. Pilopine-HS (pilocarpine ophthalmic).\" Alcon Laboratories Inc", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245565, "ingredient1": "Pimozide", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289472/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245566, "ingredient1": "Pitolisant", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Because pitolisant enhances the activity of histaminergic neurons in the brain, centrally acting histamine H1-receptor antagonists or medicines with H1-receptor antagonist properties (e.g., tri- and tetracyclic antidepressants) may impair the efficacy of pitolisant.", "source": "DDInter", "management_text": "According to the manufacturer, coadministration of pitolisant with centrally acting H1-receptor antagonists or tri- and tetracyclic antidepressants should be avoided.", "mechanism_text": "Antagonism", "recommendation": "According to the manufacturer, coadministration of pitolisant with centrally acting H1-receptor antagonists or tri- and tetracyclic antidepressants should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289473/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Wakix (pitolisant).\" Harmony Biosciences, LLC, Plymouth Meeting, PA.[3] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[4] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[6] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245567, "ingredient1": "Potassium chloride", "ingredient2": "Phenyltoloxamine", "severity": "Major", "effect": "The use of oral solid preparations of potassium chloride may diminish the efficacy of anticholinergic drugs.", "source": "DDInter", "management_text": "The use of certain oral solid formulations of potassium chloride is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.  A liquid formulation of potassium chloride should be considered.  Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Antagonism", "recommendation": "The use of certain oral solid formulations of potassium chloride is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289474/", "reference_text": "[1] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980):  508-11[2] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975):  206[3] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965):  1546[4] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984):  852-5[5] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982):  1059-61[6] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985):  56-7[7] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982):  1154-5[8] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985):  273-8[9] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977):  111-2[10] \"Product Information. K-Dur (potassium chloride).\" Schering Corporation  (2001):[11] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975):  746", "alternatives_a": "Potassium bicarbonate, Potassium gluconate, Calcium chloride, Zinc sulfate, Magnesium sulfate, Sodium acetate, Arginine, Sodium glycerophosphate, Zinc chloride, Tromethamine, Sodium phosphate, monobasic, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245568, "ingredient1": "Potassium citrate", "ingredient2": "Phenyltoloxamine", "severity": "Major", "effect": "The use of oral solid preparations of potassium chloride may diminish the efficacy of anticholinergic drugs.", "source": "DDInter", "management_text": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.  A liquid formulation of potassium citrate should be considered.  Patients prescribed a solid oral formulation should be advised to discontinue potassium therapy and contact their physician if they experience potential symptoms of upper GI injury such as severe vomiting, abdominal pain, distention, and gastrointestinal bleeding.", "mechanism_text": "Antagonism", "recommendation": "The use of oral solid formulations of potassium citrate is considered contraindicated in patients receiving agents with anticholinergic properties at sufficient doses to exert anticholinergic effects.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289475/", "reference_text": "[1] Lambert JR, Newman A \"Ulceration and stricture of the esophagus due to oral potassium chloride (slow release tablet) therapy.\" Am J Gastroenterol 73 (1980):  508-11[2] Farquharson-Roberts MA, Giddings AE, Nunn AJ \"Perforation of small bowel due to slow release potassium chloride (slow-K).\" Br Med J 3 (1975):  206[3] Wynn V \"Potassium chloride and bowel ulceration.\" Br Med J 5477 (1965):  1546[4] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Effect of potassium chloride supplements on upper gastrointestinal mucosa.\" Clin Pharmacol Ther 35 (1984):  852-5[5] McMahon FG, Ryan JR, Akdamar K, Ertan A \"Upper gastrointestinal lesions after potassium chloride supplements: a controlled clinical trial.\" Lancet 2 (1982):  1059-61[6] Leijonmarck CE, Raf L \"Gastrointestinal lesions and potassium chloride supplements.\" Lancet 1 (1985):  56-7[7] Lofgren RP, Rothe PR, Carlson GJ \"Jejunal perforation associated with slow-release potassium chloride therapy.\" South Med J 75 (1982):  1154-5[8] Leijonmarck CE, Raf L \"Ulceration of the small intestine due to slow-release potassium chloride tablets.\" Acta Chir Scand 151 (1985):  273-8[9] Weiss SM, Rutenberg HL, Paskin DL, Zaren HA \"Gut lesions due to slow-release KCI tablets.\" N Engl J Med 296 (1977):  111-2[10] \"Product Information. K-Dur (potassium chloride).\" Schering Corporation  (2001):[11] \"Product Information. Urocit-K (potassium citrate).\" Mission Pharmacal Company[12] Heffernan SJ, Murphy JJ \"Ulceration of small intestine and slow-release potassium tablets.\" Br Med J 2 (1975):  746", "alternatives_a": "Potassium bicarbonate, Potassium gluconate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245569, "ingredient1": "Pregabalin", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289476/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245570, "ingredient1": "Primidone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289477/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone, Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245571, "ingredient1": "Procarbazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided.  If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  It may be appropriate to monitor some patients for increased anticholinergic effects (e.g., constipation, urinary retention, fever, heat intolerance, blurred vision, confusion, hallucinations, dizziness, palpitations, arrhythmias, syncope), since certain populations such as the elderly and those with underlying organic brain disease tend to be more sensitive to these effects and may be susceptible to anticholinergic intoxication.  It should be noted that the manufacturers of many of the sedating antihistamines (e.g., chlorpheniramine, dexchlorpheniramine, diphenhydramine, pheniramine, promethazine) consider their use within 14 days of MAOIs to be contraindicated.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289478/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987):  1242-3[2] \"Product Information. Periactin (cyproheptadine).\" Merck & Co., Inc  (2002):[3] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis  (2002):[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[5] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004):  62-5[6] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005):  151-4[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245572, "ingredient1": "Prochlorperazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289479/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245573, "ingredient1": "Procyclidine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289480/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245574, "ingredient1": "Promazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289481/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245575, "ingredient1": "Promethazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289482/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine, Lidocaine, Tetracaine, Pheniramine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245576, "ingredient1": "Propantheline", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289483/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245577, "ingredient1": "Propiomazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289484/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245578, "ingredient1": "Dextropropoxyphene", "ingredient2": "Phenyltoloxamine", "severity": "Major", "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene.", "source": "DDInter", "management_text": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.  Dosage reductions may be appropriate.  Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects.  Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289485/", "reference_text": "[1] Abernethy DR, Greenblatt DJ, Morse DS, Shader RI \"Interaction of propoxyphene with diazepam, alprazolam and lorazepam.\" Br J Clin Pharmacol 19 (1985):  51-7[2] Hansen BS, Dam M, Brandt J, et al. \"Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man.\" Acta Neurol Scand 61 (1980):  357-67[3] Abernethy DR, Greenblatt DJ, Steel K, Shader RI \"Impairment of hepatic drug oxidation by propoxyphene.\" Ann Intern Med 97 (1982):  223-4[4] Peterson GR, Covault HP, Hostetler RM \"Acute inhibition of microsomal drug metabolism by propoxphene in narcotic tolerant/dependent mice.\" Life Sci 22 (1978):  2087-96[5] Shorr RI, Griffin MR, Daugherty JR, Ray WA \"Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene.\" J Gerontol 47 (1992):  m111-5[6] Puckett WH Jr, Visconti JA \"Orphenadrine and propoxyphene.\" N Engl J Med 283 (1970):  544[7] Pearson RE, Salter FJ \"Drug interaction? Orphenadrine with propoxyphene.\" N Engl J Med 282 (1970):  1215[8] \"Product Information. Darvon (propoxyphene).\" Lilly, Eli and Company  (2001):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245579, "ingredient1": "Protriptyline", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289486/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245580, "ingredient1": "Phenyltoloxamine", "ingredient2": "Mepyramine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289487/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245581, "ingredient1": "Quazepam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289488/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245582, "ingredient1": "Quetiapine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289489/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245583, "ingredient1": "Ramelteon", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289490/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245584, "ingredient1": "Rasagiline", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289491/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245585, "ingredient1": "Remifentanil", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289492/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245586, "ingredient1": "Remimazolam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289493/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245587, "ingredient1": "Revefenacin", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289494/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "Ciclesonide, Mometasone furoate, Budesonide, Flunisolide, Fluticasone, Cromoglicic acid, Betamethasone, Nedocromil, Triamcinolone, Beclomethasone dipropionate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245588, "ingredient1": "Botulinum toxin type B", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Use of anticholinergic drugs after administration of botulinum toxin may potentiate systemic anticholinergic effects such as dry mouth, blurred vision, and urinary disorders.  Botulinum toxin inhibits the release of acetylcholine from peripheral cholinergic nerve endings, thus additive or synergistic anticholinergic effects may occur when these agents are used together.", "source": "DDInter", "management_text": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) are used after administration of botulinum toxin.", "mechanism_text": "Synergism", "recommendation": "Patients should be advised that systemic anticholinergic side effects such as dry mouth, blurred vision, and urinary disorders may increase if agents with anticholinergic properties (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289495/", "reference_text": "[1] \"Product Information. Myobloc (rimabotulinumtoxinB).\" Elan Pharmaceuticals[2] \"Product Information. Dysport (abobotulinumtoxinA).\" Tercica Inc[3] \"Product Information. Botox (onabotulinumtoxinA).\" Allergan Inc[4] \"Product Information. Xeomin (incobotulinumtoxinA).\" Merz Pharmaceuticals  (2022):[5] \"Product Information. Jeuveau (prabotulinumtoxinA).\" Evolus, Inc.  (2022):[6] \"Product Information. Daxxify (daxibotulinumtoxinA).\" Revance Therapeutics, Inc.  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245589, "ingredient1": "Risperidone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289496/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245590, "ingredient1": "Rivastigmine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.  For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible.  Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered.  For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.  Caution is required, however, since anticholinergic withdrawal may occur.  Seizures have been reported following abrupt discontinuation of anticholinergics during acetylcholinesterase inhibitor therapy.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289497/", "reference_text": "[1] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991):  1825-32[2] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998):  8-13[3] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002):  836-42[4] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002):  1165-6[5] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003):  2716-2724[6] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004):  2082-7", "alternatives_a": "Ginkgo biloba, Aducanumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245591, "ingredient1": "Rotigotine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289498/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245592, "ingredient1": "Rufinamide", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289499/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245593, "ingredient1": "Safinamide", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289500/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245594, "ingredient1": "Scopolamine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289501/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone, Ketorolac, Homatropine, Ephedrine, Tropicamide, Phenylephrine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245595, "ingredient1": "Secobarbital", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289502/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245596, "ingredient1": "Selegiline", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289503/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ropinirole, Cabergoline, Tolcapone, Entacapone, Pramipexole", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245597, "ingredient1": "Sertraline", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289504/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245598, "ingredient1": "Iodide I-123", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.  Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week.  Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289506/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare  (2022):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245599, "ingredient1": "Iodide I-131", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.", "source": "DDInter", "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.  Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week.  Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.", "mechanism_text": "Others", "recommendation": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289507/", "reference_text": "[1] \"Product Information. Sodium Iodide I-123 (sodium iodide I-123).\" GE Healthcare  (2022):", "alternatives_a": "Ibritumomab tiuxetan, Tositumomab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245600, "ingredient1": "Sodium oxybate", "ingredient2": "Phenyltoloxamine", "severity": "Major", "effect": "The central nervous system and respiratory depressant effects of sodium oxybate, which is the sodium salt of gamma hydroxybutyrate (GHB), may be potentiated by concomitant use of other agents with CNS depressant effects.", "source": "DDInter", "management_text": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.  Otherwise, close monitoring and/or dosage reductions should be considered.  If short-term use of a CNS depressant is required (e.g., post- or perioperative opioid), a temporary interruption of sodium oxybate therapy may be appropriate.  All patients treated with sodium oxybate should be advised not to drive, operate machinery, or engage in potentially hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking the second nightly dose of sodium oxybate and until they know how the medication affects them.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of sodium oxybate with other CNS depressants should be avoided whenever possible.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289508/", "reference_text": "[1] \"Product Information. Xyrem (sodium oxybate).\" Orphan Medical  (2002):[2] \"Product Information. Xywav (calcium/magnesium/potass/sodium oxybates).\" Jazz Pharmaceuticals  (2020):", "alternatives_a": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Dalfampridine, Riluzole, Inotersen, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245601, "ingredient1": "Solifenacin", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289509/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245602, "ingredient1": "Stiripentol", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289510/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245603, "ingredient1": "Sufentanil", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289511/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245604, "ingredient1": "Suvorexant", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289512/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245605, "ingredient1": "Tacrine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Due to opposing effects, agents that possess anticholinergic activity (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; class IA antiarrhythmics especially disopyramide; carbamazepine; cimetidine; ranitidine) may negate the already small pharmacologic benefits of acetylcholinesterase inhibitors in the treatment of dementia.", "source": "DDInter", "management_text": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.  For patients requiring treatment to counteract adverse effects of acetylcholinesterase inhibitor therapy (e.g., gastrointestinal intolerance, urinary problems), an agent without anticholinergic properties should be used whenever possible.  Otherwise, a dosage reduction, slower titration, or even discontinuation of the acetylcholinesterase inhibitor should be considered.  For patients who are already receiving an acetylcholinesterase inhibitor with anticholinergic agents, every attempt should be made to discontinue the latter or substitute them with less anticholinergic alternatives.  Caution is required, however, since anticholinergic withdrawal may occur.  Seizures have been reported following abrupt discontinuation of anticholinergics during acetylcholinesterase inhibitor therapy.", "mechanism_text": "Antagonism", "recommendation": "Drugs that possess anticholinergic activity should generally be avoided in patients with Alzheimer's disease or other cognitive impairment, regardless of whether they are receiving an acetylcholinesterase inhibitor.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289513/", "reference_text": "[1] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC \"Explicit criteria for determining inappropriate medication use in nursing home residents.\" Arch Intern Med 151 (1991):  1825-32[2] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K \"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.\" J Am Geriatr Soc 46 (1998):  8-13[3] Roe CM, Anderson MJ, Spivack B \"Use of anticholinergic medications by older adults with dementia.\" J Am Geriatr Soc 50 (2002):  836-42[4] Edwards KR, O'Connor JT \"Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors.\" J Am Geriatr Soc 50 (2002):  1165-6[5] Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH \"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.\" Arch Intern Med 163 (2003):  2716-2724[6] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA \"The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?\" J Am Geriatr Soc 52 (2004):  2082-7", "alternatives_a": "Ginkgo biloba, Aducanumab", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245606, "ingredient1": "Tapentadol", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289514/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245607, "ingredient1": "Tasimelteon", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289515/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245608, "ingredient1": "Temazepam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289516/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245609, "ingredient1": "Tetrabenazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289517/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245610, "ingredient1": "Thalidomide", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Thalidomide can commonly cause drowsiness/sedation and may have additive effects with other drugs that cause central nervous system (CNS) depression.", "source": "DDInter", "management_text": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.  Patients should be advised to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  Dosage reductions may be necessary.  Thalidomide should preferably be administered at bedtime to reduce the impact of somnolence.  Alcohol use is not recommended.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when thalidomide is used with other CNS depressants such as anticonvulsants, antihistamines, antidepressants, antipsychotics, anxiolytics, opioids, and sedatives/hypnotics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289518/", "reference_text": "[1] \"Product Information. Thalomid (thalidomide).\" Celgene Corporation  (2001):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245611, "ingredient1": "Thiethylperazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289519/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245612, "ingredient1": "Thiopental", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289520/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Halothane, Isoflurane, Nitrous oxide, Desflurane, Propofol, Enflurane, Sevoflurane, Etomidate, Nitrazepam, Dexmedetomidine, Ethchlorvynol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245613, "ingredient1": "Thioridazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289521/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245614, "ingredient1": "Thiothixene", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289522/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245615, "ingredient1": "Tiotropium", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289523/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245616, "ingredient1": "Tizanidine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "The sedative effect of tizanidine may be potentiated by concomitant use of other agents with central nervous system (CNS) depressant effects.  In addition, tizanidine and many of these agents (e.g., alcohol, anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, muscle relaxants) also can exhibit hypotensive effects, which may be additive during coadministration and may increase the risk of symptomatic hypotension and orthostasis, particularly during initiation of therapy or dose escalation.", "source": "DDInter", "management_text": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.  Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to avoid rising abruptly from a sitting or recumbent position.  Patients should contact their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or excessive CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and more gradual dose titration may be appropriate when tizanidine is used with other substances that can cause CNS depression and/or hypotension, particularly in elderly or debilitated patients.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289524/", "reference_text": "[1] \"Product Information. Zanaflex (tizanidine).\" Acorda Therapeutics  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245617, "ingredient1": "Tolterodine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289525/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245618, "ingredient1": "Topiramate", "ingredient2": "Phenyltoloxamine", "severity": "Major", "effect": "Certain drugs such as carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, disopyramide) may potentiate the risk of oligohidrosis and hyperthermia associated occasionally with the use of topiramate, particularly in pediatric patients.  These agents may alter electrolyte and fluid balance (carbonic anhydrase inhibition), inhibit peripheral sweating mechanisms (anticholinergic effect), and/or interfere with core body temperature regulation in the hypothalamus (neuroleptics and phenothiazines), resulting in the inability to adjust to temperature changes, especially in hot weather.  Also, agents with anticholinergic activity frequently cause drowsiness and other central nervous system-depressant effects, which may be additively or synergistically increased in patients also treated with topiramate.", "source": "DDInter", "management_text": "Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity.  Patients, particularly pediatric patients, should be monitored closely for evidence of decreased sweating and increased body temperature, especially in warm or hot weather.  Proper hydration before and during vigorous activities or exposure to warm temperatures is recommended.  Patients (or their guardians or caregivers) should contact their physician immediately if they are not sweating as usual, with or without a fever.  Ambulatory patients treated with topiramate and agents with anticholinergic activity should also be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when topiramate is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289526/", "reference_text": "[1] \"Product Information. Topamax (topiramate).\" Ortho McNeil Pharmaceutical  (2001):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245619, "ingredient1": "Tramadol", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289527/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Dihydrocodeine, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245620, "ingredient1": "Tranylcypromine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Coadministration of monoamine oxidase inhibitors (MAOIs) and antihistamines may result in additive central nervous system depressant effects.", "source": "DDInter", "management_text": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, procarbazine) should generally be avoided.  If concomitant treatment is unavoidable, patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.  It may be appropriate to monitor some patients for increased anticholinergic effects (e.g., constipation, urinary retention, fever, heat intolerance, blurred vision, confusion, hallucinations, dizziness, palpitations, arrhythmias, syncope), since certain populations such as the elderly and those with underlying organic brain disease tend to be more sensitive to these effects and may be susceptible to anticholinergic intoxication.  It should be noted that the manufacturers of many of the sedating antihistamines (e.g., chlorpheniramine, dexchlorpheniramine, diphenhydramine, pheniramine, promethazine) consider their use within 14 days of MAOIs to be contraindicated.", "mechanism_text": "Synergism", "recommendation": "Prescribing antihistamines in combination with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289528/", "reference_text": "[1] Kahn DA \"Possible toxic interaction between cyproheptadine and phenelzine.\" Am J Psychiatry 144 (1987):  1242-3[2] \"Product Information. Periactin (cyproheptadine).\" Merck & Co., Inc  (2002):[3] \"Product Information. Benadryl (diphenhydramine).\" Parke-Davis  (2002):[4] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[5] Serio RN \"Acute delirium associated with combined diphenhydramine and linezolid use.\" Ann Pharmacother 38 (2004):  62-5[6] Ferry T, Ponceau B, Simon M, et al. \"Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases.\" Infection 33 (2005):  151-4[7] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245621, "ingredient1": "Trazodone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289529/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245622, "ingredient1": "Triazolam", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289530/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245623, "ingredient1": "Trifluoperazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289532/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245624, "ingredient1": "Triflupromazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289533/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245625, "ingredient1": "Trihexyphenidyl", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289534/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245626, "ingredient1": "Alimemazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289535/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245627, "ingredient1": "Trimethadione", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289536/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245628, "ingredient1": "Trimethobenzamide", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289537/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245629, "ingredient1": "Trimipramine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289538/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Vilazodone, Paroxetine, St. John's Wort, Nefazodone, Oxitriptan, Mirtazapine, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245630, "ingredient1": "Tripelennamine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289539/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine, Lidocaine, Tetracaine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245631, "ingredient1": "Triprolidine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289540/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245632, "ingredient1": "Trospium", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289541/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Sildenafil, Mirabegron, Alprostadil, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245633, "ingredient1": "Tuberculin purified protein derivative", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Antihistamines may diminish the response to diagnostic skin test antigens.", "source": "DDInter", "management_text": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "mechanism_text": "Antagonism", "recommendation": "Antihistamines should be discontinued approximately 2 to 4 days prior to skin testing procedures.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289542/", "reference_text": "[1] \"Multum Information Services, Inc. Expert Review Panel\"[2] NLM. National Library of Medicine. NIH. National Institutes of Health \"Trichophyton for intradermal skin testing (trichophyton mentagrophytes and trichophyton rubrum) injection [Allermed Laboratories, Inc.]  http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aaeffe62-b538-43ca-a3b9-47e28b765d89\"   (2014):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245634, "ingredient1": "Umeclidinium", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "The potential exists for additive anticholinergic effects such as mydriasis, blurred vision, heat intolerance, fever, dry mouth, tachycardia, urinary retention, constipation, and glaucoma (onset or exacerbation) when topical or inhaled anticholinergic agents are used with each other or with other agents that possess anticholinergic properties.  The risk of systemic anticholinergic effects following topical administration depends on variables such as strength of the product, size of the application area, frequency of application, and use of occlusive dressing.  Systemic effects are uncommon following oral inhalation or nasal administration due to the poor absorption of quaternary ammonium compounds from gastrointestinal and nasal mucosa.", "source": "DDInter", "management_text": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).  Caution is advised if concomitant use cannot be avoided, particularly in the elderly and those with significantly impaired renal and/or hepatic function.  Measures should be taken whenever possible to minimize ocular exposure to these drugs, such as keeping eyes closed during oral inhalation, use of a mouthpiece rather than face mask during nebulization, and not touching the eyes following topical application until hands are washed with soap and water.  Patients should be advised to contact their physician if they experience excessive anticholinergic adverse effects or signs and symptoms of angle-closure glaucoma (e.g., eye pain or discomfort; blurred vision; visual halos; colored images in association with red eyes from conjunctival congestion or corneal edema).", "mechanism_text": "Synergism", "recommendation": "Topical and inhaled anticholinergic preparations should preferably not be used in combination with other anticholinergic agents or agents with significant anticholinergic effects such as antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, and class IA antiarrhythmics (especially disopyramide).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289543/", "reference_text": "[1] \"Product Information. Atrovent (ipratropium).\" Boehringer-Ingelheim  (2002):[2] \"Product Information. Combivent (albuterol-ipratropium).\" Boehringer-Ingelheim  (2001):[3] \"Product Information. Spiriva (tiotropium).\" Boehringer Ingelheim  (2002):[4] \"Product Information. Tudorza Pressair (aclidinium).\" Forest Pharmaceuticals  (2012):[5] Cole JM, Sheehan AH, Jordan JK \"Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease.\" Ann Pharmacother 46 (2012):  1717-21[6] \"Product Information. Anoro Ellipta (umeclidinium-vilanterol).\" GlaxoSmithKline  (2014):[7] \"Product Information. Qbrexza (glycopyrrolate topical).\" Dermira, Inc.  (2018):[8] \"Product Information. Yupelri (revefenacin).\" Mylan Specialty  (2018):", "alternatives_a": "Mometasone furoate, Terbutaline, Budesonide, Mometasone, Epinephrine, Olodaterol, Fluticasone, Cromoglicic acid, Salbutamol, Orciprenaline, Pirbuterol, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245635, "ingredient1": "Valbenazine", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289544/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dalfampridine, Riluzole, Inotersen, Amifampridine, Tafamidis", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245636, "ingredient1": "Valerian", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289545/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245637, "ingredient1": "Vigabatrin", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289546/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245638, "ingredient1": "Ziconotide", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289547/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Methoxyflurane, Salsalate, Acetylsalicylic acid", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245639, "ingredient1": "Ziprasidone", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Agents with anticholinergic properties (e.g., sedating antihistamines; antispasmodics; neuroleptics; phenothiazines; skeletal muscle relaxants; tricyclic antidepressants; disopyramide) may have additive effects when used in combination.  Excessive parasympatholytic effects may result in paralytic ileus, hyperthermia, heat stroke, and the anticholinergic intoxication syndrome.  Peripheral symptoms of intoxication commonly include mydriasis, blurred vision, flushed face, fever, dry skin and mucous membranes, tachycardia, urinary retention, and constipation.  Central symptoms may include memory loss, disorientation, incoherence, hallucinations, psychosis, delirium, hyperactivity, twitching or jerking movements, stereotypy, and seizures.  Central nervous system-depressant effects may also be additively or synergistically increased when these agents are combined, especially in elderly or debilitated patients.  Use of neuroleptics in combination with other neuroleptics or anticholinergic agents may increase the risk of tardive dyskinesia.  In addition, some neuroleptics and tricyclic antidepressants may cause prolongation of the QT interval and theoretically, concurrent use of two or more drugs that can cause QT interval prolongation may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.", "source": "DDInter", "management_text": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.  Patients should be advised to notify their physician promptly if they experience potential symptoms of anticholinergic intoxication such as abdominal pain, fever, heat intolerance, blurred vision, confusion, and/or hallucinations.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.  A reduction in anticholinergic dosages may be necessary if excessive adverse effects develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when agents with anticholinergic properties are combined, particularly in the elderly and those with underlying organic brain disease, who tend to be more sensitive to the central anticholinergic effects of these drugs and in whom toxicity symptoms may be easily overlooked.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289548/", "reference_text": "[1] Stadnyk AN, Glezos JD \"Drug-induced heat stroke.\" Can Med Assoc J 128 (1983):  957-9[2] Zelman S, Guillan R \"Heat stroke in phenothiazine-treated patients: a report of three fatalities.\" Am J Psychiatry 126 (1970):  1787-90[3] Mann SC, Boger WP \"Psychotropic drugs, summer heat and humidity, and hyperplexia: a danger restated.\" Am J Psychiatry 135 (1978):  1097-100[4] Warnes H, Lehmann HE, Ban TA \"Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases.\" Can Med Assoc J 96 (1967):  1112-3[5] Gershon S, Neubauer H, Sundland DM \"Interaction between some anticholinergic agents and phenothiazines.\" Clin Pharmacol Ther 6 (1965):  749-56[6] Sarnquist F, Larson CP Jr \"Drug-induced heat stroke.\" Anesthesiology 39 (1973):  348-50[7] Johnson AL, Hollister LE, Berger PA \"The anticholinergic intoxication syndrome: diagnosis and treatment.\" J Clin Psychiatry 42 (1981):  313-7[8] Lee BS \"Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs.\" J Clin Psychiatry 47 (1986):  571[9] Forester D \"Fatal drug-induced heat stroke.\" JACEP 7 (1978):  243-4[10] Moreau A, Jones BD, Banno V \"Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.\" Can J Psychiatry 31 (1986):  339-41[11] Hvizdos AJ, Bennett JA, Wells BG, Rappaport KB, Mendel SA \"Anticholinergic psychosis in a patient receiving usual doses of haloperidol.\" Clin Pharm 2 (1983):  174-8[12] Cohen MA, Alfonso CA, Mosquera M \"Development of urinary retention during treatment with clozapine and meclizine [published erratum appears in Am J Psychiatry 1994 Jun;151(6):952].\" Am J Psychiatry 151 (1994):  619-20[13] \"Product Information. Cogentin (benztropine).\" Merck & Co., Inc  (2001):[14] Kulik AV, Wilbur R \"Delirium and stereotypy from anticholinergic antiparkinson drugs.\" Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  75-82[15] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Amisulpride, Pimavanserin", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245640, "ingredient1": "Zolpidem", "ingredient2": "Phenyltoloxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289549/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Dexmedetomidine, Ethchlorvynol, Zopiclone, Zaleplon, Dichloralphenazone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245641, "ingredient1": "Zonisamide", "ingredient2": "Phenyltoloxamine", "severity": "Major", "effect": "Certain drugs such as carbonic anhydrase inhibitors and drugs with anticholinergic activity (e.g., antihistamines, antispasmodics, neuroleptics, phenothiazines, skeletal muscle relaxants, tricyclic antidepressants, disopyramide) may potentiate the risk of oligohidrosis and hyperthermia associated occasionally with the use of zonisamide, particularly in pediatric patients.  These agents may alter electrolyte and fluid balance (carbonic anhydrase inhibition), inhibit peripheral sweating mechanisms (anticholinergic effect), and/or interfere with core body temperature regulation in the hypothalamus (neuroleptics and phenothiazines), resulting in the inability to adjust to temperature changes, especially in hot weather.  Also, agents with anticholinergic activity frequently cause drowsiness and other central nervous system-depressant effects, which may be additively or synergistically increased in patients also treated with zonisamide.", "source": "DDInter", "management_text": "Caution is advised when zonisamide is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity.  Patients, particularly pediatric patients, should be monitored closely for evidence of decreased sweating and increased body temperature, especially in warm or hot weather.  Proper hydration before and during vigorous activities or exposure to warm temperatures is recommended.  Patients (or their guardians or caregivers) should contact their physician immediately if they are not sweating as usual, with or without a fever.  Ambulatory patients treated with zonisamide and agents with anticholinergic activity should also be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when zonisamide is prescribed with other drugs that predispose patients to heat-related disorders, including carbonic anhydrase inhibitors and drugs with anticholinergic activity.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289550/", "reference_text": "[1] \"Product Information. Zonegran (zonisamide).\" Elan Pharmaceuticals  (2001):", "alternatives_a": "Tiagabine, Lamotrigine, Fosphenytoin, Felbamate, Lacosamide, Levetiracetam, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245642, "ingredient1": "Diamorphine", "ingredient2": "Tramadol", "severity": "Major", "effect": "Concomitant use of tramadol with other central nervous system (CNS) depressants including other opioids may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension and seizures may also be increased.", "source": "DDInter", "management_text": "Concomitant use of tramadol with other opioids should generally be avoided.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect.  Patients should be monitored closely for development of seizures, respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients on tramadol.  In addition, tramadol should not be used in opioid-dependent patients, and use in patients who are chronically on opioids is also not recommended.  Tramadol is contraindicated in patients with acute opioid intoxication.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of tramadol with other opioids should generally be avoided.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289552/", "reference_text": "[1] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):", "alternatives_a": "Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid", "alternatives_b": "Nalmefene, Disulfiram, Acamprosate", "updated_at": 1767369485}, {"id": 245643, "ingredient1": "Tramadol", "ingredient2": "Somapacitan", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tramadol, which is primarily metabolized by CYP450 3A4 and 2D6.  Reduced opioid efficacy can occur, including opioid withdrawal in physically dependent patients.", "source": "DDInter", "management_text": "Caution is advised when tramadol is used with CYP450 3A4 inducers.  Patients should be monitored for opioid efficacy and signs of withdrawal.  If a CYP450 3A4 inducer is discontinued, monitor for seizures, serotonin syndrome, sedation, and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when tramadol is used with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289554/", "reference_text": "[1] \"Product Information. Seglentis (celecoxib-tramadol).\" Kowa Pharmaceuticals America (formerly ProEthic)  (2022):", "alternatives_a": "Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "alternatives_b": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate", "updated_at": 1767369485}, {"id": 245644, "ingredient1": "Tramadol", "ingredient2": "St. John's Wort", "severity": "Major", "effect": "Concomitant use of agents with serotonergic activity such as serotonin reuptake inhibitors, monoamine oxidase inhibitors, tricyclic antidepressants, 5-HT1 receptor agonists, ergot alkaloids, cyclobenzaprine, lithium, St. John's wort, phenylpiperidine opioids, dextromethorphan, and tryptophan may potentiate the risk of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors.", "source": "DDInter", "management_text": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.  Patients should be closely monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  The potential risk for serotonin syndrome should be considered even when administering serotonergic agents sequentially, as some agents may demonstrate a prolonged elimination half-life.  For example, some experts suggest a 5-week washout period following use of fluoxetine and 3 weeks following the use of vortioxetine before administering another serotonergic agent.  Individual product labeling for washout periods should be consulted for current recommendations.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.", "mechanism_text": "Synergism", "recommendation": "In general, the concomitant use of multiple serotonergic agents should be avoided if possible, or otherwise approached with caution if potential benefit is deemed to outweigh the risk.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289555/", "reference_text": "[1] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[2] Achamallah NS \"Visual hallucinations after combining fluoxetine and dextromethorphan .\" Am J Psychiatry 149 (1992):  1406[3] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[4] Metz A \"Interaction between fluoxetine and buspirone.\" Can J Psychiatry 35 (1990):  722-3[5] Goldberg RJ, Huk M \"Serotonin syndrome from trazodone and buspirone.\" Psychosomatics 33 (1992):  235-6[6] \"Product Information. D.H.E. 45 (dihydroergotamine).\" Sandoz Pharmaceuticals Corporation  (2002):[7] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[8] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions. II.\" J Clin Psychopharmacol 10 (1990):  213-7[9] Ciraulo DA, Shader RI \"Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.\" J Clin Psychopharmacol 10 (1990):  48-50[10] \"Product Information. Zoloft (sertraline).\" Roerig Division  (2001):[11] \"Product Information. Prozac (fluoxetine).\" Dista Products Company  (2001):[12] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[13] Insel TR, Roy BF, Cohen RM, Murphy DL \"Possible development of the serotonin syndrome in man.\" Am J Psychiatry 139 (1982):  954-5[14] \"Product Information. Effexor (venlafaxine).\" Wyeth-Ayerst Laboratories  (2001):[15] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[16] \"Product Information. Paxil (paroxetine).\" GlaxoSmithKline  (2001):[17] \"Product Information. Flexeril (cyclobenzaprine).\" Merck & Co., Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] \"Product Information. Imitrex (sumatriptan).\" Glaxo Wellcome  (2001):[20] Ruiz F \"Fluoxetine and the serotonin syndrome.\" Ann Emerg Med 24 (1994):  983-5[21] \"Product Information. Luvox (fluvoxamine).\" Solvay Pharmaceuticals Inc  (2001):[22] Reeves RR, Bullen JA \"Serotonin syndrome produced by paroxetine and low-dose trazodone.\" Psychosomatics 36 (1995):  159-60[23] Harvey AT, Preskorn SH \"Interactions of serotonin reuptake inhibitors with tricyclic antidepressants.\" Arch Gen Psychiatry 52 (1995):  783-4[24] Baetz M, Malcolm D \"Serotonin syndrome from fluvoxamine and buspirone.\" Can J Psychiatry 40 (1995):  428-9[25] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[26] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[27] George TP, Godleski LS \"Possible serotonin syndrome with trazodone addition to fluoxetine.\" Biol Psychiatry 39 (1996):  384-5[28] Skop BP, Finkelstein JA, Mareth TR, Magoon MR, Brown TM \"The serotonin syndrome associated wtih paroxetine, an over-the-counter cold remedy, and vascular disease.\" Am J Emerg Med 12 (1994):  642-4[29] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[30] John L, Perreault MM, Tao T, Blew PG \"Serotonin syndrome associated with nefazodone and paroxetine.\" Ann Emerg Med 29 (1997):  287-9[31] \"Product Information. Zomig (zolmitriptan).\" Astra-Zeneca Pharmaceuticals  (2001):[32] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] Bhatara VS, Magnus RD, Paul KL, Preskorn SH \"Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms.\" Ann Pharmacother 32 (1998):  432-6[35] \"Product Information. Maxalt (rizatriptan).\" Merck & Co., Inc  (2001):[36] \"Product Information. Celexa (citalopram).\" Forest Pharmaceuticals  (2001):[37] Gardner DM, Lynd LD \"Sumatriptan contraindications and the serotonin syndrome.\" Ann Pharmacother 32 (1998):  33-8[38] Mathew NT, Tietjen GE, Lucker C \"Serotonin syndrome complicating migraine pharmacotherapy.\" Cephalalgia 16 (1996):  323-7[39] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[40] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[41] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[42] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[43] Gordon JB \"SSRI's and St. John's Wort: possible toxicity?\" Am Fam Physician 57 (1998):  950,953[44] Lantz MS, Buchalter E, Giambanco V \"St. John's wort and antidepressant drug interactions in the elderly.\" J Geriatr Psychiatr Neurol 12 (1999):  7-10[45] Fugh-Berman A \"Herb-drug interactions.\" Lancet 355 (2000):  134-8[46] \"Product Information. Zyvox (linezolid).\" Pharmacia and Upjohn  (2001):[47] Perry NK \"Venlafaxine-induced serotonin syndrome with relapse following amitriptyline.\" Postgrad Med J 76 (2000):  254-6[48] Manos GH \"Possible serotonin syndrome associated with buspirone added to fluoxetine.\" Ann Pharmacother 34 (2000):  871-4[49] Nijhawan PK, Katz G, Winter S \"Psychiatric illness and the serotonin syndrome: an emerging adverse drug effect leading to intensive care unit admission.\" Crit Care Med 24 (1996):  1086-9[50] Laird LK \"Issues in the monopharmacotherapy and polypharmacotherapy of obsessive-compulsive disorder.\" Psychopharmacol Bull 32 (1996):  569-78[51] Margolese HC, Chouinard G \"Serotonin syndrome from addition of low-dose trazodone to nefazodone.\" Am J Psychiatry 157 (2000):  1022[52] Mackay FJ, Dunn NR, Mann RD \"Antidepressants and the serotonin syndrome in general practice.\" Br J Gen Pract 49 (1999):  871-4[53] Smith DL, Wenegrat BG \"A case report of serotonin syndrome associated with combined nefazodone and fluoxetine.\" J Clin Psychiatry 61 (2000):  146[54] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[55] Izzo AA, Ernst E \"Interactions between herbal medicines and prescribed drugs: a systematic review.\" Drugs 61 (2001):  2163-75[56] Duggal HS, Fetchko J \"Serotonin syndrome and atypical antipsychotics.\" Am J Psychiatry 159 (2002):  672-3[57] Wigen CL, Goetz MB \"Serotonin syndrome and linezolid.\" Clin Infect Dis 34 (2002):  1651-2[58] Hammerness P, Parada H, Abrams A \"Linezolid: MAOI Activity and Potential Drug Interactions.\" Psychosomatics 43 (2002):  248-9[59] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[60] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[61] Turkel SB, Nadala JG, Wincor MZ \"Possible serotonin syndrome in association with 5-HT3 antagonist agents.\" Psychosomatics 42 (2001):  258-60[62] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[63] Lavery S, Ravi H, McDaniel WW, Pushkin YR \"Linezolid and serotonin syndrome.\" Psychosomatics 42 (2001):  432-4[64] Lane R, Baldwin D \"Selective serotonin reuptake inhibitor--induced serotonin syndrome: review.\" J Clin Psychopharmacol 17 (1997):  208-21[65] Bernard L, Stern R, Lew D, Hoffmeyer P \"Serotonin syndrome after concomitant treatment with linezolid and citalopram.\" Clin Infect Dis 36 (2003):  1197[66] Dannawi M \"Possible serotonin syndrome after combination of buspirone and St John's Wort.\" J Psychopharmacol 16 (2002):  401[67] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[68] Hachem RY, Hicks K, Huen A, Raad I \"Myelosuppression and serotonin syndrome associated with concurrent use of linezolid and selective serotonin reuptake inhibitors in bone marrow transplant recipients.\" Clin Infect Dis 37 (2003):  E8-E11[69] Gillman PK \"Linezolid and serotonin toxicity.\" Clin Infect Dis 37 (2003):  1274-5[70] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[71] Giese SY, Neborsky R \"Serotonin syndrome: potential consequences of Meridia combined with Demerol or fentanyl.\" Plast Reconstr Surg 107 (2001):  293-4[72] Jones SL, Athan E, O'Brien D \"Serotonin syndrome due to co-administration of linezolid and venlafaxine.\" J Antimicrob Chemother 54 (2004):  289-90[73] Tahir N \"Serotonin syndrome as a consequence of drug-resistant infections: an interaction between linezolid and citalopram.\" J Am Med Dir Assoc 5 (2004):  111-3[74] \"Product Information. Cymbalta (duloxetine).\" Lilly, Eli and Company  (2004):[75] Thomas CR, Rosenberg M, Blythe V, Meyer WJ 3rd \"Serotonin syndrome and linezolid.\" J Am Acad Child Adolesc Psychiatry 43 (2004):  790[76] Boyer EW, Shannon M \"The serotonin syndrome.\" N Engl J Med 352 (2005):  1112-20[77] Bergeron L, Boule M, Perreault S \"Serotonin toxicity associated with concomitant use of linezolid.\" Ann Pharmacother 39 (2005):  956-61[78] Morales N, Vermette H \"Serotonin syndrome associated with linezolid treatment after discontinuation of fluoxetine.\" Psychosomatics 46 (2005):  274-5[79] Morales-Molina JA, Mateu-de Antonio J, Marin-Casino M, Grau S \"Linezolid-associated serotonin syndrome: what we can learn from cases reported so far.\" J Antimicrob Chemother 56 (2005):  1176-8[80] DeBellis RJ, Schaefer OP, Liquori M, Volturo GA \"Linezolid-associated serotonin syndrome after concomitant treatment with citalopram and mirtazepine in a critically ill bone marrow transplant recipient.\" J Intensive Care Med 20 (2005):  351-3[81] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[82] Taylor JJ, Wilson JW, Estes LL \"Linezolid and serotonergic drug interactions: a retrospective survey.\" Clin Infect Dis 43 (2006):  180-7[83] Strouse TB, Kerrihard TN, Forscher CA, Zakowski P \"Serotonin syndrome precipitated by linezolid in a medically ill patient on duloxetine.\" J Clin Psychopharmacol 26 (2006):  681-683[84] Keegan MT, Brown DR, Rabinstein AA \"Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs.\" Anesth Analg 103 (2006):  1466-8[85] Paruchuri P, Godkar D, Anandacoomarswamy D, Sheth K, Niranjan S \"Rare case of serotonin syndrome with therapeutic doses of paroxetine.\" Am J Ther 13 (2006):  550-552[86] Steinberg M, Morin AK \"Mild serotonin syndrome associated with concurrent linezolid and fluoxetine.\" Am J Health Syst Pharm 64 (2007):  59-62[87] Packer S, Berman SA \"Serotonin syndrome precipitated by the monoamine oxidase inhibitor linezolid.\" Am J Psychiatry 164 (2007):  346-7[88] Shapiro RE, Tepper SJ \"The serotonin syndrome, triptans, and the potential for drug-drug interactions.\" Headache 47 (2007):  266-9[89] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[90] \"Product Information. Pristiq (desvenlafaxine).\" Wyeth Laboratories  (2008):[91] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[92] \"Product Information. Savella (milnacipran).\" Forest Pharmaceuticals  (2009):[93] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[94] Lee J, Franz L, Goforth HW \"Serotonin syndrome in a chronic-pain patient receiving concurrent methadone, ciprofloxacin, and venlafaxine.\" Psychosomatics 50 (2009):  638-9[95] \"Product Information. Viibryd (vilazodone).\" Trovis Pharmaceuticals LLC  (2011):[96] Mugele J, Nanagas KA, Tormoehlen LM \"Serotonin Syndrome Associated With MDPV Use: A Case Report.\" Ann Emerg Med  (2012):[97] \"Product Information. Oleptro (trazodone).\" Labopharm Inc  (2012):[98] \"Product Information. Fetzima (levomilnacipran).\" Forest Pharmaceuticals  (2013):[99] \"Product Information. Brintellix (vortioxetine).\" Takeda Pharmaceuticals America  (2013):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245645, "ingredient1": "Tramadol", "ingredient2": "Telotristat ethyl", "severity": "Moderate", "effect": "Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of tramadol, which is primarily metabolized by CYP450 3A4 and 2D6.  Reduced opioid efficacy can occur, including opioid withdrawal in physically dependent patients.", "source": "DDInter", "management_text": "Caution is advised when tramadol is used with CYP450 3A4 inducers.  Patients should be monitored for opioid efficacy and signs of withdrawal.  If a CYP450 3A4 inducer is discontinued, monitor for seizures, serotonin syndrome, sedation, and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when tramadol is used with CYP450 3A4 inducers.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289557/", "reference_text": "[1] \"Product Information. Seglentis (celecoxib-tramadol).\" Kowa Pharmaceuticals America (formerly ProEthic)  (2022):", "alternatives_a": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245646, "ingredient1": "Upadacitinib", "ingredient2": "Tramadol", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289559/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Oliceridine, Naltrexone, Oxymorphone, Tapentadol, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Fentanyl, Methadone, Naloxone, Nalbuphine", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More", "updated_at": 1767369485}, {"id": 245647, "ingredient1": "Acetylsalicylic acid", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists.  The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension.  In addition, NSAIDs can cause fluid retention, which also affects blood pressure.", "source": "DDInter", "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.  Renal function should also be evaluated periodically during prolonged coadministration.  The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289560/", "reference_text": "[1] Radack KL, Deck CC, Bloomfield SS \"Ibuprofen interferes with the efficacy of antihypertensive drugs: a randomized, double-blind, placebo-controlled trial of ibuprofen compared with acetaminophen.\" Ann Intern Med 107 (1987):  628-35[2] \"Product Information. Toradol (ketorolac).\" Roche Laboratories  (2002):[3] \"Multum Information Services, Inc. Expert Review Panel\"[4] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More", "alternatives_b": "Sacubitril", "updated_at": 1767369485}, {"id": 245648, "ingredient1": "Diroximel fumarate", "ingredient2": "Acetylsalicylic acid", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity, including aspirin at anti-inflammatory dosages, may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "Administration of non-enteric coated aspirin (up to 325 mg) prior to fumaric acid esters such as monomethyl fumarate or its prodrugs, dimethyl fumarate or diroximel fumarate, may help reduce the incidence and/or severity of flushing.  However, as there are no long-term studies evaluating the continuous use of aspirin in this situation for longer than 4 weeks, caution is advised.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "Administration of non-enteric coated aspirin (up to 325 mg) prior to fumaric acid esters such as monomethyl fumarate or its prodrugs, dimethyl fumarate or diroximel fumarate, may help reduce the incidence and/or severity of flushing.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289561/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):[8] \"Product Information. Bafiertam (monomethyl fumarate).\" Banner Life Sciences  (2023):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Siponimod, Anakinra, More", "updated_at": 1767369485}, {"id": 245649, "ingredient1": "Ibritumomab tiuxetan", "ingredient2": "Acetylsalicylic acid", "severity": "Major", "effect": "Coadministration of radiolabeled ibritumomab tiuxetan and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.", "source": "DDInter", "management_text": "Caution is advised if radiolabeled ibritumomab tiuxetan is used in combination with drugs that interfere with platelet function or coagulation.  Close clinical and laboratory observation for bleeding complications is recommended during and after treatment.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if radiolabeled ibritumomab tiuxetan is used in combination with drugs that interfere with platelet function or coagulation.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289562/", "reference_text": "[1] \"Product Information. In-111 Zevalin (ibritumomab tiuxetan).\" IDEC Pharmaceuticals Corporation", "alternatives_a": "Protein C, Acenocoumarol, Selexipag, Desirudin, Felodipine, Amlodipine, Propranolol, Metoprolol, Carvedilol, Nebivolol, Nifedipine, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245650, "ingredient1": "Acetylsalicylic acid", "ingredient2": "Monomethyl fumarate", "severity": "Moderate", "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity, including aspirin at anti-inflammatory dosages, may increase the potential for adverse renal reactions.", "source": "DDInter", "management_text": "Administration of non-enteric coated aspirin (up to 325 mg) prior to fumaric acid esters such as monomethyl fumarate or its prodrugs, dimethyl fumarate or diroximel fumarate, may help reduce the incidence and/or severity of flushing.  However, as there are no long-term studies evaluating the continuous use of aspirin in this situation for longer than 4 weeks, caution is advised.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.", "mechanism_text": "Synergism", "recommendation": "Administration of non-enteric coated aspirin (up to 325 mg) prior to fumaric acid esters such as monomethyl fumarate or its prodrugs, dimethyl fumarate or diroximel fumarate, may help reduce the incidence and/or severity of flushing.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289564/", "reference_text": "[1] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Australia Pty Ltd  (2022):[2] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Inc  (2023):[3] \"Product Information. Tecfidera (dimethyl fumarate).\" Biogen Idec Ltd  (2022):[4] \"Product Information. Skilarence (dimethyl fumarate).\" Almirall Ltd  (2022):[5] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Ltd  (2022):[6] \"Product Information. Vumerity (diroximel fumarate).\" Biogen Idec Inc  (2023):[7] \"Product Information. Furatec (dimethyl fumarate).\" Pharmacor Pty Ltd  (2022):[8] \"Product Information. Bafiertam (monomethyl fumarate).\" Banner Life Sciences  (2023):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245651, "ingredient1": "Acetylsalicylic acid", "ingredient2": "Tafasitamab", "severity": "Moderate", "effect": "Coadministration of tafasitamab with drugs that can affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextrans, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of bleeding.", "source": "DDInter", "management_text": "When possible, consideration should be given to withholding concomitant medications that may increase bleeding risk in patients treated with tafasitamab.  Close clinical and laboratory monitoring for bleeding complications is recommended if concomitant use is unavoidable.  Refer to the product labeling for guidance on frequency of laboratory monitoring and dose modifications or withholding recommendations for platelet counts below 50,000/mcL.  Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.", "mechanism_text": "Synergism", "recommendation": "When possible, consideration should be given to withholding concomitant medications that may increase bleeding risk in patients treated with tafasitamab.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289565/", "reference_text": "[1] \"Product Information. Monjuvi (tafasitamab).\" Morphosys US  (2020):[2] \"Product Information. Minjuvi (tafasitamab).\" Incyte Biosciences UK Ltd  (2022):[3] \"Product Information. Minjuvi (tafasitamab).\" Incyte Corporation  (2021):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Amivantamab, Atezolizumab, Pembrolizumab, More", "updated_at": 1767369485}, {"id": 245652, "ingredient1": "Acetylsalicylic acid", "ingredient2": "Upadacitinib", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289566/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More", "alternatives_b": "Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Siponimod, Anakinra, More", "updated_at": 1767369485}, {"id": 245653, "ingredient1": "Dihydrocodeine", "ingredient2": "Oxitriptan", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289567/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naltrexone, Acetaminophen, Opium, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245654, "ingredient1": "Dihydrocodeine", "ingredient2": "Abametapir (topical)", "severity": "Moderate", "effect": "Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450 3A4, CYP450 2B6, and CYP450 1A2 isoenzymes and increase their systemic concentrations.", "source": "DDInter", "management_text": "Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion.  If this is not feasible, the manufacturer recommends avoiding use of abametapir lotion.  If abametapir is used, monitor for increased toxicity of the CYP450 3A4, CYP450 2B6, and/or CYP450 1A2 substrate.", "mechanism_text": "Metabolism", "recommendation": "Use of CYP450 3A4, CYP450 2B6, and CYP450 1A2 substrates should generally be avoided within 2 weeks after topical application of abametapir lotion.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289568/", "reference_text": "[1] \"Product Information. Xeglyze (abametapir topical).\" Dr. Reddy's Laboratories Inc  (2020):", "alternatives_a": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245655, "ingredient1": "Dihydrocodeine", "ingredient2": "Acebutolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289569/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Penbutolol, Carteolol", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245656, "ingredient1": "Dihydrocodeine", "ingredient2": "Acrivastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289571/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245657, "ingredient1": "Dihydrocodeine", "ingredient2": "Aldesleukin", "severity": "Moderate", "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS-depressant effects with aldesleukin.", "source": "DDInter", "management_text": "Caution is advised if aldesleukin is used with sedatives, hypnotics, tranquilizers, or other CNS-active medications.  Patients should be monitored for CNS depression and other CNS adverse effects.  Treatment with aldesleukin should be discontinued if severe lethargy or somnolence develop.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if aldesleukin is used with sedatives, hypnotics, tranquilizers, or other CNS-active medications.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289573/", "reference_text": "[1] \"Product Information. Proleukin (aldesleukin).\" Chiron Therapeutics  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Agencia Espala de Medicamentos y Productos Sanitarios Healthcare \"Centro de informaci online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):", "alternatives_a": "Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Peginterferon alfa-2a, Peginterferon beta-1a, Interferon alfacon-1, Interferon beta-1a, Sargramostim, Histamine, More", "alternatives_b": "Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245658, "ingredient1": "Dihydrocodeine", "ingredient2": "Alfuzosin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289575/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Finasteride, Dutasteride, Tadalafil", "alternatives_b": "Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 245659, "ingredient1": "Dihydrocodeine", "ingredient2": "Almotriptan", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289576/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Naltrexone, Opium, Dextropropoxyphene, Ibuprofen, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245660, "ingredient1": "Dihydrocodeine", "ingredient2": "Alprazolam", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289577/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245661, "ingredient1": "Alvimopan", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Recent exposure to opioids can increase the sensitivity to mu opioid receptor antagonists.", "source": "DDInter", "management_text": "The use of alvimopan is contraindicated in patients who have received therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan administration.  Caution is advised in patients who have received more than 3 doses of an opioid within the week prior to surgery, as these patients were not studied in the postoperative ileus clinical trials.  Patients with recent exposure to opioids should be monitored for increased adverse effects such as abdominal pain, nausea and vomiting, and diarrhea.", "mechanism_text": "Synergism", "recommendation": "The use of alvimopan is contraindicated in patients who have received therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan administration.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289578/", "reference_text": "[1] \"Product Information. Entereg (alvimopan).\" GlaxoSmithKline  (2008):", "alternatives_a": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "alternatives_b": "Naltrexone, Tapentadol, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245662, "ingredient1": "Amifampridine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "The use of amifampridine is associated with a dose-related risk of seizures, and the risk may be further increased when coadministered with other drugs that can reduce the seizure threshold.", "source": "DDInter", "management_text": "Caution is advised if amifampridine is coadministered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with other risk factors for seizures (e.g., head trauma; brain tumor; severe hepatic cirrhosis; metabolic disorders; CNS infections; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; diabetes treated with oral hypoglycemic agents or insulin).  Consider discontinuation or dose reduction of amifampridine in patients who experience a seizure during treatment.  Use of amifampridine is contraindicated in patients with a history of seizures.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if amifampridine is coadministered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289579/", "reference_text": "[1] EMEA. European Medicines Agency \"EPARs. European Union Public Assessment Reports.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid\"   (2007):[2] \"Product Information. Firdapse (amifampridine).\" Catalyst Pharmaceuticals, Inc.  (2018):", "alternatives_a": "Dalfampridine, Inotersen, Riluzole, Tafamidis", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245663, "ingredient1": "Amiloride", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289580/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Finerenone", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245664, "ingredient1": "Amitriptyline", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289581/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245665, "ingredient1": "Amlodipine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289582/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Aliskiren, Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245666, "ingredient1": "Amobarbital", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289583/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Acetylsalicylic acid, Naloxone, Ibuprofen, Naltrexone", "updated_at": 1767369485}, {"id": 245667, "ingredient1": "Amoxapine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289584/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245668, "ingredient1": "Amyl Nitrite", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289585/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245669, "ingredient1": "Dihydrocodeine", "ingredient2": "Apalutamide", "severity": "Moderate", "effect": "Coadministration with apalutamide may decrease the plasma concentrations of drugs that are substrates of the metabolic enzymes CYP450 3A4, CYP450 2C19, CYP450 2C9, and uridine diphosphate glucuronosyltransferase (UGT), as well as substrates of the membrane transporters organic anion transporting polypeptide (OATP) 1B1, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP).", "source": "DDInter", "management_text": "Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, CYP450 2C19, CYP450 2C9, UGT, OATP1B1, P-gp and/or BCRP, particularly sensitive substrates or those with a narrow therapeutic range.  Substitution for these medications is recommended when possible, or monitor for potential loss of therapeutic efficacy if coadministration is required.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a CYP450 inducer like apalutamide and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, CYP450 2C19, CYP450 2C9, UGT, OATP1B1, P-gp and/or BCRP, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289586/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Erleada (apalutamide).\" Janssen Biotech, Inc.  (2018):", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Dezocine, Opium, Pentazocine, Acetylsalicylic acid, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245670, "ingredient1": "Dihydrocodeine", "ingredient2": "Apomorphine", "severity": "Moderate", "effect": "Central nervous system (CNS) depressant effects may be additively or synergistically increased in patients using apomorphine in combination with other drugs that can also cause these effects.", "source": "DDInter", "management_text": "The use of other sedating drugs should generally be avoided during apomorphine treatment.  Patients prescribed these agents concurrently should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.  Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  If patients experience increased episodes of falling asleep during normal daily activities, they should avoid driving and other potentially hazardous activities until they have contacted their physician.", "mechanism_text": "Synergism", "recommendation": "The use of other sedating drugs should generally be avoided during apomorphine treatment.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289587/", "reference_text": "[1] \"Product Information. Apokyn (apomorphine).\" Mylan Pharmaceuticals Inc  (2004):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, Phenyl salicylate, More", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245671, "ingredient1": "Dihydrocodeine", "ingredient2": "Aprepitant", "severity": "Moderate", "effect": "Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.", "source": "DDInter", "management_text": "Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.  Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289589/", "reference_text": "[1] \"Product Information. Emend (aprepitant).\" Merck & Co., Inc  (2003):[2] \"Product Information. Emend for Injection (fosaprepitant).\" Merck & Co., Inc  (2008):", "alternatives_a": "Rolapitant", "alternatives_b": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245672, "ingredient1": "Dihydrocodeine", "ingredient2": "Aripiprazole", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289590/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245673, "ingredient1": "Dihydrocodeine", "ingredient2": "Armodafinil", "severity": "Minor", "effect": "Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  Modafinil and armodafinil are modest inducers of CYP450 3A4, and pharmacokinetic studies suggest that their effects may be primarily intestinal rather than hepatic.", "source": "DDInter", "management_text": "Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  Modafinil and armodafinil are modest inducers of CYP450 3A4, and pharmacokinetic studies suggest that their effects may be primarily intestinal rather than hepatic.  Thus, clinically significant interactions would most likely be expected with drugs that have low oral bioavailability due to significant intestinal CYP450 3A4-mediated first-pass metabolism (e.g., buspirone, cyclosporine, lovastatin, midazolam, saquinavir, simvastatin, sirolimus, tacrolimus, triazolam, calcium channel blockers).  However, the potential for interaction should be considered with any drug metabolized by CYP450 3A4, especially given the high degree of interpatient variability with respect to CYP450-mediated metabolism.  Pharmacologic response to these drugs may be altered and should be monitored more closely whenever modafinil or armodafinil is added to or withdrawn from therapy.  Dosage adjustments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289591/", "reference_text": "[1] \"Product Information. Provigil (modafinil).\" Cephalon, Inc  (2001):[2] Robertson P, Decory HH, Madan A, Parkinson A \"In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.\" Drug Metab Dispos 28 (2000):  664-71[3] Robertson P Jr, Hellriegel ET, Arora S, Nelson M \"Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers.\" Clin Pharmacol Ther 71 (2002):  46-56[4] Doherty MM, Charman WN \"The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?\" Clin Pharmacokinet 41 (2002):  235-53[5] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc  (2007):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "updated_at": 1767369485}, {"id": 245674, "ingredient1": "Dihydrocodeine", "ingredient2": "Asenapine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289593/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245675, "ingredient1": "Dihydrocodeine", "ingredient2": "Atenolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289594/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Penbutolol, Penbutolol, Carteolol, Acetylsalicylic acid, Ivabradine", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245676, "ingredient1": "Dihydrocodeine", "ingredient2": "Atropine", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289595/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Ketorolac, Homatropine, Ephedrine, Tropicamide, Phenylephrine", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245677, "ingredient1": "Dihydrocodeine", "ingredient2": "Attapulgite", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289596/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pectin, Activated charcoal", "alternatives_b": "Naltrexone, Naloxone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Fentanyl, Ibuprofen, Celecoxib, Acetylsalicylic acid, Buprenorphine", "updated_at": 1767369485}, {"id": 245678, "ingredient1": "Dihydrocodeine", "ingredient2": "Azatadine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289598/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245679, "ingredient1": "Dihydrocodeine", "ingredient2": "Azelastine (nasal)", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289599/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245680, "ingredient1": "Dihydrocodeine", "ingredient2": "Azilsartan medoxomil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289600/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "updated_at": 1767369485}, {"id": 245681, "ingredient1": "Dihydrocodeine", "ingredient2": "Baclofen", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289601/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245682, "ingredient1": "Dihydrocodeine", "ingredient2": "Baricitinib", "severity": "Moderate", "effect": "Coadministration of Janus kinase (JAK) inhibitors with corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and/or opioids may increase the risk of gastrointestinal (GI) perforation.", "source": "DDInter", "management_text": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.  Patients should be advised to contact their healthcare provider if they experience signs and symptoms of GI perforation such as severe abdominal pain, fever, chills, nausea, or vomiting.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended when using JAK inhibitors in patients with a history of peptic ulceration or diverticular disease and in patients receiving concomitant treatment with drugs associated with an increased risk of GI perforation such as corticosteroids, NSAIDs, and opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289602/", "reference_text": "[1] Strate LL, Liu YL, Huang ES, Giovannucci EL, Chan AT \"Use of aspirin or nonsteroidal anti-inflammatory drugs increases risk for diverticulitis and diverticular bleeding.\" Gastroenterology 140 (2011):  1427-33[2] Medicines and Healthcare products Regulatory Agency \"Baricitinib (Olumiant): increased risk of diverticulitis, particularly in patients with risk factors.  https://www.gov.uk/drug-safety-update/baricitinib-olumiant-increased-risk-of-diverticulitis-particularly-in-patients-with-risk-factors\"   (2020):[3] \"Product Information. Olumiant (bARICITinib).\" Eli Lilly Australia Pty Ltd  (2021):[4] \"Product Information. Olumiant (baricitinib).\" Eli Lilly and Company Ltd  (2023):[5] Hoisnard L, Lebrun-Vignes B, Maury S, et al. \"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.\" Sci Rep 12 (2022):  7140[6] \"Product Information. Olumiant (baricitinib).\" Lilly, Eli and Company  (2023):[7] \"Product Information. Xeljanz (tofacitinib).\" Pfizer U.S. Pharmaceuticals Group  (2023):[8] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Ltd  (2023):[9] \"Product Information. Xeljanz (tOFACitinib).\" Pfizer Australia Pty Ltd  (2023):[10] \"Product Information. Rinvoq (upadacitinib).\" AbbVie US LLC  (2023):[11] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Ltd  (2023):[12] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Pty Ltd  (2023):[13] \"Product Information. Olumiant (baricitinib).\" Eli Lilly Canada Inc  (2022):[14] \"Product Information. Xeljanz (tofacitinib).\" Pfizer Canada ULC  (2022):[15] \"Product Information. Rinvoq (upadacitinib).\" AbbVie Corporation  (2022):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Acetaminophen, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245683, "ingredient1": "Dihydrocodeine", "ingredient2": "Belladonna", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289603/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245684, "ingredient1": "Dihydrocodeine", "ingredient2": "Benazepril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289605/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tapentadol, Naloxone, Dezocine, Oxymorphone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245685, "ingredient1": "Dihydrocodeine", "ingredient2": "Bendroflumethiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289606/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245686, "ingredient1": "Dihydrocodeine", "ingredient2": "Benzthiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289607/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245687, "ingredient1": "Dihydrocodeine", "ingredient2": "Benzatropine", "severity": "Moderate", "effect": "Central anticholinergic agents may have additive central nervous system (CNS) effects with cannabinoids, barbiturates, opiates, and alcohol.", "source": "DDInter", "management_text": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.  Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289608/", "reference_text": "[1] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245688, "ingredient1": "Dihydrocodeine", "ingredient2": "Bepridil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289609/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Dezocine, Celecoxib, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245689, "ingredient1": "Dihydrocodeine", "ingredient2": "Berotralstat", "severity": "Moderate", "effect": "Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.", "source": "DDInter", "management_text": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.  Clinical and laboratory monitoring are recommended following the initiation of berotralstat, and the individual dosage of the concomitant agents adjusted as needed.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289610/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Orladeyo (berotralstat).\" BioCryst Pharmaceuticals Inc  (2021):", "alternatives_a": "Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, Ibuprofen, Celecoxib, More", "updated_at": 1767369485}, {"id": 245690, "ingredient1": "Dihydrocodeine", "ingredient2": "Betaxolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289611/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Naloxone", "updated_at": 1767369485}, {"id": 245691, "ingredient1": "Dihydrocodeine", "ingredient2": "Biperiden", "severity": "Moderate", "effect": "Central anticholinergic agents may have additive central nervous system (CNS) effects with cannabinoids, barbiturates, opiates, and alcohol.", "source": "DDInter", "management_text": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.  Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289612/", "reference_text": "[1] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245692, "ingredient1": "Dihydrocodeine", "ingredient2": "Bismuth subgallate", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289613/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Naloxone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Fentanyl, Ibuprofen, Celecoxib, Acetylsalicylic acid, Buprenorphine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245693, "ingredient1": "Dihydrocodeine", "ingredient2": "Bismuth subsalicylate", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289614/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Naltrexone, Naloxone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Fentanyl, Ibuprofen, Celecoxib, Buprenorphine", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245694, "ingredient1": "Dihydrocodeine", "ingredient2": "Bisoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289615/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Penbutolol, Carteolol", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245695, "ingredient1": "Dihydrocodeine", "ingredient2": "Boceprevir", "severity": "Moderate", "effect": "Coadministration with boceprevir may increase the plasma concentrations of drugs that are metabolized by CYP450 3A4.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by boceprevir.", "source": "DDInter", "management_text": "Caution is advised if boceprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever boceprevir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if boceprevir must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289616/", "reference_text": "[1] \"Product Information. Victrelis (boceprevir).\" Schering-Plough Corporation  (2011):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, More", "alternatives_b": "Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, More", "updated_at": 1767369485}, {"id": 245696, "ingredient1": "Dihydrocodeine", "ingredient2": "Bosentan", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289617/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Tapentadol, Oxymorphone, Meperidine, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245697, "ingredient1": "Dihydrocodeine", "ingredient2": "Brexanolone", "severity": "Moderate", "effect": "Coadministration with central nervous system (CNS) depressants (e.g., alcohol, benzodiazepines, opioids) or antidepressants may enhance the sedative effects of brexanolone and increase the likelihood or severity of sedation-related adverse reactions.", "source": "DDInter", "management_text": "Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.  Patients should be closely monitored for excessive sedation and sudden loss of consciousness and have continuous pulse oximetry monitoring.  During the brexanolone infusion, monitor for sedative effects every 2 hours during planned, non-sleep periods, and immediately stop the infusion if there are signs or symptoms of excessive sedation.  After symptoms resolve, the infusion may be resumed at the same or lower dose as clinically appropriate.  If pulse oximetry reveals hypoxia, immediately stop the infusion and do not resume infusion following resolution of the hypoxia.  Patients should be cautioned against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until sedative effects of brexanolone and other concomitant medications have dissipated.  Patients must be accompanied during interactions with their child(ren) while receiving brexanolone because of the potential for excessive sedation and sudden loss of consciousness.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during concomitant use of brexanolone with CNS depressants, antidepressants, or other agents that cause sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289618/", "reference_text": "[1] \"Product Information. Zulresso (brexanolone).\" Sage Therapeutics, Inc.  (2019):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245698, "ingredient1": "Dihydrocodeine", "ingredient2": "Brexpiprazole", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289619/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245699, "ingredient1": "Dihydrocodeine", "ingredient2": "Brigatinib", "severity": "Moderate", "effect": "Coadministration with brigatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  Brigatinib has been shown in vitro to induce CYP450 3A4 at clinically relevant plasma concentrations.", "source": "DDInter", "management_text": "Caution is advised when brigatinib is used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever brigatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when brigatinib is used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289620/", "reference_text": "[1] \"Product Information. Alunbrig (brigatinib).\" Ariad Pharmaceuticals Inc  (2017):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Codeine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Meperidine, Acetaminophen, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, More", "updated_at": 1767369485}, {"id": 245700, "ingredient1": "Dihydrocodeine", "ingredient2": "Brimonidine (ophthalmic)", "severity": "Moderate", "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.  Additive hypotensive effects and orthostasis may also occur with some CNS depressants and other agents that have these effects, particularly during initial dosing and/or parenteral administration.", "source": "DDInter", "management_text": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289621/", "reference_text": "[1] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[2] \"Product Information. Alphagan (brimonidine ophthalmic).\" Allergan Inc  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Pekdemir M, Yanturali S, Karakus G \"More than just an ocular solution.\" Emerg Med J 22 (2005):  753-4[5] \"Product Information. Mirvaso (brimonidine topical).\" Galderma Laboratories Inc  (2013):", "alternatives_a": "Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, Abrocitinib, More", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245701, "ingredient1": "Dihydrocodeine", "ingredient2": "Brimonidine (topical)", "severity": "Moderate", "effect": "Topically administered alpha-2 adrenergic receptor agonists such as apraclonidine and brimonidine are systemically absorbed, with the potential for producing rare but clinically significant systemic effects.  Although the interaction has not been specifically studied, the possibility of an additive or potentiating effect with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, anxiolytics, sedatives, and anesthetics should be considered.  Additive hypotensive effects and orthostasis may also occur with some CNS depressants and other agents that have these effects, particularly during initial dosing and/or parenteral administration.", "source": "DDInter", "management_text": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also avoid rising abruptly from a sitting or recumbent position and notify their physician if they experience orthostasis or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Patients receiving topical alpha-2 adrenergic receptor agonists in combination with agents that can cause CNS depression should be made aware of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness and confusion, and counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289622/", "reference_text": "[1] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[2] \"Product Information. Alphagan (brimonidine ophthalmic).\" Allergan Inc  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Pekdemir M, Yanturali S, Karakus G \"More than just an ocular solution.\" Emerg Med J 22 (2005):  753-4[5] \"Product Information. Mirvaso (brimonidine topical).\" Galderma Laboratories Inc  (2013):", "alternatives_a": "Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, Abrocitinib, More", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245702, "ingredient1": "Dihydrocodeine", "ingredient2": "Brivaracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289623/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245703, "ingredient1": "Dihydrocodeine", "ingredient2": "Bromocriptine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289624/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline, Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245704, "ingredient1": "Dihydrocodeine", "ingredient2": "Brompheniramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289625/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245705, "ingredient1": "Dihydrocodeine", "ingredient2": "Bumetanide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289626/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245706, "ingredient1": "Dihydrocodeine", "ingredient2": "Buprenorphine", "severity": "Major", "effect": "Concomitant use of opioids with other central nervous system (CNS) depressants including mixed agonist-antagonist or partial agonist opioids may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased.  On the other hand, mixed agonist-antagonist or partial agonist opioids can reduce the pharmacologic effects of other opioid agonists.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary (e.g., when initiating a switch from one opioid to the other), the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Additional caution is advisable when a mixed agonist-antagonist or partial agonist opioid is added to an existing opioid regimen, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the mixed agonist-antagonist or partial agonist opioid.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Others", "recommendation": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289627/", "reference_text": "[1] Moldenhauer CC, Roach GW, Finlayson DC, et al. \"Nalbuphine antagonism of ventilatory depression following high-dose fentanyl anesthesia.\" Anesthesiology 62 (1985):  647-50[2] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[3] Strain EC, Preston KL, Liebson IA, Bigelow GE \"Precipitated withdrawal by pentazocine in methadone-maintained volunteers.\" J Pharmacol Exp Ther 267 (1993):  624-34[4] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[5] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[6] \"Product Information. Talwin NX (pentazocine).\" Sanofi Winthrop Pharmaceuticals  (2001):[7] \"Product Information. Stadol (butorphanol).\" Allscrips Pharmaceutical Company  (2001):[8] \"Product Information. Dalgan (dezocine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Suboxone (buprenorphine-naloxone).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[10] \"Product Information. Subutex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[11] \"Product Information. Butrans (buprenorphine).\" Purdue Pharma LP  (2010):", "alternatives_a": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Buprenorphine", "updated_at": 1767369485}, {"id": 245707, "ingredient1": "Dihydrocodeine", "ingredient2": "Bupropion", "severity": "Major", "effect": "The use of bupropion is associated with a dose-related risk of seizures.  The risk may be further increased when coadministered with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline).  These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Extreme caution is advised if bupropion is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with a history of seizures or other risk factors for seizures (e.g., head trauma; brain tumor; severe hepatic cirrhosis; metabolic disorders; CNS infections; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; diabetes treated with oral hypoglycemic agents or insulin).  Bupropion as well as concomitant medications should be initiated at the lower end of the dosage range and titrated gradually as needed and as tolerated.  The maximum recommended dosage for the specific bupropion formulation should not be exceeded.  Bupropion should be discontinued and not restarted in patients who experience a seizure during treatment.", "mechanism_text": "Synergism", "recommendation": "Extreme caution is advised if bupropion is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with a history of seizures or other risk factors for seizures (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289628/", "reference_text": "[1] Rosenstein DL, Nelson JC, Jacobs SC \"Seizures associated with antidepressants: a review.\" J Clin Psychiatry 54 (1993):  289-99[2] James WA, Lippmann S \"Bupropion: overview and prescribing guidelines in depression.\" South Med J 84 (1991):  222-4[3] Johnston JA, Lineberry CG, Ascher JA, et al. \"A 102-center prospective study of seizure in association with bupropion.\" J Clin Psychiatry 52 (1991):  450-6[4] Gittelman DK, Kirby MG \"A seizure following bupropion overdose.\" J Clin Psychiatry 54 (1993):  162[5] Sheehan DV, Welch JB, Fishman SM \"A case of bupropion-induced seizure.\" J Nerv Ment Dis 174 (1986):  496-8[6] Dufresne RL, Weber SS, Becker RE \"Bupropion hydrochloride.\" Drug Intell Clin Pharm 18 (1984):  957-64[7] \"Product Information. Wellbutrin (bupropion).\" Glaxo Wellcome  (2001):[8] Masco HL, Kiev A, Holloman LC, Batey SR, Johnston JA, Lineberry CG \"Safety and efficacy of bupropion and nortriptyline in outpatients with depression.\" Curr Ther Res Clin Exp 55 (1994):  851-63[9] Storrow AB \"Bupropion overdose and seizure.\" Am J Emerg Med 12 (1994):  183-4[10] \"Product Information. Wellbutrin SR (bupropion).\" Glaxo Wellcome  (2001):[11] \"Product Information. Zyban (bupropion).\" Glaxo Wellcome  (2001):[12] Pisani F, Spina E, Oteri G \"Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice.\" Epilepsia 40(Suppl 10) (1999):  S48-56[13] \"Product Information. Wellbutrin XL (bupropion).\" GlaxoSmithKline  (2003):[14] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[15] \"Product Information. Aplenzin (bupropion).\" sanofi-aventis  (2009):", "alternatives_a": "Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "alternatives_b": "Naloxone", "updated_at": 1767369485}, {"id": 245708, "ingredient1": "Dihydrocodeine", "ingredient2": "Buspirone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289629/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245709, "ingredient1": "Dihydrocodeine", "ingredient2": "Butabarbital", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289630/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245710, "ingredient1": "Dihydrocodeine", "ingredient2": "Butalbital", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289631/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245711, "ingredient1": "Dihydrocodeine", "ingredient2": "Butorphanol", "severity": "Major", "effect": "Concomitant use of opioids with other central nervous system (CNS) depressants including mixed agonist-antagonist or partial agonist opioids may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased.  On the other hand, mixed agonist-antagonist or partial agonist opioids can reduce the pharmacologic effects of other opioid agonists.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary (e.g., when initiating a switch from one opioid to the other), the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Additional caution is advisable when a mixed agonist-antagonist or partial agonist opioid is added to an existing opioid regimen, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the mixed agonist-antagonist or partial agonist opioid.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Others", "recommendation": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289632/", "reference_text": "[1] Moldenhauer CC, Roach GW, Finlayson DC, et al. \"Nalbuphine antagonism of ventilatory depression following high-dose fentanyl anesthesia.\" Anesthesiology 62 (1985):  647-50[2] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[3] Strain EC, Preston KL, Liebson IA, Bigelow GE \"Precipitated withdrawal by pentazocine in methadone-maintained volunteers.\" J Pharmacol Exp Ther 267 (1993):  624-34[4] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[5] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[6] \"Product Information. Talwin NX (pentazocine).\" Sanofi Winthrop Pharmaceuticals  (2001):[7] \"Product Information. Stadol (butorphanol).\" Allscrips Pharmaceutical Company  (2001):[8] \"Product Information. Dalgan (dezocine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Suboxone (buprenorphine-naloxone).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[10] \"Product Information. Subutex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[11] \"Product Information. Butrans (buprenorphine).\" Purdue Pharma LP  (2010):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Acetylsalicylic acid, Butorphanol", "updated_at": 1767369485}, {"id": 245712, "ingredient1": "Dihydrocodeine", "ingredient2": "Cannabidiol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289634/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245713, "ingredient1": "Dihydrocodeine", "ingredient2": "Captopril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289636/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tapentadol, Naloxone, Dezocine, Oxymorphone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245714, "ingredient1": "Dihydrocodeine", "ingredient2": "Carbamazepine", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289637/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Lacosamide", "alternatives_b": "Naloxone", "updated_at": 1767369485}, {"id": 245715, "ingredient1": "Dihydrocodeine", "ingredient2": "Pentoxyverine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289638/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245716, "ingredient1": "Dihydrocodeine", "ingredient2": "Carbinoxamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289639/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245717, "ingredient1": "Dihydrocodeine", "ingredient2": "Cariprazine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289640/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245718, "ingredient1": "Dihydrocodeine", "ingredient2": "Carisoprodol", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289641/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245719, "ingredient1": "Dihydrocodeine", "ingredient2": "Carvedilol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289642/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Penbutolol, Carteolol, Acetylsalicylic acid, Ivabradine", "alternatives_b": "Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 245720, "ingredient1": "Dihydrocodeine", "ingredient2": "Celecoxib", "severity": "Moderate", "effect": "Coadministration with celecoxib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by celecoxib.", "source": "DDInter", "management_text": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever celecoxib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if celecoxib must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289643/", "reference_text": "[1] \"Product Information. Celebrex (celecoxib).\" Searle  (2001):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen, Rabeprazole, Ketoprofen, Diclofenac, Piroxicam, Rofecoxib, Sulindac, Meclofenamic acid, More", "alternatives_b": "Tapentadol, Oxymorphone, Dezocine, Opium, Celecoxib, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245721, "ingredient1": "Dihydrocodeine", "ingredient2": "Cenobamate", "severity": "Moderate", "effect": "Coadministration with cenobamate may decrease the plasma concentrations and pharmacologic effects of CYP450 3A4 substrates.  The proposed mechanism is cenobamate-mediated induction of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cenobamate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cenobamate is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic index.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289644/", "reference_text": "[1] \"Product Information. Xcopri (cenobamate).\" SK Life Science, Inc.  (2020):", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245722, "ingredient1": "Dihydrocodeine", "ingredient2": "Ceritinib", "severity": "Moderate", "effect": "Coadministration with ceritinib may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 2C9 and/or 3A4.  In vitro data suggest that ceritinib may inhibit these isoenzymes at clinical concentrations.", "source": "DDInter", "management_text": "Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.  These drugs include alfentanil, colchicine, cyclosporine, ergot derivatives, fentanyl, lovastatin, simvastatin, oral midazolam, triazolam, phenytoin, pimozide, quinidine, sildenafil, sirolimus, tacrolimus, and warfarin.  If coadministration is required, dosage reductions for the CYP450 2C9 or 3A4 substrates should be considered.", "mechanism_text": "Metabolism", "recommendation": "Concomitant use of ceritinib and sensitive CYP450 2C9/3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289645/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Zykadia (ceritinib).\" Novartis Pharmaceuticals  (2014):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Codeine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Hydromorphone, Dezocine, Opium, Ibuprofen, Pentazocine, Acetylsalicylic acid, More", "updated_at": 1767369485}, {"id": 245723, "ingredient1": "Dihydrocodeine", "ingredient2": "Cetirizine", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289646/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc  (2007):", "alternatives_a": "Ketotifen, Olopatadine, Cromoglicic acid, Nedocromil, Phenylephrine, Azelastine, Brimonidine, Ketotifen, Fexofenadine, Loratadine, Astemizole, More", "alternatives_b": "Dextropropoxyphene, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245724, "ingredient1": "Dihydrocodeine", "ingredient2": "Clofedanol", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289647/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Benzonatate", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245725, "ingredient1": "Dihydrocodeine", "ingredient2": "Chloral hydrate", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289648/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245726, "ingredient1": "Dihydrocodeine", "ingredient2": "Chlorcyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289649/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245727, "ingredient1": "Dihydrocodeine", "ingredient2": "Chlordiazepoxide", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289650/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245728, "ingredient1": "Dihydrocodeine", "ingredient2": "Chlormezanone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289651/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245729, "ingredient1": "Dihydrocodeine", "ingredient2": "Chlorothiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289652/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245730, "ingredient1": "Dihydrocodeine", "ingredient2": "Chlorphenesin", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289653/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Salicylic acid, Fluconazole, Selenium Sulfide, Thiabendazole, Miconazole, Nystatin, Ciclopirox, Griseofulvin, Ketoconazole, Econazole, Flucytosine, More", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245731, "ingredient1": "Dihydrocodeine", "ingredient2": "Chlorpheniramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289654/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Acetylsalicylic acid, Naloxone, Naltrexone, Celecoxib", "updated_at": 1767369485}, {"id": 245732, "ingredient1": "Dihydrocodeine", "ingredient2": "Chlorpromazine", "severity": "Major", "effect": "Concomitant use of opioids with central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, antipsychotics).", "source": "DDInter", "management_text": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.  Delayed diagnosis and treatment of constipation may increase the risk of severe complications, which can result in hospitalization, surgery, and death.  Patients should be advised to maintain adequate hydration, physical activity and fiber intake, and to report any changes in the frequency or character of bowel movements as well as signs and symptoms of potential complications of ileus such as nausea, vomiting, abdominal distension, and abdominal pain.  If constipation or gastrointestinal hypomotility is identified, monitor closely and treat promptly with appropriate laxatives to prevent severe complications.  Consider prophylactic laxatives in high risk patients, such as those with a history of constipation, colonic disease, or lower abdominal surgery.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289655/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[3] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. FazaClo (clozapine).\" Jazz Pharmaceuticals  (2015):[7] \"Product Information. Versacloz (clozapine).\" Jazz Pharmaceuticals  (2015):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245733, "ingredient1": "Dihydrocodeine", "ingredient2": "Chlorthalidone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289656/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 245734, "ingredient1": "Dihydrocodeine", "ingredient2": "Chlorzoxazone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289657/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acetylsalicylic acid, Naloxone, Celecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245735, "ingredient1": "Dihydrocodeine", "ingredient2": "Cimetidine", "severity": "Moderate", "effect": "Cimetidine may increase the effects of narcotic analgesics.  Cases of respiratory depression, potentially fatal, have been reported in patients receiving cimetidine with morphine.  The mechanism is unclear but may be related to decreased metabolism of the opioid.  A similar interaction may also occur with diamorphine, for which morphine is the primary active metabolite.", "source": "DDInter", "management_text": "Patients' vital signs should be closely monitored while receiving this combination.  If respiratory depression is greater than otherwise expected, consider decreasing the dose of the opioid and/or of cimetidine as necessary.", "mechanism_text": "Metabolism", "recommendation": "Patients' vital signs should be closely monitored while receiving this combination.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289658/", "reference_text": "[1] Lam AM, Clement JL \"Effect of cimetidine premedication on morphine-induced ventilatory depression.\" Can Anaesth Soc J 31 (1984):  36-43[2] Fine A, Churchill DN \"Potentially lethal interaction of cimetidine and morphine.\" Can Med Assoc J 124 (1981):  1434, 1436[3] Lam AM \"Potentially lethal interaction of cimetidine and morphine.\" Can Med Assoc J 125 (1981):  820[4] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[5] \"Product Information. Morphine Sulfate (morphine).\" Abbott Pharmaceutical[6] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):", "alternatives_a": "Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, Amoxicillin, Pantoprazole, Misoprostol, Esomeprazole, Ranitidine, Levofloxacin, More", "alternatives_b": "Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 245736, "ingredient1": "Dihydrocodeine", "ingredient2": "Cinacalcet", "severity": "Moderate", "effect": "Coadministration with cinacalcet may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 2D6 activity by cinacalcet, which is expected to occur in patients who are CYP450 2D6 extensive metabolizers (approximately 93% of Caucasians and more than 98% of Asians and individuals of African descent).  Concurrent administration of cinacalcet (25 or 100 mg) increased the systemic exposure of amitriptyline (50 mg) and its active metabolite, nortriptyline, by approximately 20% in CYP450 2D6 extensive metabolizers.  However, because amitriptyline is metabolized by multiple CYP450 isoenzymes in addition to 2D6, the degree of interaction with cinacalcet may be less than that expected for other drugs that are primarily metabolized by 2D6.", "source": "DDInter", "management_text": "Caution is advised if cinacalcet must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range (e.g., class IC antiarrhythmic agents, phenothiazines, certain beta blockers, and most tricyclic antidepressants).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever cinacalcet is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if cinacalcet must be used concurrently with medications that undergo metabolism by CYP450 2D6, particularly those with a narrow therapeutic range (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289659/", "reference_text": "[1] \"Product Information. Sensipar (cinacalcet).\" Amgen USA  (2004):[2] Pharmaceutical Society of Australia \"APPGuide online. Australian prescription products guide online.  http://www.appco.com.au/appguide/default.asp\"   (2006):[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol, Paricalcitol", "alternatives_b": "Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Meperidine, Hydromorphone, Dezocine, Opium, Methadone, Pentazocine, More", "updated_at": 1767369485}, {"id": 245737, "ingredient1": "Dihydrocodeine", "ingredient2": "Citalopram", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289660/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245738, "ingredient1": "Dihydrocodeine", "ingredient2": "Clemastine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289661/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245739, "ingredient1": "Dihydrocodeine", "ingredient2": "Clevidipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289662/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245740, "ingredient1": "Dihydrocodeine", "ingredient2": "Clidinium", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289663/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245741, "ingredient1": "Dihydrocodeine", "ingredient2": "Clobazam", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289664/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245742, "ingredient1": "Dihydrocodeine", "ingredient2": "Clomipramine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289665/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245743, "ingredient1": "Dihydrocodeine", "ingredient2": "Clonazepam", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289666/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Lacosamide", "alternatives_b": "Naloxone", "updated_at": 1767369485}, {"id": 245744, "ingredient1": "Dihydrocodeine", "ingredient2": "Clonidine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289667/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245745, "ingredient1": "Dihydrocodeine", "ingredient2": "Clopidogrel", "severity": "Moderate", "effect": "Coadministration with opioid agonists may delay and reduce the absorption of orally administered P2Y12 inhibitors (e.g., clopidogrel, prasugrel, ticagrelor).  The proposed mechanism may involve opioid-mediated slowed gastric emptying.", "source": "DDInter", "management_text": "Although data are limited, caution is recommended when orally administered P2Y12 inhibitors are given concomitantly with opioid agonists.  In acute coronary syndrome patients who require an opioid agonist, the use of a parenteral antiplatelet agent, such as cangrelor, should be considered.", "mechanism_text": "Absorption", "recommendation": "Although data are limited, caution is recommended when orally administered P2Y12 inhibitors are given concomitantly with opioid agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289668/", "reference_text": "[1] \"Product Information. Plavix (clopidogrel).\" Bristol-Myers Squibb  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[5] \"Product Information. Effient (prasugrel).\" Lilly, Eli and Company  (2009):[6] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals  (2011):[7] Hobl EL, Stimpfl T, Ebner J, et al. \"Morphine Decreases Clopidogrel Concentrations and Effects: A Randomized, Double Blind, Placebo-Controlled Trial.\" J Am Coll Cardiol  (2013):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] Hobl EL, Reiter B, Schoergenhofer C, et al. \"Morphine Decreases Ticagrelor Concentrations but not its Antiplatelet Effects: A  Randomized Trial in Healthy Volunteers.\" Eur J Clin Invest 46 (2015):  7-14[10] Hobl EL, Reiter B, Schoergenhofer C, et al. \"Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy  volunteers.\" Clin Res Cardiol 105 (2015):  349-55[11] Kubica J, Adamski P, Ostrowska M, et al. \"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.\" Eur Heart J  (2015):[12] Kubica J, Kubica A, Jilma B, et al. \"Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors.\" Int J Cardiol 215 (2016):  201-208", "alternatives_a": "Betrixaban, Apixaban, Cilostazol, Iloprost, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, More", "alternatives_b": "Naltrexone", "updated_at": 1767369485}, {"id": 245746, "ingredient1": "Dihydrocodeine", "ingredient2": "Clorazepic acid", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289669/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245747, "ingredient1": "Dihydrocodeine", "ingredient2": "Clozapine", "severity": "Major", "effect": "Concomitant use of opioids with central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, antipsychotics).", "source": "DDInter", "management_text": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.  Delayed diagnosis and treatment of constipation may increase the risk of severe complications, which can result in hospitalization, surgery, and death.  Patients should be advised to maintain adequate hydration, physical activity and fiber intake, and to report any changes in the frequency or character of bowel movements as well as signs and symptoms of potential complications of ileus such as nausea, vomiting, abdominal distension, and abdominal pain.  If constipation or gastrointestinal hypomotility is identified, monitor closely and treat promptly with appropriate laxatives to prevent severe complications.  Consider prophylactic laxatives in high risk patients, such as those with a history of constipation, colonic disease, or lower abdominal surgery.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289670/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[3] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. FazaClo (clozapine).\" Jazz Pharmaceuticals  (2015):[7] \"Product Information. Versacloz (clozapine).\" Jazz Pharmaceuticals  (2015):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245748, "ingredient1": "Dihydrocodeine", "ingredient2": "Codeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289671/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen, Benzonatate", "alternatives_b": "Acetylsalicylic acid, Acetaminophen, Ibuprofen, Codeine", "updated_at": 1767369485}, {"id": 245749, "ingredient1": "Dihydrocodeine", "ingredient2": "Conivaptan", "severity": "Moderate", "effect": "Coadministration with conivaptan may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by conivaptan.", "source": "DDInter", "management_text": "Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever conivaptan is added to or withdrawn from therapy, or the combination avoided altogether.  If a clinical decision is made to discontinue concomitant medications at recommended doses, clinicians should allow an appropriate amount of time following the end of conivaptan administration before resuming these medications.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if conivaptan must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289672/", "reference_text": "[1] \"Product Information. Vaprisol (conivaptan).\" Cumberland Pharmaceuticals Inc  (2006):", "alternatives_a": "Tolvaptan", "alternatives_b": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "updated_at": 1767369485}, {"id": 245750, "ingredient1": "Dihydrocodeine", "ingredient2": "Cyclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289673/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245751, "ingredient1": "Dihydrocodeine", "ingredient2": "Cyclobenzaprine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289674/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245752, "ingredient1": "Dihydrocodeine", "ingredient2": "Cyproheptadine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289675/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245753, "ingredient1": "Dihydrocodeine", "ingredient2": "Dabrafenib", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289676/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Pentazocine, More", "updated_at": 1767369485}, {"id": 245754, "ingredient1": "Dihydrocodeine", "ingredient2": "Dantrolene", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289677/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acetylsalicylic acid, Naloxone, Celecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245755, "ingredient1": "Dihydrocodeine", "ingredient2": "Darifenacin", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289679/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, Phenyl salicylate, More", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245756, "ingredient1": "Dihydrocodeine", "ingredient2": "Darunavir", "severity": "Moderate", "effect": "Coadministration with darunavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by darunavir.", "source": "DDInter", "management_text": "Caution is advised if darunavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever darunavir is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if darunavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289680/", "reference_text": "[1] \"Product Information. Prezista (darunavir).\" Ortho Biotech Inc  (2006):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, More", "alternatives_b": "Codeine, Morphine, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "updated_at": 1767369485}, {"id": 245757, "ingredient1": "Dihydrocodeine", "ingredient2": "Dasatinib", "severity": "Moderate", "effect": "Coadministration with dasatinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by dasatinib, which is a time-dependent inhibitor of the isoenzyme.", "source": "DDInter", "management_text": "Caution is advised if dasatinib must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dasatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if dasatinib must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289681/", "reference_text": "[1] \"Product Information. Sprycel (dasatinib).\" Bristol-Myers Squibb  (2006):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Dezocine, Opium, Pentazocine, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245758, "ingredient1": "Dihydrocodeine", "ingredient2": "Deferasirox", "severity": "Moderate", "effect": "Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism may involve induction of CYP450 3A4 activity by deferasirox, although in vitro, the drug has been shown to inhibit CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever deferasirox is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if deferasirox must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289682/", "reference_text": "[1] \"Product Information. Exjade (deferasirox).\" Novartis Pharmaceuticals  (2005):[2] Skerjanec A, Wang J, Maren K, Rojkjaer L \"Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers.\" J Clin Pharmacol 50 (2010):  205-13", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Morphine, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Nalbuphine, Naloxone, Codeine", "updated_at": 1767369485}, {"id": 245759, "ingredient1": "Dihydrocodeine", "ingredient2": "Delavirdine", "severity": "Minor", "effect": "Serum concentrations and effects of medications that are metabolized by the 3A4 enzymatic pathways may theoretically be elevated in patients receiving delavirdine.  The mechanism is inhibition of these enzymes by delavirdine.", "source": "DDInter", "management_text": "Monitoring for clinical and laboratory evidence of safety and tolerance is recommended.  Dosage adjustments or alternatives may be needed if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Monitoring for clinical and laboratory evidence of safety and tolerance is recommended.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289683/", "reference_text": "[1] Cheng CL, Smith DE, Carver PL, Cox SR, Watkins PB, Blake DS, Kauffman CA, Meyer KM, Amidon GL, Stetson PL \"Steady-state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test.\" Clin Pharmacol Ther 61 (1997):  531-43[2] \"Product Information. Rescriptor (delavirdine).\" Pharmacia and Upjohn  (2001):[3] Barry M, Mulcahy F, Merry C, Gibbons S, Back D \"Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.\" Clin Pharmacokinet 36 (1999):  289-304[4] Voorman RL, Maio SM, Payne NA, Zhao Z, Koeplinger KA, Wang X \"Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A.\" J Pharmacol Exp Ther 287 (1998):  381-8[5] vonMoltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX, Daily JP, Harmatz JS, Shader RI \"Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors.\" J Clin Pharmacol 41 (2001):  85-91[6] Fichtenbaum CJ, Gerber JG \"Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection.\" Clin Pharmacokinet 41 (2002):  1195-211", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, Pentazocine, More", "updated_at": 1767369485}, {"id": 245760, "ingredient1": "Dihydrocodeine", "ingredient2": "Desflurane", "severity": "Moderate", "effect": "Opioids may decrease the minimum alveolar concentration required for inhalation anesthetics.  When these agents are used concomitantly, less inhalation anesthetic may be required.  In addition, inhalation anesthetics may cause respiratory depression which may be increased by opioid premedication or other agents causing respiratory depression.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.  Patients should be monitored closely for respiratory depression.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289684/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical  (2001):[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997):  100-5", "alternatives_a": "Etomidate", "alternatives_b": "Naltrexone, Tapentadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245761, "ingredient1": "Dihydrocodeine", "ingredient2": "Desipramine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289685/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245762, "ingredient1": "Dihydrocodeine", "ingredient2": "Desmopressin", "severity": "Moderate", "effect": "Coadministration with opiates may increase the plasma concentrations and pharmacologic effects of oral desmopressin.  The risk of water intoxication and/or hyponatremia may be increased.", "source": "DDInter", "management_text": "Caution is recommended if desmopressin is used in combination with opiates.  Serum electrolytes, especially sodium, as well as BUN and creatinine should be monitored regularly.  Patients should be advised to seek immediate medical attention if they develop early signs and symptoms of water intoxication or hyponatremia such as anorexia, nausea, vomiting, drowsiness, lethargy, weakness, listlessness, headache, confusion, difficulty concentrating, memory impairment, anuria, and weight gain.  Early treatment may help prevent progression to seizure, coma, respiratory arrest, and death.", "mechanism_text": "Synergism", "recommendation": "Caution is recommended if desmopressin is used in combination with opiates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289686/", "reference_text": "[1] Appel WC \"Possible roles of normeperidine and hyponatremia in a postoperative death.\" Can Med Assoc J 137 (1987):  912-3[2] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[3] \"Product Information. DDAVP (desmopressin).\" Rhone Poulenc Rorer  (2001):[4] \"Product Information. Stimate (desmopressin).\" Forest Pharmaceuticals  (2001):[5] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[6] Callreus T, Lundahl J, Hoglund P, Bengtsson P \"Changes in gastrointestinal motility influence the absorption of desmopressin.\" Eur J Clin Pharmacol 55 (1999):  305-9[7] Kokko H, Hall PD, Afrin LB \"Fentanyl-associated syndrome of inappropriate antidiuretic hormone secretion.\" Pharmacotherapy 22 (2002):  1188-92[8] Canadian Pharmacists Association \"e-CPS.  http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink\"   (2006):[9] Sarret D, Le Berre JP, Zemraoui N \"Tramadol-induced hyponatremia.\" Am J Kidney Dis 52 (2008):  1026; author reply 1027", "alternatives_a": "Terlipressin, Oxytocin", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245763, "ingredient1": "Dihydrocodeine", "ingredient2": "Desvenlafaxine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289687/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245764, "ingredient1": "Dihydrocodeine", "ingredient2": "Deutetrabenazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289688/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Dalfampridine, Inotersen, Riluzole, Tafamidis", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245765, "ingredient1": "Dihydrocodeine", "ingredient2": "Dexamethasone", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289689/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Flunisolide, Betamethasone, Phenylephrine, Triamcinolone, Azelastine, Ciclesonide, Mupirocin, Hydrocortisone, Ipratropium, Cromoglicic acid, Prednisolone, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Opium, Dextropropoxyphene, Pentazocine", "updated_at": 1767369485}, {"id": 245766, "ingredient1": "Dihydrocodeine", "ingredient2": "Dexbrompheniramine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289690/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245767, "ingredient1": "Dihydrocodeine", "ingredient2": "Dexfenfluramine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289692/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Naloxone", "updated_at": 1767369485}, {"id": 245768, "ingredient1": "Dihydrocodeine", "ingredient2": "Dexmedetomidine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289693/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245769, "ingredient1": "Dihydrocodeine", "ingredient2": "Dextromethorphan", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289694/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Benzonatate, Dalfampridine, Inotersen, Riluzole, Tafamidis", "alternatives_b": "Acetylsalicylic acid, Acetaminophen, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245770, "ingredient1": "Dihydrocodeine", "ingredient2": "Dezocine", "severity": "Major", "effect": "Concomitant use of opioids with other central nervous system (CNS) depressants including mixed agonist-antagonist or partial agonist opioids may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased.  On the other hand, mixed agonist-antagonist or partial agonist opioids can reduce the pharmacologic effects of other opioid agonists.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary (e.g., when initiating a switch from one opioid to the other), the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Additional caution is advisable when a mixed agonist-antagonist or partial agonist opioid is added to an existing opioid regimen, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the mixed agonist-antagonist or partial agonist opioid.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Others", "recommendation": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289695/", "reference_text": "[1] Moldenhauer CC, Roach GW, Finlayson DC, et al. \"Nalbuphine antagonism of ventilatory depression following high-dose fentanyl anesthesia.\" Anesthesiology 62 (1985):  647-50[2] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[3] Strain EC, Preston KL, Liebson IA, Bigelow GE \"Precipitated withdrawal by pentazocine in methadone-maintained volunteers.\" J Pharmacol Exp Ther 267 (1993):  624-34[4] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[5] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[6] \"Product Information. Talwin NX (pentazocine).\" Sanofi Winthrop Pharmaceuticals  (2001):[7] \"Product Information. Stadol (butorphanol).\" Allscrips Pharmaceutical Company  (2001):[8] \"Product Information. Dalgan (dezocine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Suboxone (buprenorphine-naloxone).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[10] \"Product Information. Subutex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[11] \"Product Information. Butrans (buprenorphine).\" Purdue Pharma LP  (2010):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 245771, "ingredient1": "Dihydrocodeine", "ingredient2": "Diazepam", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289696/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245772, "ingredient1": "Dihydrocodeine", "ingredient2": "Diazoxide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289697/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245773, "ingredient1": "Dicyclomine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289698/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245774, "ingredient1": "Diltiazem", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289700/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, Betamethasone, More", "alternatives_b": "Tapentadol, Dezocine, Naltrexone, Oxymorphone", "updated_at": 1767369485}, {"id": 245775, "ingredient1": "Dimenhydrinate", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289701/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245776, "ingredient1": "Diphenhydramine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289702/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine, Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245777, "ingredient1": "Dihydrocodeine", "ingredient2": "Valproic acid", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289703/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Naloxone", "updated_at": 1767369485}, {"id": 245778, "ingredient1": "Dolasetron", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289704/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rolapitant", "alternatives_b": "Opium, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245779, "ingredient1": "Doxazosin", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289705/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naloxone, Naltrexone, Tapentadol", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245780, "ingredient1": "Doxepin", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289706/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245781, "ingredient1": "Doxepin (topical)", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289707/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Lidocaine, Tetracaine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245782, "ingredient1": "Doxylamine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289708/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245783, "ingredient1": "Dronabinol", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289709/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Rolapitant", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245784, "ingredient1": "Dronedarone", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration with dronedarone may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme, CYP450 3A4 isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter.  The mechanism is decreased clearance via these routes due to inhibition by dronedarone.", "source": "DDInter", "management_text": "Caution is advised when dronedarone is used concomitantly with drugs that are substrates of CYP450 2D6, CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever dronedarone is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when dronedarone is used concomitantly with drugs that are substrates of CYP450 2D6, CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289710/", "reference_text": "[1] \"Product Information. Multaq (dronedarone).\" sanofi-aventis  (2009):", "alternatives_a": "Quinidine, Amiodarone, Lidocaine, Propafenone, Tocainide, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, More", "alternatives_b": "Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Ibuprofen, Celecoxib, Pentazocine, Acetylsalicylic acid, More", "updated_at": 1767369485}, {"id": 245785, "ingredient1": "Droperidol", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289711/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride", "alternatives_b": "Acetylsalicylic acid, Celecoxib", "updated_at": 1767369485}, {"id": 245786, "ingredient1": "Duloxetine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289712/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245787, "ingredient1": "Duvelisib", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration with duvelisib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  The mechanism is reduced clearance due to inhibition of CYP450 3A4 by duvelisib.", "source": "DDInter", "management_text": "Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, macrolide immunosuppressants, midazolam, triazolam, vinca alkaloids).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever duvelisib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if duvelisib is used in combination with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289713/", "reference_text": "[1] \"Product Information. Copiktra (duvelisib).\" Verastem, Inc.  (2018):[2] \"Product Information. Copiktra (duvelisib).\" Verastem, Inc.  (2021):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Codeine, Morphine, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "updated_at": 1767369485}, {"id": 245788, "ingredient1": "Echinacea", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4.  Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea.  In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.", "source": "DDInter", "management_text": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.  If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered.  Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.", "mechanism_text": "Metabolism", "recommendation": "In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289714/", "reference_text": "[1] Gorski JC, Huang SM, Pinto A, et al. \"The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.\" Clin Pharmacol Ther 75 (2004):  89-100[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Hydromorphone, Dezocine, Tramadol, Opium, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245789, "ingredient1": "Efavirenz", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289715/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, More", "alternatives_b": "Tapentadol, Oxymorphone, Meperidine, Hydromorphone, Dezocine, Opium, Pentazocine, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245790, "ingredient1": "Eletriptan", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289716/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Opium, Dextropropoxyphene, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245791, "ingredient1": "Eluxadoline", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.", "source": "DDInter", "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.  Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs.  Eluxadoline should also be discontinued if constipation occurs for more than 4 days.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289717/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Viberzi (eluxadoline).\" Actavis Pharma, Inc.  (2015):", "alternatives_a": "Diphenoxylate, Difenoxin", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245792, "ingredient1": "Enalapril", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289718/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tapentadol, Naloxone, Dezocine, Oxymorphone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245793, "ingredient1": "Enflurane", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may decrease the minimum alveolar concentration required for inhalation anesthetics.  When these agents are used concomitantly, less inhalation anesthetic may be required.  In addition, inhalation anesthetics may cause respiratory depression which may be increased by opioid premedication or other agents causing respiratory depression.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.  Patients should be monitored closely for respiratory depression.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289719/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical  (2001):[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997):  100-5", "alternatives_a": "Etomidate", "alternatives_b": "Naltrexone, Tapentadol, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245794, "ingredient1": "Entacapone", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289720/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245795, "ingredient1": "Enzalutamide", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289721/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More", "alternatives_b": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Pentazocine, Acetylsalicylic acid, More", "updated_at": 1767369485}, {"id": 245796, "ingredient1": "Eplerenone", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289722/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Finerenone", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Dezocine, Tramadol, Methadone, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245797, "ingredient1": "Eprosartan", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289723/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Naloxone", "updated_at": 1767369485}, {"id": 245798, "ingredient1": "Escitalopram", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289724/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245799, "ingredient1": "Esketamine", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.", "source": "DDInter", "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.  Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting.  Patients should be instructed not to engage in potentially hazardous activities that require complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.", "mechanism_text": "Synergism", "recommendation": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants or other drugs that can cause sedation or dizziness.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289725/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[4] \"Product Information. Spravato (esketamine).\" Janssen Pharmaceuticals  (2019):", "alternatives_a": "Etomidate", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245800, "ingredient1": "Eslicarbazepine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289726/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245801, "ingredient1": "Esmolol", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289727/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Penbutolol, Carteolol", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Naloxone", "updated_at": 1767369485}, {"id": 245802, "ingredient1": "Estazolam", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289728/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245803, "ingredient1": "Eszopiclone", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289729/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245804, "ingredient1": "Ethanol", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics.  Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills.", "source": "DDInter", "management_text": "Concomitant use of opioid analgesics with ethanol should be avoided.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of opioid analgesics with ethanol should be avoided.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289730/", "reference_text": "[1] Linnoila M, Hakkinen S \"Effects of diazepam and codeine, alone and in combination with alcohol, on simulated driving.\" Clin Pharmacol Ther 15 (1974):  368-73[2] Sturner WQ, Garriott JC \"Deaths involving propoxyphene: a study of 41 cases over a two-year period.\" JAMA 223 (1973):  1125-30[3] Girre C, Hirschhorn M, Bertaux L, et al. \"Enhancement of propoxyphene bioavailability by ethanol: relation to psychomotor and cognitive function in healthy volunteers.\" Eur J Clin Pharmacol 41 (1991):  147-52[4] Levine B, Saady J, Fierro M, Valentour J \"A hydromorphone and ethanol fatality.\" J Forensic Sci 29 (1984):  655-9[5] Sellers EM, Hamilton CA, Kaplan HL, Degani NC, Foltz RL \"Pharmacokinetic interaction of propoxyphene with ethanol.\" Br J Clin Pharmacol 19 (1985):  398-401[6] Carson DJ \"Fatal dextropropoxyphene poisoning in Northern Ireland. Review of 30 cases.\" Lancet 1 (1977):  894-7[7] Rosser WW \"The interaction of propoxyphene with other drugs.\" Can Med Assoc J 122 (1980):  149-50[8] Edwards C, Gard PR, Handley SL, Hunter M, Whittington RM \"Distalgesic and ethanol-impaired function.\" Lancet 2 (1982):  384[9] Kiplinger GF, Sokol G, Rodda BE \"Effect of combined alcohol and propoxyphene on human performance.\" Arch Int Pharmacodyn Ther 212 (1974):  175-80", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Naloxone, Celecoxib", "updated_at": 1767369485}, {"id": 245805, "ingredient1": "Ethchlorvynol", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289731/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245806, "ingredient1": "Ethosuximide", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289732/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245807, "ingredient1": "Ethotoin", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289733/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Acetylsalicylic acid, Naloxone, Ibuprofen, Celecoxib", "updated_at": 1767369485}, {"id": 245808, "ingredient1": "Etravirine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289734/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Acetylsalicylic acid, More", "updated_at": 1767369485}, {"id": 245809, "ingredient1": "Ezogabine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289736/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245810, "ingredient1": "Fedratinib", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration with fedratinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4, 2C19, and/or 2D6 isoenzymes.", "source": "DDInter", "management_text": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, and/or 2D6.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, and/or 2D6.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289737/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Inrebic (fedratinib).\" Celgene Corporation  (2019):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Morphine, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Ibuprofen, Celecoxib, Pentazocine, More", "updated_at": 1767369485}, {"id": 245811, "ingredient1": "Felbamate", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289738/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245812, "ingredient1": "Felodipine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289739/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245813, "ingredient1": "Fenfluramine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289740/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Ephedrine, Phentermine, Orlistat, Lorcaserin, Diethylpropion, Mazindol, Lacosamide", "alternatives_b": "Dextropropoxyphene, Acetaminophen, Naltrexone", "updated_at": 1767369485}, {"id": 245814, "ingredient1": "Fentanyl", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289741/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Etomidate, Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Fentanyl", "updated_at": 1767369485}, {"id": 245815, "ingredient1": "Fesoterodine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289742/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, Phenyl salicylate, More", "alternatives_b": "Naltrexone, Acetaminophen, Methadone, Ibuprofen, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245816, "ingredient1": "Flavoxate", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289744/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, Phenyl salicylate, More", "alternatives_b": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245817, "ingredient1": "Flibanserin", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "The central nervous system (CNS) effects of flibanserin such as somnolence and fatigue may be potentiated by concomitant use of other agents with CNS depressant effects.", "source": "DDInter", "management_text": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue.  Patients should not drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking flibanserin and until they know how the medication affects them.", "mechanism_text": "Synergism", "recommendation": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289745/", "reference_text": "[1] \"Product Information. Addyi (flibanserin).\" Sprout Pharmaceuticals  (2015):", "alternatives_a": "Ritodrine, Bremelanotide, Cabergoline, Black cohosh, Naproxen, Ibuprofen", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245818, "ingredient1": "Fluoxetine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289746/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245819, "ingredient1": "Fluphenazine", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, antipsychotics).", "source": "DDInter", "management_text": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.  Delayed diagnosis and treatment of constipation may increase the risk of severe complications, which can result in hospitalization, surgery, and death.  Patients should be advised to maintain adequate hydration, physical activity and fiber intake, and to report any changes in the frequency or character of bowel movements as well as signs and symptoms of potential complications of ileus such as nausea, vomiting, abdominal distension, and abdominal pain.  If constipation or gastrointestinal hypomotility is identified, monitor closely and treat promptly with appropriate laxatives to prevent severe complications.  Consider prophylactic laxatives in high risk patients, such as those with a history of constipation, colonic disease, or lower abdominal surgery.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289747/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[3] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. FazaClo (clozapine).\" Jazz Pharmaceuticals  (2015):[7] \"Product Information. Versacloz (clozapine).\" Jazz Pharmaceuticals  (2015):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Acetaminophen, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245820, "ingredient1": "Flurazepam", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289748/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245821, "ingredient1": "Fluvoxamine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289749/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245822, "ingredient1": "Fosaprepitant", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by aprepitant.", "source": "DDInter", "management_text": "Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever aprepitant or fosaprepitant is added to or withdrawn from therapy.  Chronic, continuous use of aprepitant for prevention of nausea and vomiting is not recommended because it has not been studied and because the drug interaction profile may change during long-term use.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when aprepitant or fosaprepitant is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289750/", "reference_text": "[1] \"Product Information. Emend (aprepitant).\" Merck & Co., Inc  (2003):[2] \"Product Information. Emend for Injection (fosaprepitant).\" Merck & Co., Inc  (2008):", "alternatives_a": "Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245823, "ingredient1": "Fosinopril", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289751/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tapentadol, Naloxone, Dezocine, Oxymorphone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245824, "ingredient1": "Fosphenytoin", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289752/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Lacosamide", "alternatives_b": "Naloxone", "updated_at": 1767369485}, {"id": 245825, "ingredient1": "Fospropofol", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.", "source": "DDInter", "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289753/", "reference_text": "[1] McClune S, McKay AC, Wright PM, et al. \"Synergistic interaction between midazolam and propofol.\" Br J Anaesth 69 (1992):  240-5[2] Gill SS, Wright EM, Reilly CS \"Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study.\" Br J Anaesth 65 (1990):  760-5[3] \"Product Information. Diprivan (propofol).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Pavlin DJ, Coda B, Shen DD, et al. \"Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers.\" Anesthesiology 84 (1996):  23-37[5] Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A \"Propofol decreases the clearance of midazolam by inhibiting CYP3A4: An in vivo and in vitro study.\" Clin Pharmacol Ther 66 (1999):  110-7[6] \"Product Information. Lusedra (fospropofol).\" Eisai Inc  (2008):", "alternatives_a": "Naltrexone, Tapentadol, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245826, "ingredient1": "Fostamatinib", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter.  The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.", "source": "DDInter", "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289754/", "reference_text": "[1] \"Product Information. Tavalisse (fostamatinib).\" Rigel Pharmaceuticals  (2018):", "alternatives_a": "Eltrombopag, Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Lusutrombopag, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More", "alternatives_b": "Oxymorphone, Tapentadol, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Tramadol, Opium, Dextropropoxyphene, Ibuprofen, Celecoxib, More", "updated_at": 1767369485}, {"id": 245827, "ingredient1": "Frovatriptan", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289755/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Naltrexone, Acetaminophen, Opium, Dextropropoxyphene, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245828, "ingredient1": "Furosemide", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289757/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Etacrynic acid, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Tapentadol, Dezocine, Naltrexone, Oxymorphone", "updated_at": 1767369485}, {"id": 245829, "ingredient1": "Gabapentin", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with gabapentinoids (e.g., gabapentin, pregabalin) may increase the risk of opioid overdose and serious adverse effects such as profound sedation, respiratory depression, syncope, and death due to potentially additive depressant effects on the central nervous system.", "source": "DDInter", "management_text": "Caution is advised when opioids and gabapentinoids are coadministered, particularly in patients with additional risk factors for respiratory depression such as advanced age, renal insufficiency, or chronic lung disease.  The dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Use of additional central nervous system depressants should be avoided if possible.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  For patients who have been receiving extended therapy with both an opioid and a gabapentinoid (either for analgesia or seizure control) and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms and increased seizure risk.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids and gabapentinoids are coadministered, particularly in patients with additional risk factors for respiratory depression such as advanced age, renal insufficiency, or chronic lung disease.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289758/", "reference_text": "[1] \"Product Information. Neurontin (gabapentin).\" Parke-Davis  (2001):[2] \"Product Information. Lyrica (pregabalin).\" Pfizer U.S. Pharmaceuticals Group  (2005):[3] US Food and Drug Administration \"FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) When used with CNS depressants or in patients with lung problems.  https://www.fda.gov/media/1336\"   (2020):[4] Government of Canada \"Summary Safety Review - Gabapentin - Assessing the Potential Risk of Serious Breathing Problems.  https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-gabapentin-assessing-potential-ri\"   (2020):[5] Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G \"Gabapentin enhances the analgesic effect of morphine in healthy volunteers.\" Anesth Analg 91 (2000):  185-91[6] Eipe N, Penning J \"Postoperative respiratory depression associated with pregabalin: a case series and a preoperative decision algorithm.\" Pain Res Manag 16 (2011):  353-6[7] Smith RV, Havens JR, Walsh SL \"Gabapentin misuse, abuse and diversion: a systematic review.\" Addiction 111 (2016):  1160-74[8] Peckham AM, Evoy KE, Covvey JR, Ochs L, Fairman KA, Sclar DA \"Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured U.S. population.\" Pharmacotherapy 38 (2018):  436-43", "alternatives_a": "Lacosamide", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245830, "ingredient1": "Ginkgo biloba", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures.  There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.  Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation.  Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.", "mechanism_text": "Synergism", "recommendation": "Patients should consult a healthcare provider before taking any herbal or alternative medicine.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289760/", "reference_text": "[1] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[2] Gregory PJ \"Seizure associated with Ginkgo biloba?.\" Ann Intern Med 134 (2001):  344[3] Miwa H, Iijima M, Tanaka S, Mizuno Y \"Generalized convulsions after consuming a large amount of Gingko nuts.\" Epilepsia 42 (2001):  280-1[4] Kajiyama Y, Fujii K, Takeuchi H, Manabe Y \"Ginkgo seed poisoning.\" Pediatrics 109 (2002):  325-7[5] Kupiec T, Raj V \"Fatal seizures due to potential herb-drug interactions with Ginkgo biloba.\" J Anal Toxicol 29 (2005):  755-8[6] Harms SL, Garrard J, Schwinghammer P, Eberly LE, Chang Y, Leppik IE \"Ginkgo biloba use in nursing home elderly with epilepsy or seizure disorder.\" Epilepsia 47 (2006):  323-9[7] Granger AS \"Ginkgo biloba precipitating epileptic seizures.\" Age Ageing 30 (2001):  523-5[8] Spinella M \"Herbal medicines and epilepsy: the potential for benefit and adverse effects.\" Epilepsy Behav 2 (2001):  524-32", "alternatives_a": "Rivastigmine, Galantamine, Donepezil, Tacrine, Memantine, Aducanumab", "alternatives_b": "Acetaminophen, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245831, "ingredient1": "Glycerol phenylbutyrate", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration of glycerol phenylbutyrate may lead to increased concentrations of CYP450 2D6 substrates.  The proposed mechanism is inhibition of CYP450 2D6 by phenylbutyrate, the active moiety of glycerol phenylbutyrate, which has been shown to be an in vitro inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate.", "mechanism_text": "Metabolism", "recommendation": "Caution is recommended if glycerol phenylbutyrate is administered with medicines that are substrates of CYP450 2D6, such as codeine, dextromethorphan, and some beta blockers (including metoprolol, carvedilol, labetalol, propranolol, and nebivolol).", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289761/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Ravicti (glycerol phenylbutyrate).\" Hyperion Therapeutics Inc  (2013):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Morphine, Naltrexone, Oxymorphone, Naloxone, Tapentadol, Butorphanol, Meperidine, Hydromorphone, Dezocine, Opium, Ibuprofen, More", "updated_at": 1767369485}, {"id": 245832, "ingredient1": "Glycopyrronium", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289762/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Budesonide, Aclidinium, Mometasone, Fluticasone, More", "alternatives_b": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245833, "ingredient1": "Granisetron", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289763/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rolapitant", "alternatives_b": "Opium, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245834, "ingredient1": "Guanethidine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289764/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Carteolol, Brinzolamide, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245835, "ingredient1": "Guanfacine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289765/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Rauwolfia serpentina root, Deserpidine", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Acetaminophen, Dezocine, Tramadol, Methadone, Ibuprofen, Celecoxib, Acetylsalicylic acid, More", "updated_at": 1767369485}, {"id": 245836, "ingredient1": "Halazepam", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289766/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245837, "ingredient1": "Haloperidol", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289767/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245838, "ingredient1": "Halothane", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may decrease the minimum alveolar concentration required for inhalation anesthetics.  When these agents are used concomitantly, less inhalation anesthetic may be required.  In addition, inhalation anesthetics may cause respiratory depression which may be increased by opioid premedication or other agents causing respiratory depression.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.  Patients should be monitored closely for respiratory depression.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289768/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical  (2001):[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997):  100-5", "alternatives_a": "Etomidate", "alternatives_b": "Naltrexone, Tapentadol, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245839, "ingredient1": "Dihydrocodeine", "ingredient2": "Diamorphine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289769/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid", "alternatives_b": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine", "updated_at": 1767369485}, {"id": 245840, "ingredient1": "Hydralazine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289770/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Rauwolfia serpentina root, Deserpidine", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Naloxone", "updated_at": 1767369485}, {"id": 245841, "ingredient1": "Hydrochlorothiazide", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289771/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245842, "ingredient1": "Hydrocodone", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289772/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Benzonatate", "alternatives_b": "Acetylsalicylic acid, Acetaminophen, Ibuprofen", "updated_at": 1767369485}, {"id": 245843, "ingredient1": "Hydroflumethiazide", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289773/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245844, "ingredient1": "Hydromorphone", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289774/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Hydromorphone", "updated_at": 1767369485}, {"id": 245845, "ingredient1": "Hydroxyzine", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289775/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245846, "ingredient1": "Hyoscyamine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289776/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245847, "ingredient1": "Idelalisib", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration with idelalisib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4.  Idelalisib has been shown to be a potent inhibitor of this isoenzyme.", "source": "DDInter", "management_text": "Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.g., antiarrhythmics, anticonvulsants, antineoplastics, immunosuppressants) or those that are considered sensitive substrates (e.g., ergot derivatives, statins, oral midazolam, triazolam).  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever idelalisib is added to or withdrawn from therapy, if coadministration is required.", "mechanism_text": "Metabolism", "recommendation": "Use of idelalisib should generally be avoided with drugs that are primarily metabolized by CYP450 3A4, particularly those with a narrow therapeutic range (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289777/", "reference_text": "[1] \"Product Information. Zydelig (idelalisib).\" Gilead Sciences  (2014):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Morphine, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Acetylsalicylic acid, Nalbuphine, More", "updated_at": 1767369485}, {"id": 245848, "ingredient1": "Ifosfamide", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide.", "source": "DDInter", "management_text": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.  Patients should be advised to avoid driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how the medications affect them.  If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued.  Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.", "mechanism_text": "Synergism", "recommendation": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289778/", "reference_text": "[1] Simonian NA, Gilliam FG, Chiappa KH \"Ifosfamide causes a diazepam-sensitive encephalopathy.\" Neurology 43 (1993):  2700-2[2] \"Product Information. Ifex (ifosfamide).\" Bristol-Myers Squibb  (2001):", "alternatives_a": "Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, More", "alternatives_b": "Acetylsalicylic acid, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245849, "ingredient1": "Iloperidone", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289779/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245850, "ingredient1": "Imatinib", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4.  The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.", "source": "DDInter", "management_text": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289780/", "reference_text": "[1] \"Product Information. Gleevec (imatinib).\" Novartis Pharmaceuticals  (2022):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Tapentadol, Oxymorphone, Meperidine, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245851, "ingredient1": "Imipramine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289781/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245852, "ingredient1": "Indapamide", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289782/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245853, "ingredient1": "Iohexol", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures.  Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline).  These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.  Otherwise, close monitoring is advised during and after contrast administration.  The manufacturers typically recommend avoiding concomitant administration of phenothiazines (including those used for their antihistamine properties), monoamine oxidase inhibitors, tricyclic antidepressants, central nervous system stimulants, and psychoactive drugs.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289784/", "reference_text": "[1] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975):  129-35[2] \"Product Information. Amipaque (metrizamide).\" Nycomed Inc  (2001):[3] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc  (2001):[4] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health  (2007):[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc  (2007):", "alternatives_a": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "alternatives_b": "Acetylsalicylic acid, Acetaminophen, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245854, "ingredient1": "Iopamidol", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Intrathecal administration of iodinated contrast media may induce seizures.  Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline).  These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.  Otherwise, close monitoring is advised during and after contrast administration.  The manufacturers typically recommend avoiding concomitant administration of phenothiazines (including those used for their antihistamine properties), monoamine oxidase inhibitors, tricyclic antidepressants, central nervous system stimulants, and psychoactive drugs.", "mechanism_text": "Synergism", "recommendation": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289786/", "reference_text": "[1] Hindmarsh T, Grepe A, Widen L \"Metrizamide-phenothiazine interaction: report of a case with seizures following myelography.\" Acta Radiol Diagn (Stockh) 16 (1975):  129-35[2] \"Product Information. Amipaque (metrizamide).\" Nycomed Inc  (2001):[3] \"Product Information. Osmovist 240 (iotrolan).\" Berlex Canada Inc  (2001):[4] \"Product Information. Omnipaque 180 (iohexol).\" Amersham Health  (2007):[5] \"Product Information. Isovue-M-200 (iopamidol).\" Bracco Diagnostics Inc  (2007):", "alternatives_a": "Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245855, "ingredient1": "Irbesartan", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289787/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245856, "ingredient1": "Isavuconazonium", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration with isavuconazonium sulfate (prodrug of isavuconazole) may increase the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or P-glycoprotein (P-gp).  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity and/or P-gp-mediated efflux of these drugs by isavuconazole.", "source": "DDInter", "management_text": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of the CYP450 3A4 isoenzyme or the P-gp transport protein, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289788/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Cresemba (isavuconazonium).\" Astellas Pharma US, Inc  (2015):", "alternatives_a": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245857, "ingredient1": "Isocarboxazid", "ingredient2": "Dihydrocodeine", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289789/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987):  251-2[7] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993):  1270-1[8] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[9] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[10] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[11] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[12] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[13] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[14] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[15] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[16] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245858, "ingredient1": "Isoflurane", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Opioids may decrease the minimum alveolar concentration required for inhalation anesthetics.  When these agents are used concomitantly, less inhalation anesthetic may be required.  In addition, inhalation anesthetics may cause respiratory depression which may be increased by opioid premedication or other agents causing respiratory depression.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.  Patients should be monitored closely for respiratory depression.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289790/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical  (2001):[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997):  100-5", "alternatives_a": "Etomidate", "alternatives_b": "Celecoxib, Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 245859, "ingredient1": "Isosorbide dinitrate", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289791/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245860, "ingredient1": "Isosorbide mononitrate", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289792/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Nesiritide, Vericiguat", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245861, "ingredient1": "Isradipine", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289793/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245862, "ingredient1": "Ivacaftor", "ingredient2": "Dihydrocodeine", "severity": "Moderate", "effect": "Coadministration with ivacaftor may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) efflux transporter.  The mechanism is decreased clearance via these pathways due to inhibition by ivacaftor and its pharmacologically active M1 metabolite.  The interaction has been studied with midazolam and digoxin, probe substrates for CYP450 3A4 ad P-gp, respectively.", "source": "DDInter", "management_text": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ivacaftor is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when ivacaftor is used with drugs that are substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289794/", "reference_text": "[1] \"Product Information. Kalydeco (ivacaftor).\" Vertex Pharmaceuticals  (2012):", "alternatives_a": "Nitric Oxide, Doxapram, Elexacaftor, Lumacaftor", "alternatives_b": "Codeine, Oliceridine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, More", "updated_at": 1767369485}, {"id": 245863, "ingredient1": "Dihydrocodeine", "ingredient2": "Kaolin", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289795/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Pectin, Activated charcoal", "alternatives_b": "Naltrexone, Naloxone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Fentanyl, Ibuprofen, Celecoxib, Acetylsalicylic acid, Buprenorphine", "updated_at": 1767369485}, {"id": 245864, "ingredient1": "Dihydrocodeine", "ingredient2": "Kava", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289796/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245865, "ingredient1": "Dihydrocodeine", "ingredient2": "Ketamine", "severity": "Major", "effect": "Coadministration of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.  Concomitant use of ketamine with other CNS depressants can potentiate CNS depression and/or increase the risk of developing respiratory depression.  In addition, opioid analgesics, barbiturates, and benzodiazepines may prolong the time to complete recovery from anesthesia.", "source": "DDInter", "management_text": "During concomitant use of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, close monitoring of neurologic status and respiratory parameters, including respiratory rate and pulse oximetry, is recommended.  Dosage adjustments should be considered according to the patient's clinical situation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, close monitoring of neurologic status and respiratory parameters, including respiratory rate and pulse oximetry, is recommended.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289797/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Ketalar (ketamine).\" JHP Pharmaceuticals  (2009):", "alternatives_a": "Etomidate", "alternatives_b": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245866, "ingredient1": "Dihydrocodeine", "ingredient2": "Labetalol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289798/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Penbutolol, Penbutolol, Carteolol", "alternatives_b": "Naloxone, Tramadol, Tapentadol", "updated_at": 1767369485}, {"id": 245867, "ingredient1": "Dihydrocodeine", "ingredient2": "Lamotrigine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289799/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Naloxone", "updated_at": 1767369485}, {"id": 245868, "ingredient1": "Dihydrocodeine", "ingredient2": "Lapatinib", "severity": "Moderate", "effect": "Coadministration with lapatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter.  The mechanism is decreased clearance via these routes due to inhibition by lapatinib.", "source": "DDInter", "management_text": "Caution is advised if lapatinib must be used concurrently with medications that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-gp efflux transporter, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lapatinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if lapatinib must be used concurrently with medications that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-gp efflux transporter, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289800/", "reference_text": "[1] \"Product Information. Tykerb (lapatinib).\" Novartis Pharmaceuticals  (2007):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Codeine, Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, Ibuprofen, Celecoxib, More", "updated_at": 1767369485}, {"id": 245869, "ingredient1": "Dihydrocodeine", "ingredient2": "Larotrectinib", "severity": "Moderate", "effect": "Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.", "source": "DDInter", "management_text": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever larotrectinib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  Some authorities recommend avoiding concomitant use of larotrectinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges.  These drugs include, but are not limited to:  alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when larotrectinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289801/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Vitrakvi (larotrectinib).\" Bayer Pharmaceutical Inc  (2018):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Codeine, Morphine, Oxymorphone, Tapentadol, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "updated_at": 1767369485}, {"id": 245870, "ingredient1": "Dihydrocodeine", "ingredient2": "Lasmiditan", "severity": "Moderate", "effect": "Coadministration with alcohol or other central nervous system (CNS) depressants may enhance the sedative effects of lasmiditan and increase the likelihood and/or severity of cognitive and/or neuropsychiatric adverse reactions.", "source": "DDInter", "management_text": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.  Patients should be advised against driving and other activities that require complete mental alertness for at least 8 hours after lasmiditan is administered.", "mechanism_text": "Synergism", "recommendation": "Caution is advised during coadministration of lasmiditan with alcohol, other CNS depressants, or other agents that cause sedation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289802/", "reference_text": "[1] \"Product Information. Reyvow (lasmiditan).\" Lilly, Eli and Company  (2019):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245871, "ingredient1": "Dihydrocodeine", "ingredient2": "Lefamulin", "severity": "Moderate", "effect": "When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme.  Based on interaction with midazolam, a sensitive CYP450 3A4 substrate, lefamulin may be a moderate CYP450 3A4 inhibitor.", "source": "DDInter", "management_text": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oral lefamulin is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration of a moderate CYP450 3A4 inhibitor like lefamulin and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when oral lefamulin is used concomitantly with drugs that are substrates of CYP450 3A4, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289803/", "reference_text": "[1] \"Product Information. Xenleta (lefamulin).\" Nabriva Therapeutics US, Inc.  (2019):", "alternatives_a": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "alternatives_b": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, Ibuprofen, Celecoxib, More", "updated_at": 1767369485}, {"id": 245872, "ingredient1": "Dihydrocodeine", "ingredient2": "Lemborexant", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289804/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245873, "ingredient1": "Dihydrocodeine", "ingredient2": "Letermovir", "severity": "Moderate", "effect": "Coadministration with letermovir may increase the plasma concentrations of drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or organic anion transporting polypeptide protein (OATP) 1B1 and 1B3.", "source": "DDInter", "management_text": "Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever letermovir is added to or withdrawn from therapy.  Moreover, clinicians should be aware that the magnitude of CYP450 3A- and OATP1B1/3-mediated drug interactions with coadministered drugs may be different when letermovir is used with cyclosporine.  The combined effect of the two drugs on CYP450 3A4 may be similar to that of a strong CYP450 3A4 inhibitor, hence clinicians should refer to the prescribing information for dosing recommendations of the CYP450 3A4 substrate with a strong CYP450 3A4 inhibitor.  Similarly, letermovir and cyclosporine may demonstrate some additive effects on OATP1B1 inhibition, although cyclosporine by itself is already a strong OATP1B1/3 inhibitor.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when letermovir is used concurrently with drugs that are substrates of CYP450 2C8, CYP450 3A4, and/or OATP 1B1 and 1B3, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289806/", "reference_text": "[1] \"Product Information. Prevymis (letermovir).\" Merck & Co., Inc  (2017):", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, More", "alternatives_b": "Codeine, Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, More", "updated_at": 1767369485}, {"id": 245874, "ingredient1": "Dihydrocodeine", "ingredient2": "Levamlodipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289807/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Celecoxib, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245875, "ingredient1": "Dihydrocodeine", "ingredient2": "Levetiracetam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289808/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245876, "ingredient1": "Dihydrocodeine", "ingredient2": "Levocetirizine", "severity": "Moderate", "effect": "Concurrent use of cetirizine or levocetirizine with alcohol or other agents that exhibit central nervous system (CNS) depressant effects may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of cetirizine or levocetirizine with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289809/", "reference_text": "[1] \"Product Information. Zyrtec (cetirizine).\" Pfizer U.S. Pharmaceuticals  (2001):[2] \"Product Information. Xyzal (levocetirizine).\" UCB Pharma Inc  (2007):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245877, "ingredient1": "Dihydrocodeine", "ingredient2": "Levodopa", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289810/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245878, "ingredient1": "Dihydrocodeine", "ingredient2": "Levacetylmethadol", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289811/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 245879, "ingredient1": "Dihydrocodeine", "ingredient2": "Levomilnacipran", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289812/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naltrexone, Acetaminophen, Opium, Celecoxib, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245880, "ingredient1": "Dihydrocodeine", "ingredient2": "Levorphanol", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289813/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acetylsalicylic acid, Acetaminophen, Ibuprofen, Celecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245881, "ingredient1": "Dihydrocodeine", "ingredient2": "Lindane", "severity": "Moderate", "effect": "Lindane penetrates human skin and has the potential to cause central nervous system toxicity.  Seizures have been reported after excessive use or oral ingestion of lindane.  There may be a theoretical risk of increased seizure potential when lindane is used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, theophylline).  These agents are often individually epileptogenic and may have additive effects when combined.", "source": "DDInter", "management_text": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.g., head trauma, brain tumor, metabolic disorders, alcohol and drug withdrawal, CNS infections).  Lindane should be used according to recommended dosage and directions for application.", "mechanism_text": "Synergism", "recommendation": "Caution is advised if lindane is used with any substance that can reduce the seizure threshold, particularly in the very young or the elderly and in patients with epilepsy, a history of seizures, or other risk factors for seizures (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289814/", "reference_text": "[1] Telch J, Jarvis DA \"Acute intoxication with lindane (gamma benzene hexachloride).\" Can Med Assoc J 126 (1982):  662-3[2] Munk ZM, Nantel A \"Acute lindane poisoning with development of muscle necrosis.\" Can Med Assoc J 117 (1977):  1050-4[3] Tenenbein M \"Seizures after lindane therapy.\" J Am Geriatr Soc 39 (1991):  394-5[4] Pramanik AK, Hansen RC \"Transcutaneous gamma benzene hexachloride absorption and toxicity in infants and children.\" Arch Dermatol 115 (1979):  1224-5[5] Matsuoka LY \"Convulsions following application of gamma benzene hexachloride.\" J Am Acad Dermatol 5 (1981):  98-9[6] Solomon BA, Haut SR, Carr EM, Shalita AR \"Neurotoxic reaction to lindane in an HIV-seropositive patient: an old medication's new problem.\" J Fam Pract 40 (1995):  291-6[7] \"Product Information. Kwell (lindane).\" Reed and Carnrick, Jersey City, NJ.[8] Ramchander V, Cameron ES, Reid HF \"Lindane toxicity in an infant.\" West Indian Med J 40 (1991):  41-3[9] Cox R, Krupnick J, Bush N, Houpt A \"Seizures caused by concomitant use of lindane and dextroamphetamine in a child with attention deficit hyperactivity disorder.\" J Miss State Med Assoc 41 (2000):  690-2", "alternatives_a": "Disulfiram", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245882, "ingredient1": "Dihydrocodeine", "ingredient2": "Linezolid", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289815/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987):  251-2[7] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993):  1270-1[8] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[9] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[10] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[11] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[12] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[13] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[14] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[15] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[16] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):", "alternatives_a": "Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, More", "alternatives_b": "Oliceridine, Naltrexone", "updated_at": 1767369485}, {"id": 245883, "ingredient1": "Dihydrocodeine", "ingredient2": "Lisinopril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289816/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "alternatives_b": "Tapentadol, Naloxone, Dezocine, Oxymorphone", "updated_at": 1767369485}, {"id": 245884, "ingredient1": "Dihydrocodeine", "ingredient2": "Lithium carbonate", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289817/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245885, "ingredient1": "Dihydrocodeine", "ingredient2": "Lofexidine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289818/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine", "alternatives_b": "Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245886, "ingredient1": "Dihydrocodeine", "ingredient2": "Lonafarnib", "severity": "Moderate", "effect": "Coadministration with lonafarnib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  Lonafarnib is a potent CYP450 3A time-dependent and mechanism-based inhibitor in vitro.", "source": "DDInter", "management_text": "Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lonafarnib is added to or withdrawn from therapy.  Patients should be monitored for the development of adverse effects.  The prescribing information recommends avoiding concomitant use of lonafarnib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges when possible.  These drugs include, but are not limited to:  alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when lonafarnib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289819/", "reference_text": "[1] \"Product Information. Zokinvy (lonafarnib).\" Eiger BioPharmaceuticals  (2020):", "alternatives_a": "Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, Agalsidase beta, More", "alternatives_b": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "updated_at": 1767369485}, {"id": 245887, "ingredient1": "Dihydrocodeine", "ingredient2": "Loperamide", "severity": "Moderate", "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.", "source": "DDInter", "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289821/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0", "alternatives_a": "Diphenoxylate, Difenoxin", "alternatives_b": "Dezocine, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 245888, "ingredient1": "Dihydrocodeine", "ingredient2": "Lorazepam", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289822/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245889, "ingredient1": "Dihydrocodeine", "ingredient2": "Lorlatinib", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289823/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Acetylsalicylic acid, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245890, "ingredient1": "Dihydrocodeine", "ingredient2": "Losartan", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289824/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245891, "ingredient1": "Dihydrocodeine", "ingredient2": "Loxapine", "severity": "Major", "effect": "Concomitant use of opioids with central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, antipsychotics).", "source": "DDInter", "management_text": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.  Delayed diagnosis and treatment of constipation may increase the risk of severe complications, which can result in hospitalization, surgery, and death.  Patients should be advised to maintain adequate hydration, physical activity and fiber intake, and to report any changes in the frequency or character of bowel movements as well as signs and symptoms of potential complications of ileus such as nausea, vomiting, abdominal distension, and abdominal pain.  If constipation or gastrointestinal hypomotility is identified, monitor closely and treat promptly with appropriate laxatives to prevent severe complications.  Consider prophylactic laxatives in high risk patients, such as those with a history of constipation, colonic disease, or lower abdominal surgery.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289825/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[3] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. FazaClo (clozapine).\" Jazz Pharmaceuticals  (2015):[7] \"Product Information. Versacloz (clozapine).\" Jazz Pharmaceuticals  (2015):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Acetylsalicylic acid, Naloxone, Naltrexone, Celecoxib", "updated_at": 1767369485}, {"id": 245892, "ingredient1": "Dihydrocodeine", "ingredient2": "Lumateperone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289826/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245893, "ingredient1": "Dihydrocodeine", "ingredient2": "Lurasidone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289827/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245894, "ingredient1": "Dihydrocodeine", "ingredient2": "Maprotiline", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289828/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245895, "ingredient1": "Dihydrocodeine", "ingredient2": "Mebrofenin", "severity": "Moderate", "effect": "Prior administration of opioids may delay transit of Technetium Tc 99m mebrofenin due to opioid-induced contraction of the distal common bile duct, which may result in nonvisualization.", "source": "DDInter", "management_text": "Nonvisualization may occur in patients who have been receiving opioids prior to cholescintigraphy.", "mechanism_text": "Others", "recommendation": "Nonvisualization may occur in patients who have been receiving opioids prior to cholescintigraphy.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289830/", "reference_text": "[1] Flancbaum L, Choban PS, Sinha R, Jonasson O \"Morphine cholescintigraphy in the evaluation of hospitalized patients with suspected acute cholecystitis.\" Ann Surg 220 (1994): 25-31[2] \"Product Information. Choletec (mebrofenin).\" Bracco Diagnostics Inc, Princeton, NJ.[3] Chen CC, Holder LE, Maunoury C, Drachenberg CI \"Morphine augmentation increases galllbladder visualization in patients pretreated with cholecystokinin.\" J Nucl Med 38 (1997): 644-7[4] Kim EE, Pjura G, Lowry P, Nguyen M, Pollack M \"Morphine-augmented cholescintigraphy in the diagnosis of acute cholecystitis.\" AJR Am J Roentgenol 147 (1986): 1177-9[5] Oates E, Selland DL, Chin CT, Achong DM \"Gallbladder nonvisualization with pericholecystic rim sign: morphine-augmentation optimizes diagnosis of acute cholecystitis.\" J Nucl Med 37 (1996): 267-9[6] Fink-Bennett D, Balon H, Robbins T, Tsai D \"Morphine-augmented cholescintigraphy: its efficacy in detecting acute cholecystitis.\" J Nucl Med 32 (1991): 1231-3[7] \"Product Information. Fycompa (perampanel).\" Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. \"Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed.\" New York, NY: Pergamon Press Inc. (1990):[9] Warrington SJ, Ankier SI, Turner P \"Evaluation of possible interactions between ethanol and trazodone or amitriptyline.\" Neuropsychobiology 15 (1986): 31-7[10] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc, Rockville, MD.", "alternatives_a": "Naltrexone, Acetaminophen, Tramadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245896, "ingredient1": "Dihydrocodeine", "ingredient2": "Meclizine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289831/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245897, "ingredient1": "Dihydrocodeine", "ingredient2": "Melatonin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289832/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245898, "ingredient1": "Dihydrocodeine", "ingredient2": "Mepenzolate", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289833/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245899, "ingredient1": "Dihydrocodeine", "ingredient2": "Meperidine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289834/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Meperidine", "updated_at": 1767369485}, {"id": 245900, "ingredient1": "Dihydrocodeine", "ingredient2": "Mephenytoin", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289835/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Acetylsalicylic acid, Naloxone, Ibuprofen, Celecoxib", "updated_at": 1767369485}, {"id": 245901, "ingredient1": "Dihydrocodeine", "ingredient2": "Methylphenobarbital", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289836/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Lacosamide, Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Acetylsalicylic acid, Naloxone, Ibuprofen, Naltrexone", "updated_at": 1767369485}, {"id": 245902, "ingredient1": "Dihydrocodeine", "ingredient2": "Meprobamate", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289837/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Acetylsalicylic acid, Naloxone, Naltrexone, Celecoxib", "updated_at": 1767369485}, {"id": 245903, "ingredient1": "Dihydrocodeine", "ingredient2": "Mesoridazine", "severity": "Major", "effect": "Concomitant use of opioids with central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, antipsychotics).", "source": "DDInter", "management_text": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.  Delayed diagnosis and treatment of constipation may increase the risk of severe complications, which can result in hospitalization, surgery, and death.  Patients should be advised to maintain adequate hydration, physical activity and fiber intake, and to report any changes in the frequency or character of bowel movements as well as signs and symptoms of potential complications of ileus such as nausea, vomiting, abdominal distension, and abdominal pain.  If constipation or gastrointestinal hypomotility is identified, monitor closely and treat promptly with appropriate laxatives to prevent severe complications.  Consider prophylactic laxatives in high risk patients, such as those with a history of constipation, colonic disease, or lower abdominal surgery.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289838/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[3] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. FazaClo (clozapine).\" Jazz Pharmaceuticals  (2015):[7] \"Product Information. Versacloz (clozapine).\" Jazz Pharmaceuticals  (2015):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245904, "ingredient1": "Dihydrocodeine", "ingredient2": "Metaxalone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289839/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245905, "ingredient1": "Dihydrocodeine", "ingredient2": "Methadone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289840/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine, Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Methadone", "updated_at": 1767369485}, {"id": 245906, "ingredient1": "Dihydrocodeine", "ingredient2": "Methdilazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289841/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245907, "ingredient1": "Dihydrocodeine", "ingredient2": "Methocarbamol", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289842/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245908, "ingredient1": "Dihydrocodeine", "ingredient2": "Methohexital", "severity": "Moderate", "effect": "Narcotic analgesics may reduce the dosage of barbiturate anesthetics needed to induce anesthesia by as much as 40%.", "source": "DDInter", "management_text": "Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.", "mechanism_text": "Synergism", "recommendation": "Respiratory and cardiovascular status should be closely monitored, and anesthetic dosages titrated accordingly.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289843/", "reference_text": "[1] DeLapa RJ \"Influence of alphaprodine hydrochloride on intravenous barbiturate induction dosage.\" J Oral Surg 18 (1960):  163-8[2] Dundee JW, Halliday NJ, McMurray TJ, Harper KW \"Pretreatment with opioids: the effect on thiopentone induction requirements and on the onset of action of midazolam.\" Anaesthesia 41 (1986):  159-61[3] Stambaugh JE, Hemphill DM, Wainer IW, Schwartz I \"A potentially toxic drug interaction between pethidine (meperidine) and phenobarbitone.\" Lancet 1 (1977):  398-9[4] Stambaugh JE, Wainer IW, Schwartz I \"The effect of phenobarbital on the metabolism of meperidine in normal volunteers.\" J Clin Pharmacol 18 (1978):  482-90", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone, Etomidate", "alternatives_b": "Naltrexone, Opium, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245909, "ingredient1": "Dihydrocodeine", "ingredient2": "Methotrimeprazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289844/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245910, "ingredient1": "Dihydrocodeine", "ingredient2": "Methoxyflurane", "severity": "Moderate", "effect": "Opioids may decrease the minimum alveolar concentration required for inhalation anesthetics.  When these agents are used concomitantly, less inhalation anesthetic may be required.  In addition, inhalation anesthetics may cause respiratory depression which may be increased by opioid premedication or other agents causing respiratory depression.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.  Patients should be monitored closely for respiratory depression.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289845/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical  (2001):[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997):  100-5", "alternatives_a": "Salicylic acid, Acetaminophen, Choline salicylate, Diflunisal, Salsalate, Acetylsalicylic acid", "alternatives_b": "Naltrexone, Tapentadol, Acetaminophen, Dezocine, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245911, "ingredient1": "Dihydrocodeine", "ingredient2": "Methscopolamine", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289846/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Ketorolac, Homatropine, Ephedrine, Tropicamide, Phenylephrine", "alternatives_b": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245912, "ingredient1": "Dihydrocodeine", "ingredient2": "Methsuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289847/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245913, "ingredient1": "Dihydrocodeine", "ingredient2": "Methyldopa", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289848/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Rauwolfia serpentina root, Deserpidine", "alternatives_b": "Tapentadol, Oxymorphone, Butorphanol, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245914, "ingredient1": "Dihydrocodeine", "ingredient2": "Methylene blue", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289849/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987):  251-2[7] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993):  1270-1[8] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[9] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[10] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[11] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[12] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[13] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[14] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[15] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[16] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245915, "ingredient1": "Dihydrocodeine", "ingredient2": "Metoclopramide", "severity": "Moderate", "effect": "By diminishing gastrointestinal motility, narcotic analgesics may antagonize the pharmacologic effects of gastrointestinal prokinetic agents.", "source": "DDInter", "management_text": "The potential for reduced efficacy of gastrokinetic agents should be considered during coadministration with opioid analgesics.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Antagonism", "recommendation": "The potential for reduced efficacy of gastrokinetic agents should be considered during coadministration with opioid analgesics.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289850/", "reference_text": "[1] Manara AR, Shelly MP, Quinn K, Park GR \"The effect of metoclopramide on the absorption of oral controlled release morphine.\" Br J Clin Pharmacol 25 (1988):  518-21[2] \"Product Information. Reglan (metoclopramide).\" Wyeth-Ayerst Laboratories  (2001):[3] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61", "alternatives_a": "Cisapride", "alternatives_b": "Naltrexone", "updated_at": 1767369485}, {"id": 245916, "ingredient1": "Dihydrocodeine", "ingredient2": "Metolazone", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289851/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More", "alternatives_b": "Tapentadol, Naloxone, Dezocine, Oxymorphone", "updated_at": 1767369485}, {"id": 245917, "ingredient1": "Dihydrocodeine", "ingredient2": "Metoprolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289852/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Penbutolol, Carteolol, Penbutolol", "alternatives_b": "Tapentadol, Naltrexone, Oxymorphone", "updated_at": 1767369485}, {"id": 245918, "ingredient1": "Dihydrocodeine", "ingredient2": "Metyrosine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289854/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Riociguat, Ambrisentan, Macitentan, Tadalafil", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245919, "ingredient1": "Dihydrocodeine", "ingredient2": "Midazolam", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289856/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naloxone, Naltrexone, Celecoxib", "updated_at": 1767369485}, {"id": 245920, "ingredient1": "Dihydrocodeine", "ingredient2": "Mifepristone", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with mifepristone may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by mifepristone.", "source": "DDInter", "management_text": "Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever mifepristone is added to or withdrawn from therapy.  Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if mifepristone must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289857/", "reference_text": "[1] \"Product Information. Mifeprex (mifepristone).\" Danco Laboratories  (2001):[2] He K, Woolf TF, Hollenberg PF \"Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).\" J Pharmacol Exp Ther 288 (1999):  791-7[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone", "alternatives_b": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Pentazocine, Acetylsalicylic acid, More", "updated_at": 1767369485}, {"id": 245921, "ingredient1": "Dihydrocodeine", "ingredient2": "Milnacipran", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289858/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Opium, Acetaminophen, Naloxone, Celecoxib", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245922, "ingredient1": "Dihydrocodeine", "ingredient2": "Minoxidil", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289859/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, Cromoglicic acid, Abrocitinib, More", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Naloxone", "updated_at": 1767369485}, {"id": 245923, "ingredient1": "Dihydrocodeine", "ingredient2": "Mirtazapine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289860/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245924, "ingredient1": "Dihydrocodeine", "ingredient2": "Mitotane", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289861/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, Celecoxib, More", "updated_at": 1767369485}, {"id": 245925, "ingredient1": "Dihydrocodeine", "ingredient2": "Modafinil", "severity": "Minor", "effect": "Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  Modafinil and armodafinil are modest inducers of CYP450 3A4, and pharmacokinetic studies suggest that their effects may be primarily intestinal rather than hepatic.", "source": "DDInter", "management_text": "Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  Modafinil and armodafinil are modest inducers of CYP450 3A4, and pharmacokinetic studies suggest that their effects may be primarily intestinal rather than hepatic.  Thus, clinically significant interactions would most likely be expected with drugs that have low oral bioavailability due to significant intestinal CYP450 3A4-mediated first-pass metabolism (e.g., buspirone, cyclosporine, lovastatin, midazolam, saquinavir, simvastatin, sirolimus, tacrolimus, triazolam, calcium channel blockers).  However, the potential for interaction should be considered with any drug metabolized by CYP450 3A4, especially given the high degree of interpatient variability with respect to CYP450-mediated metabolism.  Pharmacologic response to these drugs may be altered and should be monitored more closely whenever modafinil or armodafinil is added to or withdrawn from therapy.  Dosage adjustments may be required if an interaction is suspected.", "mechanism_text": "Metabolism", "recommendation": "Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.", "risk_level": "Minor", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289863/", "reference_text": "[1] \"Product Information. Provigil (modafinil).\" Cephalon, Inc  (2001):[2] Robertson P, Decory HH, Madan A, Parkinson A \"In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil.\" Drug Metab Dispos 28 (2000):  664-71[3] Robertson P Jr, Hellriegel ET, Arora S, Nelson M \"Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers.\" Clin Pharmacol Ther 71 (2002):  46-56[4] Doherty MM, Charman WN \"The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?\" Clin Pharmacokinet 41 (2002):  235-53[5] \"Product Information. Nuvigil (armodafinil).\" Cephalon Inc  (2007):", "alternatives_a": "Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245926, "ingredient1": "Dihydrocodeine", "ingredient2": "Moexipril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289864/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Tapentadol, Naloxone, Dezocine, Oxymorphone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245927, "ingredient1": "Dihydrocodeine", "ingredient2": "Molindone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289865/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245928, "ingredient1": "Dihydrocodeine", "ingredient2": "Morphine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289866/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Diphenoxylate, Difenoxin, Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Morphine", "updated_at": 1767369485}, {"id": 245929, "ingredient1": "Dihydrocodeine", "ingredient2": "Nabilone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289867/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Rolapitant", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245930, "ingredient1": "Dihydrocodeine", "ingredient2": "Nadolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289868/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Penbutolol, Carteolol", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245931, "ingredient1": "Dihydrocodeine", "ingredient2": "Nafcillin", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289869/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More", "alternatives_b": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Dextropropoxyphene, Ibuprofen, More", "updated_at": 1767369485}, {"id": 245932, "ingredient1": "Dihydrocodeine", "ingredient2": "Nalbuphine", "severity": "Major", "effect": "Concomitant use of opioids with other central nervous system (CNS) depressants including mixed agonist-antagonist or partial agonist opioids may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased.  On the other hand, mixed agonist-antagonist or partial agonist opioids can reduce the pharmacologic effects of other opioid agonists.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary (e.g., when initiating a switch from one opioid to the other), the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Additional caution is advisable when a mixed agonist-antagonist or partial agonist opioid is added to an existing opioid regimen, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the mixed agonist-antagonist or partial agonist opioid.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Others", "recommendation": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289870/", "reference_text": "[1] Moldenhauer CC, Roach GW, Finlayson DC, et al. \"Nalbuphine antagonism of ventilatory depression following high-dose fentanyl anesthesia.\" Anesthesiology 62 (1985):  647-50[2] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[3] Strain EC, Preston KL, Liebson IA, Bigelow GE \"Precipitated withdrawal by pentazocine in methadone-maintained volunteers.\" J Pharmacol Exp Ther 267 (1993):  624-34[4] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[5] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[6] \"Product Information. Talwin NX (pentazocine).\" Sanofi Winthrop Pharmaceuticals  (2001):[7] \"Product Information. Stadol (butorphanol).\" Allscrips Pharmaceutical Company  (2001):[8] \"Product Information. Dalgan (dezocine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Suboxone (buprenorphine-naloxone).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[10] \"Product Information. Subutex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[11] \"Product Information. Butrans (buprenorphine).\" Purdue Pharma LP  (2010):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Acetylsalicylic acid, Nalbuphine, Celecoxib", "updated_at": 1767369485}, {"id": 245933, "ingredient1": "Dihydrocodeine", "ingredient2": "Naloxone", "severity": "Moderate", "effect": "This warning does not apply to the naloxone component in non-injectable formulations of naloxone-containing combination medicines.  Naloxone injection is an antagonist that will reverse the actions of opiates.  This reversal can occur when the opiate drug is being used clinically and when it is being abused.  Physically dependent patients may experience withdrawal symptoms.  Abrupt postoperative opioid reversal has resulted in hypotension, ventricular tachycardia and fibrillation, pulmonary edema, cardiac arrest, encephalopathy, and death.", "source": "DDInter", "management_text": "Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.", "mechanism_text": "Antagonism", "recommendation": "Patients receiving naloxone injection should be monitored for changes in vital signs, nausea, vomiting, diarrhea, aches, fever, runny nose, sneezing, nervousness, irritability, shivering, abdominal cramps.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289871/", "reference_text": "[1] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[2] \"Product Information. Narcan (naloxone).\" DuPont Pharmaceuticals  (2001):[3] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[4] Cerner Multum, Inc. \"Australian Product Information.\" O 0", "alternatives_a": "Sorbitol, Tegaserod, Naloxegol, Bisacodyl, Naldemedine, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, More", "alternatives_b": "Naltrexone, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245934, "ingredient1": "Dihydrocodeine", "ingredient2": "Naltrexone", "severity": "Major", "effect": "Naltrexone can antagonize the effects of opioids via competitive inhibition of opioid receptors.  Patients receiving naltrexone may not benefit from opioid-containing medications such as cough and cold products, antidiarrheal preparations, and narcotic analgesics.", "source": "DDInter", "management_text": "The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.g., methadone) or partial agonists (e.g., buprenorphine).  Naltrexone should also not be given to patients in acute opioid withdrawal.  In an urgent situation when analgesia may be required in a patient who has received full blocking doses of naltrexone, consideration should be given to regional analgesia, conscious sedation with a benzodiazepine, use of non-opioid analgesics, or general anesthesia.  If opioid analgesia is required, the amount of opioid needed may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.  A rapidly-acting opioid analgesic that minimizes the duration of respiratory depression is preferred.  Clinicians should be aware that reversal of full naltrexone blockade by administration of large doses of opiates can cause histamine release.  Therefore, patients may experience non-opioid receptor-mediated effects such as facial swelling, itching, generalized erythema, and bronchoconstriction.  Irrespective of the drug chosen to reverse naltrexone blockade, the patient should be monitored closely by appropriately trained personnel in a setting equipped and staffed for cardiopulmonary resuscitation.", "mechanism_text": "Antagonism", "recommendation": "The use of naltrexone is considered contraindicated in patients receiving opioids or dependent on opioids, including those maintained on opiate agonists (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289872/", "reference_text": "[1] \"Product Information. ReVia (naltrexone).\" DuPont Pharmaceuticals  (2001):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen, Acamprosate, Varenicline, Disulfiram, Nalmefene, Nicotine, Ephedrine, Phentermine, More", "alternatives_b": "Acetylsalicylic acid, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245935, "ingredient1": "Dihydrocodeine", "ingredient2": "Naratriptan", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289873/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rimegepant, Eptinezumab, Dihydroergotamine, Ubrogepant, Ergotamine, Galcanezumab, Atogepant, Methysergide, Erenumab, Fremanezumab", "alternatives_b": "Naltrexone, Opium, Dextropropoxyphene, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245936, "ingredient1": "Dihydrocodeine", "ingredient2": "Nebivolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289874/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine, Sacubitril, Aliskiren, Penbutolol, Carteolol", "alternatives_b": "Naltrexone, Tapentadol, Acetaminophen, Tramadol, Naloxone", "updated_at": 1767369485}, {"id": 245937, "ingredient1": "Dihydrocodeine", "ingredient2": "Nefazodone", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289875/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245938, "ingredient1": "Dihydrocodeine", "ingredient2": "Nevirapine", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289876/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Velpatasvir, More", "alternatives_b": "Tapentadol, Oxymorphone, Meperidine, Hydromorphone, Dezocine, Opium, Dextropropoxyphene, Celecoxib, Pentazocine, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245939, "ingredient1": "Dihydrocodeine", "ingredient2": "Nicardipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289877/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Celecoxib, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245940, "ingredient1": "Dihydrocodeine", "ingredient2": "Nifedipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289878/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Acetylsalicylic acid, Ivabradine", "alternatives_b": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "updated_at": 1767369485}, {"id": 245941, "ingredient1": "Dihydrocodeine", "ingredient2": "Nilotinib", "severity": "Moderate", "effect": "Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter and/or CYP450 2D6, CYP450 3A4, or UGT1A1 isoenzymes.  The mechanism is decreased clearance via these routes due to inhibition by nilotinib.", "source": "DDInter", "management_text": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nilotinib is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289879/", "reference_text": "[1] \"Product Information. Tasigna (nilotinib).\" Novartis Pharmaceuticals  (2007):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Oxymorphone, Tapentadol, Meperidine, Butorphanol, Acetaminophen, Hydromorphone, Dezocine, Opium, Ibuprofen, Pentazocine, Acetylsalicylic acid, More", "updated_at": 1767369485}, {"id": 245942, "ingredient1": "Dihydrocodeine", "ingredient2": "Nimodipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289880/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Tramadol, Celecoxib, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245943, "ingredient1": "Dihydrocodeine", "ingredient2": "Nisoldipine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289881/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245944, "ingredient1": "Dihydrocodeine", "ingredient2": "Nitroglycerin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289882/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More", "alternatives_b": "Tapentadol, Dezocine, Naltrexone, Oxymorphone", "updated_at": 1767369485}, {"id": 245945, "ingredient1": "Dihydrocodeine", "ingredient2": "Nitroprusside", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289883/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245946, "ingredient1": "Dihydrocodeine", "ingredient2": "Nitrous oxide", "severity": "Moderate", "effect": "Opioids may decrease the minimum alveolar concentration required for inhalation anesthetics.  When these agents are used concomitantly, less inhalation anesthetic may be required.  In addition, inhalation anesthetics may cause respiratory depression which may be increased by opioid premedication or other agents causing respiratory depression.", "source": "DDInter", "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.  Patients should be monitored closely for respiratory depression.  Supportive therapy should be provided if needed.", "mechanism_text": "Synergism", "recommendation": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289884/", "reference_text": "[1] \"Product Information. Ultane (sevoflurane).\" Abbott Pharmaceutical  (2001):[2] Inagaki Y, Kuzukawa A \"Effects of epidural and intravenous buprenorphine on halothane minimum alveolar anesthetic concentration and hemodynamic responses.\" Anesth Analg 84 (1997):  100-5", "alternatives_a": "Etomidate", "alternatives_b": "Naltrexone, Tapentadol, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245947, "ingredient1": "Dihydrocodeine", "ingredient2": "Nortriptyline", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289885/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245948, "ingredient1": "Dihydrocodeine", "ingredient2": "Olanzapine", "severity": "Major", "effect": "Concomitant use of opioids with central nervous system (CNS) depressants (e.g., benzodiazepines, sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, antipsychotics).", "source": "DDInter", "management_text": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.  Delayed diagnosis and treatment of constipation may increase the risk of severe complications, which can result in hospitalization, surgery, and death.  Patients should be advised to maintain adequate hydration, physical activity and fiber intake, and to report any changes in the frequency or character of bowel movements as well as signs and symptoms of potential complications of ileus such as nausea, vomiting, abdominal distension, and abdominal pain.  If constipation or gastrointestinal hypomotility is identified, monitor closely and treat promptly with appropriate laxatives to prevent severe complications.  Consider prophylactic laxatives in high risk patients, such as those with a history of constipation, colonic disease, or lower abdominal surgery.", "mechanism_text": "Synergism", "recommendation": "Close monitoring of bowel function is recommended during concomitant use of opioids with antipsychotic agents that exhibit anticholinergic effects, particularly in the elderly.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289886/", "reference_text": "[1] \"Product Information. Clozaril (clozapine).\" Novartis Pharmaceuticals  (2001):[2] \"Product Information. Zyprexa (olanzapine).\" Lilly, Eli and Company  (2001):[3] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[4] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. FazaClo (clozapine).\" Jazz Pharmaceuticals  (2015):[7] \"Product Information. Versacloz (clozapine).\" Jazz Pharmaceuticals  (2015):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naloxone", "updated_at": 1767369485}, {"id": 245949, "ingredient1": "Dihydrocodeine", "ingredient2": "Oliceridine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289887/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Acetylsalicylic acid, Oliceridine, Ibuprofen, Acetaminophen", "updated_at": 1767369485}, {"id": 245950, "ingredient1": "Dihydrocodeine", "ingredient2": "Olmesartan", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289888/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Sacubitril, Aliskiren", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Naloxone", "updated_at": 1767369485}, {"id": 245951, "ingredient1": "Dihydrocodeine", "ingredient2": "Olopatadine (nasal)", "severity": "Moderate", "effect": "Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance.", "source": "DDInter", "management_text": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.  In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289889/", "reference_text": "[1] \"Product Information. Patanase (olopatadine nasal).\" Alcon Laboratories Inc  (2008):[2] \"Product Information. Ryaltris (mometasone-olopatadine nasal).\" Hikma Americas, Inc  (2022):", "alternatives_a": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245952, "ingredient1": "Dihydrocodeine", "ingredient2": "Ondansetron", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289892/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rolapitant", "alternatives_b": "Opium, Naltrexone", "updated_at": 1767369485}, {"id": 245953, "ingredient1": "Dihydrocodeine", "ingredient2": "Opicapone", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289893/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245954, "ingredient1": "Dihydrocodeine", "ingredient2": "Opium", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289894/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Diphenoxylate, Difenoxin, Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Acetaminophen, Opium, Ibuprofen, Celecoxib, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 245955, "ingredient1": "Dihydrocodeine", "ingredient2": "Orphenadrine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289895/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245956, "ingredient1": "Dihydrocodeine", "ingredient2": "Osilodrostat", "severity": "Moderate", "effect": "Coadministration with osilodrostat may increase the plasma concentrations of drugs that are metabolized by CYP450 1A2, 2C19, 2D6, and/or 3A4.  Osilodrostat has been shown to be a moderate inhibitor of CYP450 1A2, a mild to borderline moderate inhibitor of CYP450 2C19, and a weak inhibitor of CYP450 2D6 and 3A4.", "source": "DDInter", "management_text": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever osilodrostat is added to or withdrawn from therapy.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when osilodrostat is used concurrently with drugs that are substrates of CYP450 1A2, 2C19, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289896/", "reference_text": "[1] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Inc  (2020):[2] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases Australia Pty Ltd  (2022):[3] \"Product Information. Isturisa (osilodrostat).\" Recordati Rare Diseases UK Ltd  (2021):", "alternatives_a": "Ketoconazole", "alternatives_b": "Morphine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Acetaminophen, Dezocine, Opium, Ibuprofen, Celecoxib, More", "updated_at": 1767369485}, {"id": 245957, "ingredient1": "Dihydrocodeine", "ingredient2": "Oxazepam", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289897/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245958, "ingredient1": "Dihydrocodeine", "ingredient2": "Oxcarbazepine", "severity": "Moderate", "effect": "Coadministration with oxcarbazepine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.  The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by oxcarbazepine.", "source": "DDInter", "management_text": "Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.  Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oxcarbazepine is added to or withdrawn from therapy.  When initiating treatment or changing the dosage, it may take 2 to 3 weeks to reach the corresponding level of induction.  Similarly, the induction is expected to gradually decrease over 2 to 3 weeks following discontinuation of oxcarbazepine.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289898/", "reference_text": "[1] Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC \"Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.\" Ther Drug Monit 15 (1993):  39-42[2] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[3] Rosche J, Froscher W, Abendroth D, Liebel J \"Possible oxcarbazepine interaction with cyclosporine serum levels: A single case study.\" Clin Neuropharmacol 24 (2001):  113-6", "alternatives_a": "Lacosamide", "alternatives_b": "Naloxone", "updated_at": 1767369485}, {"id": 245959, "ingredient1": "Dihydrocodeine", "ingredient2": "Oxybutynin", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289899/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Pentosan polysulfate, Calcium chloride, Phenazopyridine, Alprostadil, Mirabegron, Acetohydroxamic acid, Yohimbine, Avanafil, Papaverine, Vardenafil, Phenyl salicylate, More", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245960, "ingredient1": "Dihydrocodeine", "ingredient2": "Oxycodone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289900/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Oxycodone", "updated_at": 1767369485}, {"id": 245961, "ingredient1": "Dihydrocodeine", "ingredient2": "Oxymorphone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289901/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Oxymorphone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid", "updated_at": 1767369485}, {"id": 245962, "ingredient1": "Dihydrocodeine", "ingredient2": "Ozanimod", "severity": "Moderate", "effect": "Coadministration of opioid analgesics with drugs that possess monoamine oxidase inhibition (MAOI) activity, including selective MAO-B inhibitors, has been associated with rare reports of severe and sometimes fatal adverse reactions.  Because an active metabolite of ozanimod inhibits MAO-B in vitro, the interaction may theoretically occur with ozanimod.  There appear to be two types of interaction, an excitatory and a depressive one.  Symptoms of the excitatory reaction may include agitation, headache, diaphoresis, hyperpyrexia, flushing, shivering, myoclonus, rigidity, tremor, diarrhea, hypertension, tachycardia, seizures, and coma.  Death has occurred in some cases.  In contrast, symptoms of the depressive reaction probably stem from potentiation of CNS effects by MAOIs and include respiratory depression, cyanosis, hypotension, and coma.  There have also been reports of serotonin syndrome, which is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors, with symptoms similar to the excitatory reaction described above.  Some opioids such as fentanyl, meperidine, methadone, tapentadol, and tramadol can inhibit serotonin reuptake and are more likely to cause serotonin syndrome.  However, serotonin syndrome has also occurred with other opioids.", "source": "DDInter", "management_text": "Until more information is available, concomitant use of ozanimod with opioid analgesics should be avoided when possible.  Blood pressure and other vitals should be monitored if coadministration is required.", "mechanism_text": "Synergism", "recommendation": "Until more information is available, concomitant use of ozanimod with opioid analgesics should be avoided when possible.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289902/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Pettinger WA, Soyangco FG, Oates JA \"Inhibition of monoamine oxidase in man by furazolidone.\" Clin Pharmacol Ther 9 (1968):  442-7[4] Schulz R, Antonin KH, Hoffmann E, et al. \"Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.\" Clin Pharmacol Ther 46 (1989):  528-36[5] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[6] Goldberg LI \"Monoamine oxidase inhibitors: adverse reactions and possible mechanisms.\" JAMA 190 (1964):  456-62[7] Vigran IM \"Dangerous potentiation of meperidine hydrochloride by pargyline hydrochloride.\" JAMA 187 (1964):  953-4[8] Nierenberg DW, Semprebon M \"The central nervous system serotonin syndrome.\" Clin Pharmacol Ther 53 (1993):  84-8[9] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[10] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[11] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[12] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[13] Starr C \"Interaction between pethidine and selegiline.\" Lancet 337 (1991):  554[14] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[15] Youssef MS, Wilkinson PA \"Epidural fentanyl and monoamine oxidase inhibitors.\" Anaesthesia 43 (1988):  210-2[16] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[17] \"Product Information. Eldepryl (selegiline).\" Somerset Pharmaceuticals Inc  (2001):[18] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[19] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987):  251-2[20] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993):  1270-1[21] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[22] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[23] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[24] Limbird LE eds., Gilman AG, Hardman JG \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: McGraw-Hill  (1995):[25] Darcy PF, Griffin JP \"Interactions with drugs used in the treatment of depressive illness.\" Adverse Drug React Toxicol Rev 14 (1995):  211-31[26] \"Product Information. Matulane (procarbazine).\" Roche Laboratories  (2001):[27] De Vita VT, Hahn MA, Oliverio VT \"Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590).\" Proc Soc Exp Biol Med 120 (1965):  561-5[28] Fischer P \"Serotonin syndrome in the elderly after antidepressive monotherapy.\" J Clin Psychopharmacol 15 (1995):  440-2[29] Corkeron MA \"Serotonin syndrome - a potentially fatal complication of antidepressant therapy.\" Med J Aust 163 (1995):  481-2[30] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[31] Staufenberg EF, Tantam D \"Malignant hyperpyrexia syndrome in combined treatment.\" Br J Psychiatry 154 (1989):  577-8[32] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[33] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[34] \"Product Information. Furoxone (furazolidone).\" Roberts Pharmaceutical Corporation  (2001):[35] \"Product Information. Actiq (fentanyl).\" Abbott Pharmaceutical  (2001):[36] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[37] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[38] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[39] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[40] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[41] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[42] Weiner AL \"Meperidine as a potential cause of serotonin syndrome in the emergency department.\" Acad Emerg Med 6 (1999):  156-8[43] Upton R, Graff A, Williamson E, et al. \"American Herbal Pharmacopoeia and Therapeutic Compendium. Monograph printed in Herbalgram.\" Herbalgram 40 (1997):  1-38(monograph)[44] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[45] \"Product Information. Meperidine Hydrochloride (meperidine).\" Astra-Zeneca Pharmaceuticals  (2022):[46] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[47] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[48] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[49] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[50] Bodner RA, Lynch T, Lewis L, Kahn D \"Serotonin syndrome.\" Neurology 45 (1995):  219-23[51] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):[52] \"Product Information. Azilect (rasagiline).\" Teva Pharmaceuticals USA  (2006):[53] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[54] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[55] Cerner Multum, Inc. \"Australian Product Information.\" O 0[56] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[57] \"Product Information. Methylene Blue (methylene blue).\" American Regent Laboratories Inc  (2012):[58] \"Product Information. Zeposia (ozanimod).\" Celgene Corporation  (2020):", "alternatives_a": "Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More", "alternatives_b": "Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245963, "ingredient1": "Dihydrocodeine", "ingredient2": "Paliperidone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289904/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Acetylsalicylic acid, Naloxone, Naltrexone, Celecoxib", "updated_at": 1767369485}, {"id": 245964, "ingredient1": "Dihydrocodeine", "ingredient2": "Palonosetron", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289905/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "Rolapitant", "alternatives_b": "Opium, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245965, "ingredient1": "Dihydrocodeine", "ingredient2": "Paraldehyde", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289906/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245966, "ingredient1": "Dihydrocodeine", "ingredient2": "Paramethadione", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289907/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245967, "ingredient1": "Dihydrocodeine", "ingredient2": "Paroxetine", "severity": "Moderate", "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome.  The interaction has primarily been reported with the phenylpiperidine opioids (e.g., meperidine, fentanyl) and tramadol, which are known to possess some serotonergic activity, although a few cases have involved other opioids such as oxycodone, methadone, morphine, hydromorphone, codeine, and buprenorphine.", "source": "DDInter", "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort.  Patients should be monitored for symptoms of the serotonin syndrome during treatment.  Particular caution is advised when increasing the dosages of these agents.  If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.  Moderately ill patients may also benefit from the administration of a serotonin antagonist (e.g., cyproheptadine, chlorpromazine).  Severe cases should be managed under consultation with a toxicologist and may require sedation, neuromuscular paralysis, intubation, and mechanical ventilation in addition to the other measures.  Patients should also be advised of potentially additive central nervous system effects from these agents and to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289908/", "reference_text": "[1] Meyer D, Halfin V \"Toxicity secondary to meperidine in patients on monoamine oxidase inhibitors: a case report and critical review.\" J Clin Psychopharmacol 1 (1981):  319-21[2] Zornberg GL, Bodkin JA, Cohen BM \"Severe adverse interaction between pethidine and selegiline.\" Lancet 337 (1991):  246[3] Hansen TE, Dieter K, Keepers GA \"Interaction of fluoxetine and pentazocine.\" Am J Psychiatry 147 (1990):  949-50[4] Sternbach H \"The serotonin syndrome.\" Am J Psychiatry 148 (1991):  705-13[5] Noble WH, Baker A \"MAO inhibitors and coronary artery surgery: a patient death.\" Can J Anaesth 39 (1992):  1061-6[6] Insler SR, Kraenzler EJ, Licina MG, Savage RM, Starr NJ \"Cardiac surgery in a patient taking monoamine oxidase inhibitors - an adverse fentanyl reaction.\" Anesth Analg 78 (1994):  593-7[7] Mason BJ, Blackburn KH \"Possible serotonin syndrome associated with tramadol and sertraline coadministration.\" Ann Pharmacother 31 (1997):  175-7[8] Mills KC \"Serotonin syndrome: A clinical update.\" Crit Care Clin 13 (1997):  763[9] Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG \"Serotonin syndrome resulting from drug interactions.\" Med J Aust 169 (1998):  523-5[10] Egberts AC, ter Borg J, Brodie-Meijer CC \"Serotonin syndrome attributed to tramadol addition to paroxetine therapy.\" Int Clin Psychopharmacol 12 (1997):  181-2[11] Rosebraugh CJ, floxkhart DA, Yasuda SU, Woosley RL \"Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient.\" J Clin Pharmacol 41 (2001):  224-7[12] Lange-Asschenfeldt C, Weigmann H, Hiemke C, Mann K \"Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology.\" J Clin Psychopharmacol 22 (2002):  440-1[13] Kesavan S, Sobala GM \"Serotonin syndrome with fluoxetine plus tramadol.\" J R Soc Med 92 (1999):  474-5[14] Gonzalez-Pinto A, Imaz H, De Heredia JL, Gutierrez M, Mico JA \"Mania and tramadol-fluoxetine combination.\" Am J Psychiatry 158 (2001):  964-5[15] Dougherty JA, Young H, Shafi T \"Serotonin syndrome induced by amitriptyline, meperidine, and venlafaxine.\" Ann Pharmacother 36 (2002):  1647-1648[16] Martin TG \"Serotonin syndrome.\" Ann Emerg Med 28 (1996):  520-6[17] Tissot TA \"Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use.\" Anesthesiology 98 (2003):  1511-1512[18] Roy S, Fortier LP \"Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine.\" Can J Anaesth 50 (2003):  32-5[19] Gillman PK \"Possible serotonin syndrome with moclobemide and pethidine.\" Med J Aust 162 (1995):  554[20] Houlihan DJ \"Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine.\" Ann Pharmacother 38 (2004):  411-3[21] \"Venlafaxine + tramadol: serotonin syndrome.\" Prescrire Int 13 (2004):  57[22] Mahlberg R, Kunz D, Sasse J, Kirchheiner J \"Serotonin syndrome with tramadol and citalopram.\" Am J Psychiatry 161 (2004):  1129[23] Mittino D, Mula M, Monaco F \"Serotonin syndrome associated with tramadol-sertraline coadministration.\" Clin Neuropharmacol 27 (2004):  150-1[24] Lantz MS, Buchalter EN, Giambanco V \"Serotonin syndrome following the administration of tramadol with paroxetine.\" Int J Geriatr Psychiatry 13 (1998):  343-5[25] Gillman PK \"Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity.\" Br J Anaesth  (2005):[26] Kitson R, Carr B \"Tramadol and severe serotonin syndrome.\" Anaesthesia 60 (2005):  934-5[27] Gnanadesigan N, Espinoza RT, Smith R, Israel M, Reuben DB \"Interaction of serotonergic antidepressants and opioid analgesics: Is serotonin syndrome going undetected?\" J Am Med Dir Assoc 6 (2005):  265-9[28] Hunter B, Kleinert MM, Osatnik J, Soria E \"Serotonergic syndrome and abnormal ocular movements: worsening of rigidity by remifentanil?\" Anesth Analg 102 (2006):  1589[29] Ailawadhi S, Sung KW, Carlson LA, Baer MR \"Serotonin syndrome caused by interaction between citalopram and fentanyl.\" J Clin Pharm Ther 32 (2007):  199-202[30] Vizcaychipi MP, Walker S, Palazzo M \"Serotonin syndrome triggered by tramadol.\" Br J Anaesth 99 (2007):  919[31] Das PK, Warkentin DI, Hewko R, Forrest DL \"Serotonin syndrome after concomitant treatment with linezolid and meperidine.\" Clin Infect Dis 46 (2008):  264-5[32] Rang ST, Field J, Irving C \"Serotonin toxicity caused by an interaction between fentanyl and paroxetine.\" Can J Anaesth 55 (2008):  521-5[33] Guo SL, Wu TJ, Liu CC, Ng CC, Chien CC, Sun HL \"Meperidine-induced serotonin syndrome in a susceptible patient.\" Br J Anaesth  (2009):[34] Davis JJ, Buck NS, Swenson JD, Johnson KB, Greis PE \"Serotonin syndrome manifesting as patient movement during total intravenous anesthesia with propofol and remifentanil.\" J Clin Anesth 25 (2013):  52-4[35] Hillman AD, Witenko CJ, Sultan SM, Gala G \"Serotonin syndrome caused by fentanyl and methadone in a burn injury.\" Pharmacotherapy 35 (2015):  112-7[36] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5[37] Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F \"Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance  Database.\" J Clin Psychopharmacol  (2015):[38] Shakoor M, Ayub S, Ahad A, Ayub Z \"Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor.\" Am J Case Rep 15 (2014):  562-4[39] Larson KJ, Wittwer ED, Nicholson WT, Weingarten TN, Price DL, Sprung J \"Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.\" J Clin Anesth 27 (2015):  247-51[40] US Food and Drug Administration (FDA) \"FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes.  https://www.fda.gov/downloads/Drugs/DrugSafety/UCM491302.pdf\"   (2018):", "alternatives_a": "", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245968, "ingredient1": "Dihydrocodeine", "ingredient2": "Pegvisomant", "severity": "Moderate", "effect": "In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.  The mechanism of interaction is unknown.", "source": "DDInter", "management_text": "Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.", "mechanism_text": "Others", "recommendation": "Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289909/", "reference_text": "[1] \"Product Information. Somavert (pegvisomant).\" Pharmacia and Upjohn  (2003):", "alternatives_a": "Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245969, "ingredient1": "Dihydrocodeine", "ingredient2": "Pentazocine", "severity": "Major", "effect": "Concomitant use of opioids with other central nervous system (CNS) depressants including mixed agonist-antagonist or partial agonist opioids may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased.  On the other hand, mixed agonist-antagonist or partial agonist opioids can reduce the pharmacologic effects of other opioid agonists.", "source": "DDInter", "management_text": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary (e.g., when initiating a switch from one opioid to the other), the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression.  Additional caution is advisable when a mixed agonist-antagonist or partial agonist opioid is added to an existing opioid regimen, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the mixed agonist-antagonist or partial agonist opioid.  A dosage adjustment for one or both drugs may be required.", "mechanism_text": "Others", "recommendation": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289910/", "reference_text": "[1] Moldenhauer CC, Roach GW, Finlayson DC, et al. \"Nalbuphine antagonism of ventilatory depression following high-dose fentanyl anesthesia.\" Anesthesiology 62 (1985):  647-50[2] Gilman AG, eds., Nies AS, Rall TW, Taylor P \"Goodman and Gilman's the Pharmacological Basis of Therapeutics.\" New York, NY: Pergamon Press Inc.  (1990):[3] Strain EC, Preston KL, Liebson IA, Bigelow GE \"Precipitated withdrawal by pentazocine in methadone-maintained volunteers.\" J Pharmacol Exp Ther 267 (1993):  624-34[4] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[5] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[6] \"Product Information. Talwin NX (pentazocine).\" Sanofi Winthrop Pharmaceuticals  (2001):[7] \"Product Information. Stadol (butorphanol).\" Allscrips Pharmaceutical Company  (2001):[8] \"Product Information. Dalgan (dezocine).\" Astra-Zeneca Pharmaceuticals  (2001):[9] \"Product Information. Suboxone (buprenorphine-naloxone).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[10] \"Product Information. Subutex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2002):[11] \"Product Information. Butrans (buprenorphine).\" Purdue Pharma LP  (2010):", "alternatives_a": "Dihydrocodeine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "alternatives_b": "Pentazocine, Acetylsalicylic acid, Acetaminophen, Ibuprofen", "updated_at": 1767369485}, {"id": 245970, "ingredient1": "Dihydrocodeine", "ingredient2": "Pentobarbital", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289911/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone", "alternatives_b": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245971, "ingredient1": "Dihydrocodeine", "ingredient2": "Perampanel", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289912/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Dextropropoxyphene, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245972, "ingredient1": "Dihydrocodeine", "ingredient2": "Pergolide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289913/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Acetaminophen, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245973, "ingredient1": "Dihydrocodeine", "ingredient2": "Perindopril", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289914/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Atorvastatin, Simvastatin, Lovastatin, Rosuvastatin, Niacin, Pravastatin, Acetylsalicylic acid, Ezetimibe, Bempedoic acid, Fenofibrate", "alternatives_b": "Tapentadol, Oxymorphone, Dezocine, Tramadol, Naloxone", "updated_at": 1767369485}, {"id": 245974, "ingredient1": "Dihydrocodeine", "ingredient2": "Perphenazine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289915/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245975, "ingredient1": "Dihydrocodeine", "ingredient2": "Phenacemide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289916/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245976, "ingredient1": "Dihydrocodeine", "ingredient2": "Phenelzine", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.  Concomitant use of pentazocine with MAOIs may also cause CNS excitation and hypertension through their respective effects on catecholamines.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.  However, morphine has been safely used in MAOI-treated patients who previously had an adverse reaction with meperidine and is generally suggested as an alternative to meperidine in anesthesia.  A sensitivity test should be performed in which repeated, small, incremental doses of morphine are administered over the course of several hours while overall clinical status and vital signs are carefully monitored.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289917/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[7] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[8] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[9] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[10] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[11] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[12] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[13] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[14] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):[15] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[16] Cerner Multum, Inc. \"Australian Product Information.\" O 0[17] Mateo-Carrasco H, Munoz-Aguilera EM, Garcia-Torrecillas JM, Abu Al-Robb H \"Serotonin syndrome probably triggered by a morphine-phenelzine interaction.\" Pharmacotherapy 35 (2015):  e102-5", "alternatives_a": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245977, "ingredient1": "Dihydrocodeine", "ingredient2": "Phenindamine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289918/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245978, "ingredient1": "Dihydrocodeine", "ingredient2": "Phenobarbital", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289919/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone, Lacosamide", "alternatives_b": "Acetylsalicylic acid, Naloxone, Ibuprofen, Naltrexone", "updated_at": 1767369485}, {"id": 245979, "ingredient1": "Dihydrocodeine", "ingredient2": "Phenoxybenzamine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289920/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Cyclandelate, Tolazoline, Isoxsuprine, Pentoxifylline, Niacin", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245980, "ingredient1": "Dihydrocodeine", "ingredient2": "Phensuximide", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289921/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Lacosamide", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245981, "ingredient1": "Dihydrocodeine", "ingredient2": "Phentolamine", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289922/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245982, "ingredient1": "Dihydrocodeine", "ingredient2": "Phenytoin", "severity": "Moderate", "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels.", "source": "DDInter", "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.  Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.  Some manufacturers of products containing codeine advise against the concomitant use of codeine with CYP450 3A4 inducers.  If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended.  Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy.  Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "mechanism_text": "Metabolism", "recommendation": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289923/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] Cerner Multum, Inc. \"Australian Product Information.\" O 0[3] \"Product Information. Codeine Sulfate (codeine).\" Lannett Company Inc  (2015):[4] \"Product Information. Acetaminophen-Codeine Phosphate (acetaminophen-codeine).\" Qualitest Products Inc  (2015):[5] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[6] \"Product Information. Tuzistra XR (chlorpheniramine-codeine).\" Vernalis Pharmaceuticals Inc  (2016):[7] Caraco Y, Sheller J, Wood AJ \"Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects.\" J Pharmacol Exp Ther 281 (1997):  330-6", "alternatives_a": "Lacosamide", "alternatives_b": "Naloxone", "updated_at": 1767369485}, {"id": 245983, "ingredient1": "Dihydrocodeine", "ingredient2": "Pimavanserin", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289924/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Opium, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245984, "ingredient1": "Dihydrocodeine", "ingredient2": "Pimozide", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289925/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245985, "ingredient1": "Dihydrocodeine", "ingredient2": "Pindolol", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289926/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Penbutolol, Penbutolol, Carteolol", "alternatives_b": "Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 245986, "ingredient1": "Dihydrocodeine", "ingredient2": "Pitolisant", "severity": "Moderate", "effect": "Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4.  Pitolisant is a borderline/weak inducer of CYP450 3A4.", "source": "DDInter", "management_text": "Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.  Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary.  It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289928/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Wakix (pitolisant).\" Harmony Biosciences, LLC  (2019):", "alternatives_a": "Dalfampridine, Inotersen, Riluzole, Tafamidis", "alternatives_b": "Codeine, Naltrexone, Oxymorphone, Tapentadol, Meperidine, Hydromorphone, Dezocine, Opium, Pentazocine, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245987, "ingredient1": "Dihydrocodeine", "ingredient2": "Polyethylene glycol (3350 with electrolytes)", "severity": "Moderate", "effect": "The risk of seizures induced by the use of bowel cleansing preparations may be increased in patients on concomitant medications that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), systemic steroids, carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline.", "source": "DDInter", "management_text": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.  Bowel cleansing preparations should not be used if these patients have impaired renal function or perfusion, dehydration, or uncorrected electrolyte abnormalities.  Baseline and postprocedure labs including serum electrolytes, calcium, phosphate, BUN, and creatinine should be considered, particularly in the elderly.  Patients should be advised not to exceed the recommended dosage of their bowel cleansing preparation and to drink sufficient quantities of clear fluids before, during, and after the bowel preparation process.  Administration of an electrolyte rehydration solution may help attenuate the electrolyte abnormalities and hypovolemia.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when bowel cleansing preparations are prescribed in patients treated with agents that can lower the seizure threshold.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289929/", "reference_text": "[1] Salik JM, Kurtin P \"Severe hyponatremia after colonoscopy preparation in a patient with the acquired immune deficiency syndrome.\" Am J Gastroenterol 80 (1985):  177-9[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] \"Product Information. Fleet Phospho Soda (sodium acid phophate-sodium phosphate).\" Fleet, CB  (2007):[4] \"Product Information. Visicol (sodium acid phophate-sodium phosphate).\" Salix Pharmaceuticals  (2007):[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] \"Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates).\" Braintree Laboratories  (2010):[7] \"Product Information. Suclear (polyethylene glycol 3350 with electrolytes).\" Braintree Laboratories  (2013):", "alternatives_a": "Acetaminophen, Naloxone, Naltrexone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245988, "ingredient1": "Dihydrocodeine", "ingredient2": "Polythiazide", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289930/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Trichlormethiazide, Methyclothiazide, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More", "alternatives_b": "Naltrexone, Oxymorphone, Tapentadol, Acetaminophen, Dezocine, Tramadol, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245989, "ingredient1": "Dihydrocodeine", "ingredient2": "Pralsetinib", "severity": "Moderate", "effect": "Coadministration with pralsetinib may alter the plasma concentrations of drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5.", "source": "DDInter", "management_text": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.  Some authorities recommend avoiding coadministration of pralsetinib with CYP450 2C8, 2C9, 3A4, and/or 3A5 substrates for which minimal concentration changes may lead to therapeutic failure or serious toxicities.  If coadministration is required, dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever pralsetinib is added to or withdrawn from therapy.  The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.", "mechanism_text": "Metabolism", "recommendation": "Caution is advised if pralsetinib is used concomitantly with drugs that are substrates of CYP450 2C8, 2C9, 3A4, and/or 3A5, particularly sensitive substrates or those with a narrow therapeutic range.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289931/", "reference_text": "[1] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[2] \"Product Information. Gavreto (pralsetinib).\" Blueprint Medicines Corporation  (2020):", "alternatives_a": "Entrectinib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Avapritinib, Bosutinib, Vemurafenib, Selumetinib, Vandetanib, Cobimetinib, More", "alternatives_b": "Oxymorphone, Tapentadol, Butorphanol, Hydromorphone, Dezocine, Opium, Pentazocine, Acetylsalicylic acid, Naloxone, Nalbuphine", "updated_at": 1767369485}, {"id": 245990, "ingredient1": "Dihydrocodeine", "ingredient2": "Pramipexole", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289932/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amantadine, Cabergoline", "alternatives_b": "Naloxone", "updated_at": 1767369485}, {"id": 245991, "ingredient1": "Dihydrocodeine", "ingredient2": "Prasugrel", "severity": "Moderate", "effect": "Coadministration with opioid agonists may delay and reduce the absorption of orally administered P2Y12 inhibitors (e.g., clopidogrel, prasugrel, ticagrelor).  The proposed mechanism may involve opioid-mediated slowed gastric emptying.", "source": "DDInter", "management_text": "Although data are limited, caution is recommended when orally administered P2Y12 inhibitors are given concomitantly with opioid agonists.  In acute coronary syndrome patients who require an opioid agonist, the use of a parenteral antiplatelet agent, such as cangrelor, should be considered.", "mechanism_text": "Absorption", "recommendation": "Although data are limited, caution is recommended when orally administered P2Y12 inhibitors are given concomitantly with opioid agonists.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289933/", "reference_text": "[1] \"Product Information. Plavix (clopidogrel).\" Bristol-Myers Squibb  (2001):[2] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[3] Cerner Multum, Inc. \"Australian Product Information.\" O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare \"Centro de informacin online de medicamentos de la AEMPS - CIMA.  https://cima.aemps.es/cima/publico/home.html\"   (2008):[5] \"Product Information. Effient (prasugrel).\" Lilly, Eli and Company  (2009):[6] \"Product Information. Brilinta (ticagrelor).\" Astra-Zeneca Pharmaceuticals  (2011):[7] Hobl EL, Stimpfl T, Ebner J, et al. \"Morphine Decreases Clopidogrel Concentrations and Effects: A Randomized, Double Blind, Placebo-Controlled Trial.\" J Am Coll Cardiol  (2013):[8] Cerner Multum, Inc. \"Canadian Product Information.\" O 0 (2015):[9] Hobl EL, Reiter B, Schoergenhofer C, et al. \"Morphine Decreases Ticagrelor Concentrations but not its Antiplatelet Effects: A  Randomized Trial in Healthy Volunteers.\" Eur J Clin Invest 46 (2015):  7-14[10] Hobl EL, Reiter B, Schoergenhofer C, et al. \"Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy  volunteers.\" Clin Res Cardiol 105 (2015):  349-55[11] Kubica J, Adamski P, Ostrowska M, et al. \"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.\" Eur Heart J  (2015):[12] Kubica J, Kubica A, Jilma B, et al. \"Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors.\" Int J Cardiol 215 (2016):  201-208", "alternatives_a": "Betrixaban, Apixaban, Cilostazol, Iloprost, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, More", "alternatives_b": "Acetaminophen, Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245992, "ingredient1": "Dihydrocodeine", "ingredient2": "Prazosin", "severity": "Moderate", "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.", "source": "DDInter", "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289934/", "reference_text": "[1] Sternbach H \"Fluoxetine-associated potentiation of calcium-channel blockers.\" J Clin Psychopharmacol 11 (1991):  390-1[2] Feder R \"Bradycardia and syncope induced by fluoxetine.\" J Clin Psychiatry 52 (1991):  139[3] Ellison JM, Milofsky JE, Ely E \"Fluoxetine-induced bradycardia and syncope in two patients.\" J Clin Psychiatry 51 (1990):  385-6[4] Rodriguez de la Torre B, Dreher J, Malevany I, et al. \"Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients.\" Ther Drug Monit 23 (2001):  435-40[5] Cerner Multum, Inc. \"Australian Product Information.\" O 0[6] Pacher P, Kecskemeti V \"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?\" Curr Pharm Des 10 (2004):  2463-75[7] Andrews C, Pinner G \"Postural hypotension induced by paroxetine.\" BMJ 316 (1998):  595", "alternatives_a": "Rauwolfia serpentina root, Deserpidine", "alternatives_b": "Tramadol, Naloxone, Naltrexone, Tapentadol", "updated_at": 1767369485}, {"id": 245993, "ingredient1": "Dihydrocodeine", "ingredient2": "Pregabalin", "severity": "Major", "effect": "Concomitant use of opioids with gabapentinoids (e.g., gabapentin, pregabalin) may increase the risk of opioid overdose and serious adverse effects such as profound sedation, respiratory depression, syncope, and death due to potentially additive depressant effects on the central nervous system.", "source": "DDInter", "management_text": "Caution is advised when opioids and gabapentinoids are coadministered, particularly in patients with additional risk factors for respiratory depression such as advanced age, renal insufficiency, or chronic lung disease.  The dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Use of additional central nervous system depressants should be avoided if possible.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  For patients who have been receiving extended therapy with both an opioid and a gabapentinoid (either for analgesia or seizure control) and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms and increased seizure risk.", "mechanism_text": "Synergism", "recommendation": "Caution is advised when opioids and gabapentinoids are coadministered, particularly in patients with additional risk factors for respiratory depression such as advanced age, renal insufficiency, or chronic lung disease.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289935/", "reference_text": "[1] \"Product Information. Neurontin (gabapentin).\" Parke-Davis  (2001):[2] \"Product Information. Lyrica (pregabalin).\" Pfizer U.S. Pharmaceuticals Group  (2005):[3] US Food and Drug Administration \"FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR) When used with CNS depressants or in patients with lung problems.  https://www.fda.gov/media/1336\"   (2020):[4] Government of Canada \"Summary Safety Review - Gabapentin - Assessing the Potential Risk of Serious Breathing Problems.  https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-gabapentin-assessing-potential-ri\"   (2020):[5] Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G \"Gabapentin enhances the analgesic effect of morphine in healthy volunteers.\" Anesth Analg 91 (2000):  185-91[6] Eipe N, Penning J \"Postoperative respiratory depression associated with pregabalin: a case series and a preoperative decision algorithm.\" Pain Res Manag 16 (2011):  353-6[7] Smith RV, Havens JR, Walsh SL \"Gabapentin misuse, abuse and diversion: a systematic review.\" Addiction 111 (2016):  1160-74[8] Peckham AM, Evoy KE, Covvey JR, Ochs L, Fairman KA, Sclar DA \"Predictors of gabapentin overuse with or without concomitant opioids in a commercially insured U.S. population.\" Pharmacotherapy 38 (2018):  436-43", "alternatives_a": "Lacosamide", "alternatives_b": "Naloxone", "updated_at": 1767369485}, {"id": 245994, "ingredient1": "Dihydrocodeine", "ingredient2": "Primidone", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289936/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Nitrazepam, Zopiclone, Dichloralphenazone, Lacosamide", "alternatives_b": "Naloxone, Naltrexone", "updated_at": 1767369485}, {"id": 245995, "ingredient1": "Dihydrocodeine", "ingredient2": "Procarbazine", "severity": "Major", "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma.  The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.", "source": "DDInter", "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine).  At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.", "mechanism_text": "Synergism", "recommendation": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289937/", "reference_text": "[1] Browne B, Linter S \"Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment.\" Br J Psychiatry 151 (1987):  210-2[2] Evans-Prosser CD \"The use of pethidine and morphine in the presence of monoamine oxidase inhibitors.\" Br J Anaesth 40 (1968):  279-82[3] \"Product Information. MS Contin (morphine).\" Purdue Frederick Company  (2002):[4] \"Product Information. Roxicodone (oxycodone).\" Roxane Laboratories Inc  (2001):[5] \"Product Information. Levo-Dromoran (levorphanol).\" Roche Laboratories  (2001):[6] Garbutt JC \"Potentiation of propoxyphene by phenelzine.\" Am J Psychiatry 144 (1987):  251-2[7] Zornberg GL, Hegarty JD \"Adverse interaction between propoxyphene and phenelzine.\" Am J Psychiatry 150 (1993):  1270-1[8] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[9] Michaels I, Serrins M, Shier NQ, Barash PG \"Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors.\" Anesth Analg 63 (1984):  1041-4[10] \"Product Information. Nubain (nalbuphine).\" Endo Laboratories LLC  (2001):[11] \"Product Information. Nardil (phenelzine).\" Parke-Davis  (2001):[12] \"Product Information. Buprenex (buprenorphine).\" Reckitt and Colman Pharmaceuticals Inc  (2001):[13] \"Product Information. Parnate (tranylcypromine).\" SmithKline Beecham  (2001):[14] \"Product Information. Marplan (isocarboxazid).\" Roche Laboratories  (2001):[15] \"Product Information. Emsam (selegiline).\" Bristol-Myers Squibb  (2006):[16] \"Product Information. Talacen (acetaminophen-pentazocine).\" Sanofi-Synthelabo Inc  (2006):", "alternatives_a": "Pertuzumab, Olaparib, Oxaliplatin, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More", "alternatives_b": "Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245996, "ingredient1": "Dihydrocodeine", "ingredient2": "Prochlorperazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289938/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone", "updated_at": 1767369485}, {"id": 245997, "ingredient1": "Dihydrocodeine", "ingredient2": "Procyclidine", "severity": "Moderate", "effect": "Central anticholinergic agents may have additive central nervous system (CNS) effects with cannabinoids, barbiturates, opiates, and alcohol.", "source": "DDInter", "management_text": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.  Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them.  Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Patients taking central anticholinergic agents in combination with other CNS depressants should be monitored for potentially excessive or prolonged CNS depression, especially if they are elderly or debilitated.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289939/", "reference_text": "[1] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):", "alternatives_a": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "alternatives_b": "", "updated_at": 1767369485}, {"id": 245998, "ingredient1": "Dihydrocodeine", "ingredient2": "Promazine", "severity": "Major", "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death.  The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).", "source": "DDInter", "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.  If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed.  Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them.  Cough medications containing opioids (e.g., codeine, hydrocodone) should not be prescribed to patients using benzodiazepines or other CNS depressants including alcohol.  For patients who have been receiving extended therapy with both an opioid and a benzodiazepine and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms.  Severe cases of benzodiazepine withdrawal, primarily in patients who have received excessive doses over a prolonged period, may result in numbness and tingling of extremities, hypersensitivity to light and noise, hallucinations, and epileptic seizures.", "mechanism_text": "Synergism", "recommendation": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate.", "risk_level": "Major", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289940/", "reference_text": "[1] US Food and Drug Administration \"FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning.  http://www.fda.gov/downloads/Drugs/DrugSafety/UCM518672.pdf\"   (2016):", "alternatives_a": "Amisulpride", "alternatives_b": "Naltrexone, Acetaminophen, Dezocine, Ibuprofen, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}, {"id": 245999, "ingredient1": "Dihydrocodeine", "ingredient2": "Promethazine", "severity": "Moderate", "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.", "source": "DDInter", "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.  Cautious dosage titration may be required, particularly at treatment initiation.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289941/", "reference_text": "[1] Hamilton MJ, Bush M, Smith P, Peck AW \"The effects of bupropion, a new antidepressant drug, and diazepam, and their interaction in man.\" Br J Clin Pharmacol 14 (1982):  791-7[2] Stambaugh JE, Lane C \"Analgesic efficacy and pharmacokinetic evaluation of meperidine and hydroxyzine, alone and in combination.\" Cancer Invest 1 (1983):  111-7[3] Sotaniemi EA, Anttila M, Rautio A, et al. \"Propranolol and sotalol metabolism after a drinking party.\" Clin Pharmacol Ther 29 (1981):  705-10[4] Grabowski BS, Cady WJ, Young WW, Emery JF \"Effects of acute alcohol administration on propranolol absorption.\" Int J Clin Pharmacol Ther Toxicol 18 (1980):  317-9[5] Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB, Bergstrom RF \"The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.\" Clin Pharmacol Ther 43 (1988):  412-9[6] MacLeod SM, Giles HG, Patzalek G, Thiessen JJ, Sellers EM \"Diazepam actions and plasma concentrations following ethanol ingestion.\" Eur J Clin Pharmacol 11 (1977):  345-9[7] Divoll M, Greenblatt DJ, Lacasse Y, Shader RI \"Benzodiazepine overdosage: plasma concentrations and clinical outcome.\" Psychopharmacology (Berl) 73 (1981):  381-3[8] Naylor GJ, McHarg A \"Profound hypothermia on combined lithium carbonate and diazepam treatment.\" Br Med J 2 (1977):  22[9] Stovner J, Endresen R \"Intravenous anaesthesia with diazepam.\" Acta Anaesthesiol Scand 24 (1965):  223-7[10] Driessen JJ, Vree TB, Booij LH, van der Pol FM, Crul JF \"Effect of some benzodiazepines on peripheral neuromuscular function in the rat in-vitro hemidiaphragm preparation.\" J Pharm Pharmacol 36 (1984):  244-7[11] Feldman SA, Crawley BE \"Interaction of diazepam with the muscle-relaxant drugs.\" Br Med J 1 (1970):  336-8[12] Ochs HR, Greenblatt DJ, Verburg-Ochs B \"Propranolol interactions with diazepam, lorazepam and alprazolam.\" Clin Pharmacol Ther 36 (1984):  451-5[13] Desager JP, Hulhoven R, Harvengt C, Hermann P, Guillet P, Thiercelin JF \"Possible interactions between zolpidem, a new sleep inducer and chlorpromazine, a phenothiazine neuroleptic.\" Psychopharmacology (Berl) 96 (1988):  63-6[14] Tverskoy M, Fleyshman G, Ezry J, Bradley EL, Jr  Kissin I \"Midazolam-morphine sedative interaction in patients.\" Anesth Analg 68 (1989):  282-5[15] \"Product Information. Iopidine (apraclonidine ophthalmic).\" Alcon Laboratories Inc[16] Greiff JMC, Rowbotham D \"Pharmacokinetic drug interactions with gastrointestinal motility modifying agents.\" Clin Pharmacokinet 27 (1994):  447-61[17] Greb WH, Buscher G, Dierdorf HD, Koster FE, Wolf D, Mellows G \"The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine.\" Acta Psychiatr Scand 80 Suppl (1989):  95-8[18] Markowitz JS, Wells BG, Carson WH \"Interactions between antipsychotic and antihypertensive drugs.\" Ann Pharmacother 29 (1995):  603-9[19] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[20] \"Product Information. Artane (trihexyphenidyl).\" Lederle Laboratories  (2001):[21] \"Product Information. Ultiva (remifentanil).\" Mylan Institutional (formally Bioniche Pharma USA Inc)  (2001):[22] \"Product Information. Seroquel (quetiapine).\" Astra-Zeneca Pharmaceuticals  (2001):[23] \"Product Information. Meridia (sibutramine).\" Knoll Pharmaceutical Company  (2001):[24] \"Product Information. Tasmar (tolcapone).\" Valeant Pharmaceuticals  (2001):[25] Miller LG \"Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.\" Arch Intern Med 158 (1998):  2200-11[26] \"Product Information. Precedex (dexmedetomidine).\" Abbott Pharmaceutical  (2001):[27] \"Product Information. Trileptal (oxcarbazepine).\" Novartis Pharmaceuticals  (2001):[28] Ferslew KE, Hagardorn AN, McCormick WF \"A fatal interaction of methocarbamol and ethanol in an accidental poisoning.\" J Forensic Sci 35 (1990):  477-82[29] Plushner SL \"Valerian: valeriana officinalis.\" Am J Health Syst Pharm 57 (2000):  328-35[30] \"Product Information. Xatral (alfuzosin).\" Sanofi-Synthelabo Canada Inc  (2002):[31] \"Product Information. Lexapro (escitalopram).\" Forest Pharmaceuticals  (2002):[32] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[33] Cerner Multum, Inc. \"Australian Product Information.\" O 0[34] \"Product Information. Fycompa (perampanel).\" Eisai Inc  (2012):[35] \"Product Information. Belsomra (suvorexant).\" Merck & Co., Inc  (2014):[36] \"Product Information. Rexulti (brexpiprazole).\" Otsuka American Pharmaceuticals Inc  (2015):", "alternatives_a": "Ketotifen, Fexofenadine, Loratadine, Astemizole, Desloratadine, Azelastine, Terfenadine, Pheniramine, Lidocaine, Tetracaine, Pheniramine, More", "alternatives_b": "Naltrexone", "updated_at": 1767369485}, {"id": 246000, "ingredient1": "Dihydrocodeine", "ingredient2": "Propantheline", "severity": "Moderate", "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.", "source": "DDInter", "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.", "mechanism_text": "Synergism", "recommendation": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.", "risk_level": "Moderate", "type": "pharmacodynamic", "metabolism_info": null, "source_url": "https://ddinter2.scbdd.com/server/interact/289942/", "reference_text": "[1] \"Product Information. Demerol (meperidine).\" Sanofi Winthrop Pharmaceuticals  (2002):[2] \"Product Information. Dolophine (methadone).\" Lilly, Eli and Company  (2002):[3] \"Product Information. Tylenol with Codeine (acetaminophen-codeine).\" Janssen Pharmaceuticals  (2001):[4] \"Product Information. Duragesic Transdermal System (fentanyl).\" Janssen Pharmaceutica, Titusville, NJ.[5] \"Product Information. Ultram (tramadol).\" McNeil Pharmaceutical  (2001):[6] \"Product Information. OxyContin (oxycodone).\" Purdue Frederick Company  (2001):[7] \"Product Information. Kadian (morphine).\" Astra-Zeneca Pharmaceuticals  (2001):[8] \"Product Information. DepoDur (morphine liposomal).\" Endo Laboratories LLC  (2004):[9] Cerner Multum, Inc. \"UK Summary of Product Characteristics.\" O 0[10] \"Product Information. Opana (oxymorphone).\" Endo Laboratories LLC  (2006):[11] \"Product Information. Nucynta (tapentadol).\" PriCara Pharmaceuticals  (2009):[12] \"Product Information. Exalgo (hydromorphone).\" Covidien  (2010):[13] \"Product Information. Belbuca (buprenorphine).\" Endo Pharmaceuticals Solutions Inc  (2016):[14] \"Product Information. Alfentanil Hydrochloride (alfentanil).\" Akorn Inc  (2017):[15] \"Product Information. SUFentanil Citrate (sufentanil).\" Akorn Inc  (2017):[16] \"Product Information. Lortab (acetaminophen-hydrocodone).\" Akorn Inc  (2017):[17] \"Product Information. Levorphanol Tartrate (levorphanol).\" Sentynl Therapeutics  (2017):[18] \"Product Information. Naloxone HCl-Pentazocine HCl (naloxone-pentazocine).\" Actavis U.S. (Amide Pharmaceutical Inc)  (2018):[19] \"Product Information. Apadaz (acetaminophen-benzhydrocodone).\" KemPharm, Inc  (2018):", "alternatives_a": "Papaverine, Alosetron, Isometheptene", "alternatives_b": "Naltrexone, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone", "updated_at": 1767369485}]